



US 20130209450A1

(19) **United States**

(12) **Patent Application Publication**
Cohen et al.

(10) **Pub. No.: US 2013/0209450 A1**

(43) **Pub. Date: Aug. 15, 2013**

(54) **COMPOSITIONS AND METHODS FOR
TREATING GLIOBLASTOMA GBM**

Publication Classification

(76) Inventors: **Yael Cohen**, Kiryat-Ono (IL); **Livnat Bangio**, Petach-Tikva (IL); **Andrew J. Brenner**, Boerne, TX (US); **Eyal Breitbart**, Hashmonaim (IL)

(51) **Int. Cl.**
A61K 38/17 (2006.01)
A61K 39/395 (2006.01)
A61N 5/10 (2006.01)
A61K 48/00 (2006.01)

(52) **U.S. Cl.**
 CPC *A61K 38/177* (2013.01); *A61K 48/005* (2013.01); *A61K 39/39558* (2013.01); *A61N 5/1001* (2013.01); *A61N 5/1077* (2013.01); *A61N 2005/1087* (2013.01)
 USPC **424/133.1**; 424/93.2; 600/1; 600/3

(21) Appl. No.: **13/520,452**

(22) PCT Filed: **Jan. 5, 2011**

(86) PCT No.: **PCT/IL11/00009**

§ 371 (c)(1),
(2), (4) Date: **Dec. 19, 2012**

(57) **ABSTRACT**

Methods of treating a malignant glioma in a subject are disclosed. The methods comprise administering to the subject a therapeutically effective amount of a viral vector comprising: (i) a first polynucleotide sequence encoding a Fas-chimera (Fas-c), said first polynucleotide sequence comprising SEQ ID NOs: 2 and 3; and (ii) a second polynucleotide sequence encoding an endothelial cell-specific promoter or a periendothelial cell-specific promoter.

Related U.S. Application Data

(60) Provisional application No. 61/282,228, filed on Jan. 5, 2010, provisional application No. 61/282,248, filed on Jan. 7, 2010.

FIG. 1



FIG. 2




FIG. 3





FIG. 4






FIG. 5A FIG. 5B FIG. 5C




FIG. 5D FIG. 5E FIG. 5F

COMPOSITIONS AND METHODS FOR TREATING GLIOBLASTOMA GBM

FIELD AND BACKGROUND OF THE INVENTION

[0001] The present invention, in some embodiments thereof, relates to compositions and methods for treating malignant gliomas and, more particularly, but not exclusively, for treating Glioblastoma multiforme (GBM).

[0002] Malignant gliomas, the most common adult-onset neurological neoplasms, encompass a family of primary central nervous system tumors including glioblastoma, astrocytoma, oligodendroglioma, and ependymoma, along with the juvenile onset neoplasms such as juvenile pilocytic astrocytoma.

[0003] Malignant gliomas are typically characterized by over-expression of growth factors/tumor associated antigens believed to significantly contribute to the unchecked growth of such tumors. Various malignant gliomas, such as glioblastomas, exhibit epidermal growth factor receptor (EGFR) overexpression leading to increased aggressiveness and poor prognosis. Malignant gliomas may also display over-expression of platelet-derived growth factor receptor, a phenomenon which has also been correlated with increased malignancy and poor prognosis.

[0004] Malignant gliomas, the most common type of primary brain tumors, are aggressive, highly invasive, and neurologically destructive tumors which are among the deadliest of all human cancers. Of the estimated 17,000 new brain tumors diagnosed each year in the United States, about half are malignant gliomas. Malignant glioma cells produce very invasive brain tumors with infiltration of both white and gray matter. At the time of diagnosis, microscopic extension through much of the neural axis by malignant glioma is the rule. Such extension by motile invading cells underlies the incurability by surgery of most gliomas, even when they appear small and restricted in nature.

[0005] Glioblastoma multiforme (GBM), the most serious form of malignant glioma, are extremely aggressive brain tumors which generally arise in the upper brain (cerebrum), but which may also occur elsewhere in the central nervous system, such as in the spinal cord, cerebellum, brain stem, or optic chiasm. Low-grade gliomas, which include astrocytomas, oligodendrogliomas, and pilocytic astrocytomas, account for 25% of all primary brain tumors, and over time most of these low-grade tumors dedifferentiate into more malignant gliomas. Diffuse astrocytomas are predominantly located in the cerebral hemispheres of adults and have an inherent tendency to progress to anaplastic astrocytoma and (secondary) glioblastoma. The majority of glioblastomas develop de novo (primary glioblastomas), without an identifiable less-malignant precursor lesion.

[0006] Despite optimal therapy with surgery, radiotherapy, and temozolomide chemotherapy, the median survival of patients with glioblastomas is only 12-15 months. When these tumors recur, conventional salvage therapies produce minimal benefit, with only 8-15% of patients alive and free from progression at 6 months (6M-PFS).

[0007] Neovascularization is a major feature of glioblastomas (Maher et al., 2001, *Genes Dev.* 15:1311-1333). Angiogenesis activators are extremely important in tumor growth, as reflected by the fact that neovascularization must occur for solid tumors to grow beyond a diameter of 2-3 mm (Goldbrunner et al., 2000, *J. Neurooncol.* 50:53-62). One of the

molecules that regulates this process is the vascular endothelial growth factor (VEGF). VEGF mRNA is overexpressed in the highly vascularized glioblastoma multiforme (Maher et al., 2001, *Genes Dev.* 15:1311-1333). It has been demonstrated that the transfection of antisense-VEGF-complementary-DNA as well VEGF antisense RNA encoding vectors result in down-regulation of the endogenous VEGF and inhibits growth of gliomas in mice (Sasaki et al., 1999, *Int. J. Dev. Neurosci.* 17:579-591; Zheng et al., 2000, *Acta Pharmacol. Sin.* 21:211-214). A similar effect was observed upon the local delivery of the angiogenesis inhibitor endostatin (Read et al., 2001, *Nat. Biotechnol.* 19:29-34). However, this strategy has a cytostatic effect. It is effective in inhibiting tumor growth but not in actually eliminating them.

[0008] Bevacizumab (Avastin®) is a humanized monoclonal antibody that binds VEGF, preventing it from activating its receptors, especially VEGFR2, abrogating subsequent biologic effects. This drug has shown benefit in colorectal, non-small cell lung, and breast cancers, and is approved by the Food and Drug Administration for these indications. Several studies have now evaluated the combination of bevacizumab and the chemotherapeutic agent irinotecan in recurrent malignant gliomas and the results have been more encouraging.

[0009] In one phase II study, the combination of bevacizumab and irinotecan produced a response rate of 67% and 6M-PFS of 56% in recurrent anaplastic gliomas, and a response rate of 57% and a 6M-PFS of 46% in recurrent glioblastomas.

[0010] These preliminary findings have been recently confirmed by a large multi-center randomized phase II study of 167 patients with recurrent GBM who were treated with bevacizumab alone or in combination with irinotecan [Cloughesy T, Prados M, Wen P, et al. Society for Neuro-Oncology 12th Annual Meeting, 2007].

[0011] Patients receiving bevacizumab alone had a response rate of 20% and a 6M-PFS of 35.1%, while patients receiving the combination of bevacizumab in combination with irinotecan had a response rate of 34% and 6M-PFS of 51%. The median survival was 9.7 months for bevacizumab (Avastin) alone, and 8.7 months for the combination. In addition, treatment with bevacizumab was also associated with a significant reduction in peritumoral edema and the need for corticosteroids. As a result of these studies, the combination of bevacizumab with irinotecan is increasingly used for the treatment of patients with recurrent malignant gliomas.

[0012] Another agent proposed for the treatment of malignant gliomas is Aflibercept (VEGF-Trap). This is a soluble hybrid receptor, composed of portions of VEGFR-1 and VEGFR-2 fused to an immunoglobulin G1 Fc domain. Like bevacizumab, it is designed to deplete circulating VEGF, but has significantly greater affinity for VEGF than bevacizumab itself.

[0013] In addition, inhibitors of VEGF receptors have been proposed for the treatment of malignant gliomas. In a phase II trial study of a potent pan-VEGFR inhibitor, cediranib (AZD2171; Recentin) in patients with recurrent glioblastomas, response rates in excess of 50% were observed and the 6M-PFS was increased to approximately 25%. Studies with other inhibitors of VEGFR such as sorafenib (Nexavar), sunitinib (Sutent), vandetanib (ZD6474; Zactima), pazopanib (GW786034), and vatalanib (PTK787) in glioblastomas are also in progress.

[0014] In comparison with drugs targeting VEGF or VEGFR, agents inhibiting other angiogenic pathways have produced less success. Drugs that inhibit PDGF receptors such as imatinib mesylate (Gleevec) were ineffective, due partly to its poor penetration across the blood-brain barrier. Cilengitide, a drug that inhibits $\alpha v\beta 3$ and $\alpha v\beta 5$ integrins has shown modest activity in glioblastomas and studies combining it with other agents are in progress.

[0015] The use of viral vectors as gene delivery agents has been proposed for the treatment of malignant gliomas. Such viruses may be engineered to produce anticancer activity by expressing transgenes whose products exert a tumoricidal effect.

[0016] Several of such approaches have shown anti-tumor efficiency in experimental studies, and the first clinical trials for the treatment of malignant glioma were conducted in the 1990s. HSV-tk gene therapy has been the pioneering and most commonly used approach, but oncolytic conditionally replicating adenoviruses and herpes simplex virus mutant vectors, p53, interleukins, interferons, and antisense oligonucleotides have also been used.

[0017] U.S. Pat. No. 5,747,340 teaches use of a murine endothelial cell-specific promoter which shows selectivity towards angiogenic cells.

[0018] International Application WO/2008/132729 teaches viral vectors comprising endothelial cell specific promoters which directs expression of a transgene in angiogenic cells for the treatment of cancer.

SUMMARY OF THE INVENTION

[0019] According to an aspect of some embodiments of the present invention there is provided a use of a viral vector for preparation of a medicament for the treatment of a malignant glioma, the nucleic acid construct comprising:

[0020] (i) a first polynucleotide sequence encoding a Fas-chimera (Fas-c), the first polynucleotide sequence comprising SEQ ID NOs: 2 and 3; and

[0021] (ii) a second polynucleotide sequence encoding an endothelial cell-specific promoter or a periendothelial cell-specific promoter.

[0022] According to an aspect of some embodiments of the present invention there is provided a use of a viral vector for the treatment of a malignant glioma, the nucleic acid construct comprising:

[0023] (i) a first polynucleotide sequence encoding a Fas-chimera (Fas-c), the first polynucleotide sequence comprising SEQ ID NOs: 2 and 3; and

[0024] (ii) a second polynucleotide sequence encoding an endothelial cell-specific promoter or a periendothelial cell-specific promoter.

[0025] According to an aspect of some embodiments of the present invention there is provided a method of treating a malignant glioma in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a viral vector comprising:

[0026] (i) a first polynucleotide sequence encoding a Fas-chimera (Fas-c), the first polynucleotide sequence comprising SEQ ID NOs: 2 and 3; and

[0027] (ii) a second polynucleotide sequence encoding an endothelial cell-specific promoter or a periendothelial cell-specific promoter, thereby treating the malignant glioma.

[0028] According to some embodiments of the present invention the promoter is set forth in SEQ ID NO: 12.

[0029] According to some embodiments of the present invention the promoter is set forth in SEQ ID NO: 13.

[0030] According to some embodiments of the present invention the viral vector is an adenoviral vector.

[0031] According to some embodiments of the present invention the adenoviral vector is a non-replicating adenoviral vector.

[0032] According to some embodiments of the present invention the promoter comprises at least one copy of a sequence set forth in SEQ ID NO: 6.

[0033] According to some embodiments of the present invention the promoter comprises at least two copies of a sequence set forth in SEQ ID NO: 6.

[0034] According to some embodiments of the present invention the promoter comprises a sequence as set forth in SEQ ID NO: 7.

[0035] According to some embodiments of the present invention the promoter comprises a sequence as set forth in SEQ ID NO: 8.

[0036] According to some embodiments of the present invention the promoter comprises a hypoxia response element (HRE) as set forth in SEQ ID NO: 5.

[0037] According to some embodiments of the present invention the viral vector consists of a sequence as set forth in SEQ ID NO: 9 or SEQ ID NO: 10.

[0038] According to some embodiments of the present invention the malignant glioma is selected from the group consisting of glioblastoma, astrocytoma, oligodendroglioma, and ependymoma, and juvenile pilocystic astrocytoma.

[0039] According to some embodiments of the present invention the therapeutically effective amount of the nucleic acid construct is about 10^3 to about 10^{16} virus particles.

[0040] According to some embodiments of the present invention the therapeutically effective amount of the nucleic acid construct is about 10^5 to about 10^{13} virus particles.

[0041] According to some embodiments of the present invention the therapeutically effective amount of the nucleic acid construct is about 10^7 to about 10^{12} virus particles.

[0042] According to some embodiments of the present invention the therapeutically effective amount of the nucleic acid construct is about 1×10^{12} to about 5×10^{12} virus particles.

[0043] According to some embodiments of the present invention the therapeutically effective amount of the nucleic acid construct is about 1×10^{13} to about 5×10^{13} virus particles.

[0044] According to some embodiments of the present invention the administering comprises intravenous administration.

[0045] According to some embodiments of the present invention the administering comprises local administration.

[0046] According to some embodiments of the present invention the administering is in at least two, or at least three or more doses of said viral vector.

[0047] Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.

BRIEF DESCRIPTION OF THE DRAWINGS

[0048] Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings and images. With specific reference now to the drawings and images in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.

[0049] In the drawings:

[0050] FIG. 1 is a time chart illustrating an exemplary treatment schedule to measure the in-vivo effects of VB-111 in nude rats pre-inoculated with U87 tumor cells.

[0051] FIG. 2 is a graph illustrating the effect of VB-111 on survival of rats pre-inoculated with U87 tumor cells.

[0052] FIG. 3 is a graph illustrating the effect of VB-111 on tumor size (as measured by luciferase activity) of rats pre-inoculated with U87 tumor cells.

[0053] FIG. 4 is a graph illustrating the effect of VB-111 on tumor size (as measured by MRI) of rats pre-inoculated with U87 tumor cells.

[0054] FIGS. 5A-F are photographs of brain slices illustrating the effect of VB-111 on tumor size (as measured by MRI) of rats pre-inoculated with U87 tumor cells.

DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE INVENTION

[0055] The present invention, in some embodiments thereof, relates to compositions and methods for treating malignant gliomas and, more particularly, but not exclusively, for treating Glioblastoma multiforme (GBM).

[0056] Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.

[0057] Malignant gliomas, the most common subtype of primary brain tumors, are aggressive, highly invasive, and neurologically destructive tumors. These tumors are considered to be among the deadliest of all human cancers. In its most aggressive form, glioblastoma (GBM), median survival ranges from 9 to 12 months. Despite several decades of technological advances in neurosurgery and radiation therapy there has been no significant change in the overall statistics.

[0058] Gene therapy approaches for the treatment of malignant gliomas have been attempted. However, while these approaches have proved successful in vitro and in animal models, these strategies have met with limited success in clinical trials. It is believed that the low in vivo infection efficiency of the vectors is connected to the histological structure of the glioblastomas. These are very solid tumors, which are almost completely impermeable to diffusion of big particles such as viruses.

[0059] The present inventors surprisingly found that treatment of glioblastomas in animals could be carried out effectively using viral vectors encoding a toxic molecule (Fas-chimera (Fas-c)) under the control of a promoter which directs transcription in endothelial cells.

[0060] Using an animal model of glioblastoma whereby rats were pre-inoculated with U87 tumor cells, the present inventors showed that administration of such viral vectors

decreased the size of the luciferase-tagged tumors as measured by luciferase activity (FIG. 3) and MRI (FIGS. 4 and 5). The present inventors further showed that administration of such viral vectors increased survival of the rats (FIG. 2).

[0061] Thus, according to one aspect of the present invention, there is provided a method of treating a malignant glioma in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a viral vector comprising:

[0062] (i) a first polynucleotide sequence encoding a Fas-chimera (Fas-c); and

[0063] (ii) a second polynucleotide sequence encoding an endothelial cell-specific promoter or a periendothelial cell-specific promoter, thereby treating the malignant glioma.

[0064] As used herein, the phrase “malignant glioma” refers to a primary central nervous system tumor typically characterized by over-expression of growth factor receptors and/or tumor associated antigens. According to one embodiment the malignant glioma exhibits epidermal growth factor receptor (EGFR) overexpression. According to one embodiment the malignant glioma exhibits platelet-derived growth factor receptor (PDGFR) overexpression. According to another embodiment the malignant glioma exhibits both platelet-derived growth factor receptor (PDGFR) overexpression and epidermal growth factor receptor (EGFR) overexpression.

[0065] Examples of malignant gliomas include, but are not limited to glioblastoma, astrocytoma, oligodendroglioma, ependymoma; and juvenile onset neoplasms such as juvenile pilocytic astrocytoma.

[0066] Contemplated subjects to be treated include mammals—e.g. humans. According to one embodiment the subject has received a prior treatment for the malignant glioma (e.g. radiotherapy and/or chemotherapy) and the malignant glioma has relapsed. According to another embodiment, the subject has not received a prior treatment for the malignant glioma.

[0067] The phrase “viral vector” refers to a replication competent or replication-deficient viral particle which are capable of transferring nucleic acid molecules into a host.

[0068] The present inventors contemplate use of Replication Defective Vectors and Replication Defective Vector-Producing Packaging Cells. Examples of such vectors are adenoviral vectors, AAV vectors and retroviral vectors and others described in Shir et al, Cellular and Molecular Neurobiology, Vol. 21, No. 6, December 2001, the contents of which are incorporated herein by reference.

[0069] The term “virus” refers to any of the obligate intracellular parasites having no protein-synthesizing or energy-generating mechanism. The viral genome may be RNA or DNA contained with a coated structure of protein of a lipid membrane. Examples of viruses useful in the practice of the present invention include baculoviridae, parvoviridae, picomoviridae, herpesviridae, poxyviridae, adenoviridae, picotomaviridae. The term recombinant virus includes chimeric (or even multimeric) viruses, i.e. vectors constructed using complementary coding sequences from more than one viral subtype. (See, e.g. Feng, et al. Nature Biotechnology 15:866-870) The term “adenovirus” is synonymous with the term “adenoviral vector” and refers to viruses of the genus adenoviridae. The term adenoviridae refers collectively to animal adenoviruses of the genus mastadenovirus including but not limited to human, bovine, ovine, equine, canine, porcine, murine and simian adenovirus subgenera. In particular, human adenoviruses includes the A-F subgenera as well as

the individual serotypes thereof the individual serotypes and A-F subgenera including but not limited to human adenovirus types 1, 2, 3, 4, 4a, 5, 6, 7, 8, 9, 10, 11 (Ad11A and Ad 11P), 12, 13, 14, 15, 16, 17, 18, 19, 19a, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 34a, 35, 35p, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, and 91. The term bovine adenoviruses includes but is not limited to bovine adenovirus types 1, 2, 3, 4, 7, and 10. The term canine adenoviruses includes but is not limited to canine types 1 (strains CLL, Glaxo, RI261, Utrecht, Toronto 26-61) and 2. The term equine adenoviruses includes but is not limited to equine types 1 and 2. The term porcine adenoviruses includes but is not limited to porcine types 3 and 4. In one embodiment of the invention, the adenovirus is derived from the human adenovirus serotypes 2 or 5. For purposes of this invention, adenovirus vectors can be replication-competent or replication deficient in a target cell. In some embodiments, the adenovirus vectors are conditionally or selectively replicating adenoviruses, wherein a gene[s] required for viral replication is [are] operatively linked to a cell and/or context-specific promoter. Examples of selectively replicating or conditionally replicating viral vectors are known in the art (see, for example, U.S. Pat. No. 7,691,370). In one embodiment, the adenovirus vector is a conditionally replicating adenovirus wherein the E1 gene is under transcriptional control of the pre-proendothelin promoter PPE-1 (PPE-1, SEQ ID NO: 13). In another embodiment, the adenovirus vector is a conditionally replicating or selectively replicating adenovirus wherein the E1 gene is under transcriptional control of the modified pre-proendothelin promoter PPE-1-3X (PPE-1-3X, SEQ ID NO: 12). In some embodiments, adenovirus vectors suitable for use with the present invention include all adenovirus serotypes having hexon protein structure. Viral vectors suitable for therapeutic use include adenoviral vectors, retroviral vectors, AAV, herpesvirus vectors and the like. Engineering and production of viral vectors is well known in the art, as described in detail in, for example, U.S. Pat. No. 7,732,129 or 6,649,158, which are incorporated herein by reference, in their entirety. In specific embodiments, the adenovirus is a C-type adenovirus (Ad5, Ad2), a B-type adenovirus (Ad3, Ad16, Ad21, Ad35, Ad50), an E-type adenovirus (Ad4) or an F-type adenovirus (Ad41).

[0070] As used herein, the phrase adenoviral vector refers to a vector in which, among the nucleic acid molecules in the viral particle, sequences necessary to function as a viral vector are based on the adenoviral genome.

[0071] According to one embodiment the adenoviral vector is a non-replicating serotype 5 (Ad5) adenoviral vector.

[0072] According to another embodiment, the adenoviral vector comprises a sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 11.

[0073] It will be appreciated that the present invention also contemplates use of oncolytic viruses which reproduce themselves in cancer cells and subsequently kill the initially infected cells by lysis. Such viruses proceed to infect adjacent cells thus repeating the cycle. Contemplated example of oncolytic viruses include, but are not limited to Herpes Simplex Virus, conditionally replicative Ads (CRAds) and reoviruses.

[0074] Two major strategies for development of CRAd vectors have been developed, mainly focusing on the genetic engineering of the early 1 (E1) genes to restrict virus replication to target cells and to spare normal tissue. Genetic complementation-type (type 1) CRAds, such as Ad524, have a mutation in the immediately early (E1A) or early (E1B) adenoviral

region, which is complemented in tumor cells but not in normal cells. In trans complementation-type (type 2) CRAds, virus replication is controlled via a tumor/tissue-specific promoter.

[0075] Reovirus is a naturally occurring oncolytic virus that requires activated Ras signaling pathways of tumor cells for its replication. Ras pathways are activated in most malignant gliomas via upstream signaling by receptor tyrosine kinases.

[0076] As mentioned the viral vectors of this aspect of the present invention comprise:

[0077] (i) a first polynucleotide sequence encoding a Fas-chimera (Fas-c); and

[0078] (ii) a second polynucleotide sequence encoding an endothelial cell-specific promoter or a periendothelial cell-specific promoter, thereby treating the malignant glioma.

[0079] Typically, such viral vectors are constructed using genetic recombination technology—i.e. recombinant viral vectors.

[0080] The Fas-chimera (Fas-c), is a previously described fusion of two “death receptors”, constructed from the extracellular region of TNFR1 (SEQ ID NO: 2) and the transmembrane and intracellular regions of Fas (SEQ ID NO: 3) [Boldin M P et al. J Biol Chem (1995) 270(14):7795-8].

[0081] According to one embodiment the Fas-c is encoded by a polynucleotide as set forth in SEQ ID NO: 4.

[0082] It will be appreciated that the present invention also contemplates use of a viral construct (e.g. an adenoviral construct) comprising an endothelial/periendothelial cell-specific promoter operatively linked to other cytotoxic polypeptides for the treatment of malignant glioma.

[0083] Such polypeptides, include but are not limited to suicide polypeptides such as p53 and egr-1-TNF-alpha, cytotoxic pro-drug/enzymes for drug susceptibility therapy such as ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase, and antimetastatic polypeptides such as 5 E1A.

[0084] The term “promoter” as used herein refers to a DNA sequence which directs transcription of a polynucleotide sequence operatively linked thereto in the cell in a constitutive or inducible manner. The promoter may also comprise enhancer elements which stimulate transcription from the linked promoter.

[0085] As used herein, the phrase endothelial cell-specific promoter refers to a promoter which directs expression of a gene operatively linked thereto in endothelial cells, wherein the level of expression in endothelial cells is at least 2 times higher than in non-endothelial cells. According to a particular embodiment, the level of expression in endothelial cells is at least 5 times higher than in non-endothelial cells.

[0086] As used herein, the phrase periendothelial cell-specific promoter refers to a promoter which directs expression of a gene operatively linked thereto in periendothelial cells (i.e., pericytes in small vessels or smooth muscle cells in larger vessels), wherein the level of expression in endothelial cells is at least 2 times higher than in non-periendothelial cells. According to a particular embodiment, the level of expression in periendothelial cells is at least 5 times higher than in non-periendothelial cells.

[0087] Exemplary endothelial cell-specific promoters or periendothelial cell-specific promoters include, but are not limited to the preproendothelin-1 (PPE-1) promoter, and modifications thereof such as described herein below, the TIE-1 promoter, the TIE-2 promoter, the Endoglin promoter,

the von Willerband promoter, the KDR/flk-1 promoter, The FLT-1 promoter, the Egr-1 promoter, the ICAM-1 promoter, the VCAM-1 promoter, the PECAM-1 promoter and the aortic carboxypeptidase-like protein (ACLP) promoter.

[0088] The preproendothelial promoter refers to the preproendothelin-1 promoter, of mammalian origin. In one embodiment, the preproendothelin 1 promoter is a murine preproendothelin 1 promoter as set forth in SEQ ID NO: 13.

[0089] According to one embodiment the promoter comprises at least one copy of an enhancer element that confers endothelial cell specific transcriptional activity. According to one embodiment the enhancer element is naturally found positioned between the -364 bp and -320 bp of the murine PPE-1 promoter (as set forth in SEQ ID NO: 6). Preferably, the promoter comprises at least two and more preferably three of the above described enhancer elements. According to a specific embodiment, the promoter comprises two of the above described enhancer elements on one strand of the promoter DNA and one of the above described enhancer element on the complementary strand of the promoter DNA (as set forth in SEQ ID NO:7).

[0090] According to another embodiment, the promoter further comprises at least one hypoxia response element—e.g. comprising a sequence as set forth in SEQ ID NO: 5.

[0091] An exemplary promoter which can be used in the context of the present invention comprises a sequence as set forth in SEQ ID NO: 12. This promoter is also referred to herein as the PPE-1-3x promoter. This sequence comprises SEQ ID NO: 5 and SEQ ID NO: 7 (which itself comprises two copies of SEQ ID NO: 6 either side of one copy of SEQ ID NO: 8).

[0092] According to a particular embodiment of this aspect of the present invention, the viral vector consists of a sequence as set forth in SEQ ID NOs: 9 or 10. This viral vector is also referred to herein as VB111 and AD5PPE-1-3X-fas-chimera.

[0093] This sequence comprises SEQ ID NO: 12 in the antisense orientation at position 460-1437.

[0094] This sequence also comprises SEQ ID NO: 7 in the antisense orientation at position 894-1036; a single copy of SEQ ID NO: 8 in the antisense orientation at position 951-997; a first copy of SEQ ID NO: 6 in the antisense orientation at position 907-950; a second copy of SEQ ID NO: 6 in the antisense orientation at position 993-1036; and a third copy of SEQ ID NO: 6 at position 823-866 in the sense orientation.

[0095] In some embodiments of the invention, the viral vector comprises additional polynucleotide sequences capable of enhancing or inhibiting transcriptional activity of an endothelial specific promoter. According to an aspect of some embodiments of the invention, the additional polynucleotide sequence includes an isolated polynucleotide comprising at least 6 nucleotides of element X of a preproendothelin (PPE-1) promoter, the element X having a wild type sequence as set forth by SEQ ID NO:6, wherein the at least 6 nucleotides comprise at least 2 consecutive sequences derived from SEQ ID NO:6, each of the at least 2 consecutive sequences comprises at least 3 nucleotides, at least one of the at least 3 nucleotide being positioned next to at least one nucleotide position in SEQ ID NO:6, the at least one nucleotide position in SEQ ID NO:6 is selected from the group consisting of:

[0096] (i) at least one nucleotide of wild type M4 sequence set forth by SEQ ID NO: 15 (CAATC);

[0097] (ii) at least one nucleotide of wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG);

[0098] (iii) at least one nucleotide of wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC);

[0099] (iv) at least one nucleotide of wild type M6 sequence set forth by SEQ ID NO: 17 (GGGTG);

[0100] (v) at least one nucleotide of wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT);

[0101] (vi) at least one nucleotide of wild type M1 sequence set forth by SEQ ID NO: 20 (GTACT); and

[0102] (v) at least one nucleotide of wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT);

[0103] wherein the at least one nucleotide position is mutated as compared to SEQ ID NO:6 by at least one nucleotide substitution, at least one nucleotide deletion and/or at least one nucleotide insertion, with the proviso that a mutation of the at least one nucleotide position does not result in nucleotides GGTA at position 21-24 of SEQ ID NO:6 and/or in nucleotides CATG at position 29-32 of SEQ ID NO:6, such that when the isolated polynucleotide is integrated into the PPE-1 promoter and placed upstream of a reporter gene (e.g., luciferase coding sequence) the expression level of the reporter gene is upregulated or downregulated as compared to when SEQ ID NO:6 is similarly integrated into the PPE-1 promoter and placed upstream of the reporter gene coding sequence.

[0104] According to some embodiments of the invention, the isolated polynucleotide is not naturally occurring in a genome or a whole chromosome sequence of an organism.

[0105] As used herein the phrase “naturally occurring” refers to as found in nature, without any man-made modifications.

[0106] As described above, the at least 6 nucleotides of element X comprise at least 2 consecutive sequences derived from SEQ ID NO:6.

[0107] As used herein the phrase “consecutive sequence derived from SEQ ID NO:6” refers to a nucleic acid sequence (a polynucleotide) in which the nucleotides appear in the same order as in the nucleic acid sequence of SEQ ID NO:6 from which they are derived. It should be noted that the order of nucleotides is determined by the chemical bond (phosphodiester bond) formed between a 3'-OH of a preceding nucleotide and the 5'-phosphate of the following nucleotide.

[0108] According to some embodiments of the invention, each of the at least 2 consecutive sequences comprises at least 3 nucleotides, e.g., 3 nucleotides, 4 nucleotides, 5 nucleotides, 6 nucleotides, 7 nucleotides, 8 nucleotides, 9 nucleotides, 10 nucleotides, 11 nucleotides, 12 nucleotides, 13 nucleotides, 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, 30 nucleotide, 31 nucleotides, 32 nucleotides, 33 nucleotides, 34 nucleotides, 35 nucleotides, 36 nucleotides, 37 nucleotides, 38 nucleotides, 39 nucleotides, 40 nucleotides, 41 nucleotides of SEQ ID NO:6.

[0109] As described, the isolated polynucleotide comprises at least 2 consecutive sequences derived from SEQ ID NO:6. According to some embodiments of the invention, the isolated polynucleotide comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 consecutive sequences derived from SEQ ID NO:6.

[0110] As used herein the phrase “wild type” with respect to a nucleotide sequence refers to the nucleic acid sequence as appears in SEQ ID NO:6. Examples include, but are not

limited to wild type M4 sequence (SEQ ID NO: 15), wild type M5 sequence (SEQ ID NO: 16), wild type M8 (SEQ ID NO:19), wild type M6 sequence (SEQ ID NO:17), wild type M7 sequence (SEQ ID NO:18), wild type M1 (SEQ ID NO:20) and wild type M3 sequence (SEQ ID NO:21).

[0111] According to some embodiments of the invention, the mutation is an insertion of at least one nucleotide in a nucleotide position with respect to SEQ ID NO:6. According to some embodiments of the invention, the insertion includes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 nucleotides, e.g., at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 55, at least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least about 85, at least about 90, at least about 95, at least about 100, at least about 200, at least about 300, or more nucleotides.

[0112] It should be noted that the sequence which is inserted by the mutation can be derived from any source (e.g., species, tissue or cell type), and is not limited to the source of the sequence of element X.

[0113] According to some embodiments of the invention, the mutation is a combination of any of the mutation types described above, i.e., substitution, insertion and deletion. For example, while one nucleotide position in SEQ ID NO:6 can be subject to a substitution mutation, another nucleotide position in SEQ ID NO:6 can be subject to a deletion or insertion. Additionally or alternatively, while one nucleotide position in SEQ ID NO:6 can be subject to a deletion mutation, another nucleotide position in SEQ ID NO:6 can be subject to a substitution or insertion. Additionally or alternatively, while one nucleotide position in SEQ ID NO:6 can be subject to an insertion mutation, another nucleotide position in SEQ ID NO:6 can be subject to a substitution or deletion. It should be noted that various other combinations are possible.

[0114] According to specific embodiments of the invention, the mutation in the isolated polynucleotide of the invention does not result in nucleotides GGTA at position 21-24 of SEQ ID NO:6 and/or in nucleotides CATG at position 29-32 of SEQ ID NO:6.

[0115] As used herein the phrase “integrated into the PPE-1 promoter” refers to a nucleotide sequence (the isolated polynucleotide) which is covalently conjugated within the PPE-1 promoter sequence.

[0116] According to some embodiments of the invention, the isolated polynucleotide further comprises at least one copy of a nucleic acid sequence selected from the group consisting of:

[0117] (i) wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC),

[0118] (ii) wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG),

[0119] (iii) wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC),

[0120] (iv) wild type M6 sequence set forth by SEQ ID NO: 17 (GGGTG),

[0121] (v) wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT);

[0122] (vi) wild type M1 sequence set forth by SEQ ID NO: 20 (GTACT), and

[0123] (vii) wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT).

[0124] According to some embodiments of the invention, the isolated polynucleotide is integrated into (within), downstream of, or upstream of any known (or unknown) promoter

sequence to thereby regulate (e.g., increase, decrease, modulate tissue-specificity, modulate inductive or constitutive expression) the transcriptional promoting activity of the promoter.

[0125] According to some embodiments of the invention, the isolated polynucleotide is for increasing expression of a heterologous polynucleotide operably linked thereto in endothelial cells. Such a polynucleotide can include wild type sequences of M4 and/or M5 in the presence or absence of additional sequences from element X, and/or in the presence of other mutated sequences from element X.

[0126] According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC).

[0127] According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG).

[0128] According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC) and at least one copy of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG).

[0129] According to some embodiments of the invention, the at least one nucleotide position which is mutated as compared to SEQ ID NO:6 is at least one nucleotide of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC). It should be noted that such an isolated polynucleotide may further include a wild type M6 sequence (SEQ ID NO:17) and/or a wild type M7 sequence (SEQ ID NO:18)

[0130] Non-limiting examples of isolated polynucleotides which include at least one copy of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC) and a mutation in at least one nucleotide of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs:55-62.

[0131] Non-limiting examples of isolated polynucleotides which include at least one copy of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG) and a mutation in at least one nucleotide of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs: 63-66.

[0132] Non-limiting examples of isolated polynucleotides which include at least one copy of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), at least one copy of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG) and a mutation in at least one nucleotide of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs: 67-70.

[0133] According to some embodiments of the invention, the isolated polynucleotide further comprising at least one copy of wild type M1 sequence set forth by SEQ ID NO: (GTACT).

[0134] Non-limiting examples of isolated polynucleotides which include at least one copy of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), at least one copy of the wild type M1 sequence set forth by SEQ ID NO: 20 (GTACT), and a mutation in at least one nucleotide of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs: 71-105.

[0135] Non-limiting examples of isolated polynucleotides which include at least one copy of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), at least one copy of the

wild type M1 sequence set forth by SEQ ID NO: 20 (GTACT) and a mutation in at least one nucleotide of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOS: 106-136.

[0136] Non-limiting examples of isolated polynucleotides which include at least one copy of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), at least one copy of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M1 sequence set forth by SEQ ID NO: 20 (GTACT) and a mutation in at least one nucleotide of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOS:137-152.

[0137] According to some embodiments of the invention, the isolated polynucleotide reduces expression of a heterologous polynucleotide operably linked thereto in endothelial cells. Such a polynucleotide can include mutations in M4 and/or M5 in the presence or absence of additional sequences from element X, and/or in the presence of other mutated sequences from element X.

[0138] According to some embodiments of the invention, the at least one nucleotide position which is mutated as compared to SEQ ID NO:6 is at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC).

[0139] Non-limiting examples of isolated polynucleotides which includes a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO:46 (CATTC) are provided in SEQ ID NOS:153-162.

[0140] According to some embodiments of the invention, the at least one nucleotide position which is mutated as compared to SEQ ID NO:6 is at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG).

[0141] Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG) are provided in SEQ ID NOS:163-171.

[0142] According to some embodiments of the invention, the at least one nucleotide position which is mutated as compared to SEQ ID NO:6 is at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC) and at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG).

[0143] Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC) and a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG) are provided in SEQ ID NOS:172-180.

[0144] According to some embodiments of the invention, the isolated polynucleotide is for increasing expression of a heterologous polynucleotide operably linked thereto in cells other than endothelial cells. Such a polynucleotide can include mutations in M4 and/or M5 and wild type sequences of M6 and/or M7, in the presence or absence of additional sequences from element X, and/or in the presence of other mutated sequences from element X.

[0145] According to some embodiments of the invention, the isolated polynucleotide comprises a mutation in M4 (SEQ ID NO: 15) and/or in M5 (SEQ ID NO: 16) and at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and/or at least one copy of wild type M7 set forth by SEQ ID NO:18.

[0146] Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC) and

at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) are provided in SEQ ID NOS:181-182.

[0147] Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG) and at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) are provided in SEQ ID NOS:183-189.

[0148] Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG) and at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) are provided in SEQ ID NOS:190-191.

[0149] According to some embodiments of the invention, the isolated polynucleotide further comprises at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT).

[0150] Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC) and at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT) are provided in SEQ ID NOS:192-195.

[0151] Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG) and at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT) are provided in SEQ ID NOS:196-198.

[0152] Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG) and at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT) are provided in SEQ ID NOS:199-202.

[0153] According to some embodiments of the invention, the isolated polynucleotide further comprises at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT).

[0154] Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), at least one, copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT) are provided in SEQ ID NOS:203-205.

[0155] Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT) are provided in SEQ ID NOS:206-207.

[0156] Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M6 set forth by SEQ ID NO: 17

(GGGTG) and at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT) are provided in SEQ ID NOs:208-209.

[0157] According to some embodiments of the invention, the isolated polynucleotide reduces expression in cells of a heterologous polynucleotide operably linked thereto. Such a polynucleotide can include mutations in M4, M5, M6 and/or M7, in the presence or absence of additional sequences from element X, and/or in the presence of other mutated sequences from element X.

[0158] According to some embodiments of the invention, the isolated polynucleotide comprises at least one mutation in wild type M4 (SEQ ID NO: 15) and/or in wild type M5 (SEQ ID NO:47) and in wild type M6 set forth by SEQ ID NO: 17 (GGGTG).

[0159] Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC) and a mutation in at least one nucleotide position of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) are provided in SEQ ID NOs:210-213.

[0160] Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG) and a mutation in at least one nucleotide position of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) are provided in SEQ ID NOs:214-222.

[0161] Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), and a mutation in at least one nucleotide position of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) are provided in SEQ ID NOs:223-231.

[0162] According to some embodiments of the invention, the isolated polynucleotide further comprises at least one mutation in wild type M7 set forth by SEQ ID NO: 18 (ACTTT).

[0163] Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC) and a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT) are provided in SEQ ID NOs:232-236.

[0164] Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG) and a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT) are provided in SEQ ID NOs:237-240.

[0165] Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), and a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT) are provided in SEQ ID NOs:241-248.

[0166] According to some embodiments of the invention, the isolated polynucleotide further comprises at least one mutation in wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and at least one mutation in wild type M7 set forth by SEQ ID NO: 18 (ACTTT).

[0167] Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide position of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT) are provided in SEQ ID NOs: 249-258.

[0168] Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), a mutation in at least one nucleotide position of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT) are provided in SEQ ID NOs: 259-264.

[0169] Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), a mutation in at least one nucleotide position of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT) are provided in SEQ ID NOs:265-270.

[0170] According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) with additional wild type or mutated sequences derived from element X (SEQ ID NO:6).

[0171] Non-limiting examples of isolated polynucleotides which includes a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC) and at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs: 271-279.

[0172] Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG) and at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs:280-287.

[0173] Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG) and at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs:288-291.

[0174] Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs:294-298.

[0175] Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs:299-301.

[0236] According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of wild type M3 sequence (SEQ ID NO: 21) and at least one copy of wild type M8 sequence (SEQ ID NO: 19), with at least one mutation in wild type M6 (SEQ ID NO: 17) and/or in wild type M7 (SEQ ID NO:50).

[0237] Non-limiting examples of isolated polynucleotides which include at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT), with a mutation in at least one nucleotide of the wild type M6 sequence (SEQ ID NO: 17), and/or a mutation in at least one nucleotide of the wild type M7 (SEQ ID NO: 18) are provided in SEQ ID NOs:593-600.

[0238] The present inventors have envisaged that an isolated polynucleotide which includes the wild type M8 sequence (SEQ ID NO: 19) and/or the wild type M3 (SEQ ID NO: 21) sequence in addition to tissue specific enhancers (e.g., wild type M4 and/or wild type M5), and/or induced enhancers (e.g., developmentally related- or stress related-enhancers) is expected to exert a more specific regulatory effect by suppressing expression in non-target cells or under non-induced conditions.

[0239] According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and an endothelial specific enhancer sequence.

[0240] According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of wild type M4 sequence set forth by SEQ ID NO: 15.

[0241] According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of wild type M5 sequence set forth by SEQ ID NO:16.

[0242] According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC), at least one copy of wild type M4 sequence set forth by SEQ ID NO: 15 and at least one copy of wild type M5 sequence set forth by SEQ ID NO:16.

[0243] According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) and an endothelial specific enhancer sequence.

[0244] According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) and at least one copy of wild type M4 sequence set forth by SEQ ID NO: 15.

[0245] According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) and at least one copy of wild type M5 sequence set forth by SEQ ID NO:16.

[0246] According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT), at least one copy of wild type M4 sequence set forth by SEQ ID NO: 15 and at least one copy of wild type M5 sequence set forth by SEQ ID NO:16.

[0247] According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT), at least one copy of wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and an endothelial specific enhancer sequence.

[0248] According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT), at least one copy of wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of wild type M4 sequence set forth by SEQ ID NO: 15.

[0249] According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT), at least one copy of wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of wild type M5 sequence set forth by SEQ ID NO: 16.

[0250] According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT), at least one copy of wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC), at least one copy of wild type M4 sequence set forth by SEQ ID NO: 15 and at least one copy of wild type M5 sequence set forth by SEQ ID NO: 16.

[0251] According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT), at least one copy of wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one enhancer element such as wild type M6 (SEQ ID NO: 17) and/or wild type M7 sequence (SEQ ID NO:18).

[0252] According to some embodiments of the invention, the isolated polynucleotide includes at least one copy of wild type M8 with additional flanking sequences such as at least one copy of a wild type M8 sequence (SEQ ID NO:19), at least one copy of wild type M7 (SEQ ID NO: 18) and/or wild type M9 sequence (SEQ ID NO: 14, CTGGA); and/or the isolated polynucleotide includes at least one copy of wild type M8 and at least one mutation in M7, with or without M9 (SEQ ID NO: 22). Such polynucleotides can be used as a non-specific repressor.

[0253] According to some embodiments of the invention, the isolated polynucleotide is for increasing expression of a heterologous polynucleotide operably linked thereto in cells/tissues.

[0254] According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of wild type M6 sequence set forth by SEQ ID NO: 17 (GGGTG) and/or at least one copy of wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT).

[0255] According to some embodiments of the invention, the isolated polynucleotide includes at least one copy of wild type M6 (SEQ ID NO: 17) and a mutation in at least one nucleotide of wild type M8 (SEQ ID NO: 19).

[0256] Non-limiting examples of isolated polynucleotide which include at least one copy of wild type M6 (SEQ ID NO: 17) and a mutation in at least one nucleotide of the wild type M8 (SEQ ID NO: 19) are provided in SEQ ID NOs:23-26.

[0257] According to some embodiments of the invention, the isolated polynucleotide includes at least one copy of wild type M7 (SEQ ID NO: 18) and a mutation in at least one nucleotide of wild type M8 (SEQ ID NO: 19).

[0258] Non-limiting examples of isolated polynucleotide which include at least one copy of wild type M7 (SEQ ID NO: 18) and a mutation in at least one nucleotide of the wild type M8 (SEQ ID NO: 19) are provided in SEQ ID NOs:27-28.

[0259] According to some embodiments of the invention, the isolated polynucleotide includes at least one copy of wild type M6 (SEQ ID NO: 17), at least one copy of wild type M7 (SEQ ID NO: 18) and a mutation in at least one nucleotide of wild type M8 (SEQ ID NO: 19).

[0260] According to some embodiments of the invention, the isolated polynucleotide includes at least one copy of wild type M1 (SEQ ID NO: 20) and a mutation in at least one nucleotide of wild type M8 (SEQ ID NO: 19).

[0261] Non-limiting examples of isolated polynucleotide which include at least one copy of wild type M1 (SEQ ID NO: 20) and a mutation in at least one nucleotide of the wild type M8 (SEQ ID NO: 19) are provided in SEQ ID NOs:43-54 and 601-632.

[0262] According to some embodiments of the invention, the isolated polynucleotide includes at least one copy of wild type M1 (SEQ ID NO: 20), at least one copy of wild type M6 (SEQ ID NO: 17) and/or at least one copy of wild type M7 (SEQ ID NO: 18) and a mutation in at least one nucleotide of wild type M8 (SEQ ID NO: 19).

[0263] Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of wild type M8 (SEQ ID NO: 19) and at least one copy of wild type M1 (SEQ ID NO: 20), wild type M6 (SEQ ID NO: 17) and/or wild type M7 (SEQ ID NO: 18) are provided in SEQ ID NOs:29-42.

[0264] Additional examples of regulatory isolated polynucleotides which can be used according to some embodiments of the invention are provided (SEQ ID NOs: 633-644) in the Examples section which follows.

[0265] According to an aspect of some embodiments of the invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence which comprises a first polynucleotide comprising the pre-proendothelin (PPE-1) promoter set forth by SEQ ID NO:13 and a second polynucleotide comprising at least one copy of a nucleic acid sequence selected from the group consisting of:

[0266] (i) wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC),

[0267] (ii) wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG),

[0268] (iii) wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC),

[0269] (iv) wild type M6 sequence set forth by SEQ ID NO: 17 (GGGTG),

[0270] (v) wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT);

[0271] (vi) wild type M1 sequence set forth by SEQ ID NO: 20 (GTACT), and

[0272] (vii) wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT);

[0273] with the proviso that the second polynucleotide is not SEQ ID NO:6 (element X), and wherein the isolated polynucleotide is not SEQ ID NO:12 (PPE-1-3X).

[0274] According to some embodiments of the invention, each of the wild type M4, M5, M8, M6, M7 and/or M1 sequences is placed in a head to tail (5'→3') orientation with respect to the PPE-1 promoter set forth by SEQ ID NO:13.

[0275] According to some embodiments of the invention, each of the wild type M4, M5, M8, M6, M7 and/or M1

sequences is placed in a tail to head (3'→5') orientation with respect to the PPE-1 promoter set forth by SEQ ID NO:13.

[0276] According to some embodiments of the invention, the wild type M4, M5, M8, M6, M7 and/or M1 sequences are placed in various orientations (head to tail or tail to head) and/or sequential order with respect to the other wild type M4, M5, M8, M6, M7 and/or M1 sequences, and/or with respect to the orientation of SEQ ID NO:13.

[0277] Construction of such viral vectors may be effected using known molecular biology techniques such as those described in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Springs Harbor Laboratory, New York (1989, 1992), in Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley and Sons, Baltimore, Md. (1989), Chang et al., *Somatic Gene Therapy*, CRC Press, Ann Arbor, Mich. (1995), Vega et al., *Gene Targeting*, CRC Press, Ann Arbor Mich. (1995), Vectors: *A Survey of Molecular Cloning Vectors and Their Uses*, Butterworths, Boston Mass. (1988) and Gilboa et al. [*Biotechniques* 4 (6): 504-512, 1986].

[0278] Construction of the viral vector of SEQ ID NO: 9 is described in International Application WO/2008/132729, the contents of which are incorporated herein by reference.

[0279] The viral vector of this aspect of the present invention may be administered per se or as part of a pharmaceutical composition which also includes a physiologically acceptable carrier. The purpose of a pharmaceutical composition is to facilitate administration of the active ingredient to an organism.

[0280] As used herein a "pharmaceutical composition" refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.

[0281] Herein the term "active ingredient" refers to the viral vector of the present invention accountable for the biological effect.

[0282] Hereinafter, the phrases "physiologically acceptable carrier" and "pharmaceutically acceptable carrier" which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound. An adjuvant is included under these phrases.

[0283] Herein the term "excipient" refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.

[0284] Techniques for formulation and administration of drugs may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, Pa., latest edition, which is incorporated herein by reference.

[0285] Suitable routes of administration may, for example, include oral, rectal, transmucosal, especially transnasal, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intracardiac, e.g., into the right or left ventricular cavity, into the common coronary artery, intravenous, intraperitoneal, intranasal, or intraocular injections. Injection of the viral vectors into a spinal fluid can also be used as a mode of administration.

[0286] In order to enhance delivery of the virus to the central nervous system (CNS) various approaches may be taken. These include: neurosurgical strategies (e.g., intracerebral injection or intracerebroventricular infusion) and molecular manipulation of the virus. Thus for example, Tang et al., *Gene Therapy* (2007) 14, 523-532 teaches re-directing Ad5 vectors to the MTF transcytosis pathway in order to cross the BBB by manipulating the virus to express a full-length melanotransferrin (sCAR-MTf) polypeptide.

[0287] Other approaches for enhancing the delivery of the virus to the CNS include pharmacological strategies designed to increase the lipid solubility of an agent (e.g., conjugation of water-soluble agents to lipid or cholesterol carriers); and the transitory disruption of the integrity of the BBB by hyperosmotic disruption (resulting from the infusion of a mannitol solution into the carotid artery or the use of a biologically active agent such as an angiotensin peptide).

[0288] The present invention also contemplates engineering of the viral vectors in order to avoid, suppress or manipulate the immune response, ideally resulting in sustained expression and immune tolerance to the transgene product—such methods are described for example in Nayak et al., *Gene Therapy* (12 Nov. 2009), incorporated herein by reference.

[0289] Alternately, one may administer the pharmaceutical composition in a local rather than systemic manner, for example, via injection of the pharmaceutical composition directly into the brain of a patient and even more directly into the tumor cells themselves.

[0290] Pharmaceutical compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

[0291] Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

[0292] For injection, the active ingredients of the pharmaceutical composition may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

[0293] For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

[0294] For administration by nasal inhalation, the active ingredients for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in a dispenser may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

[0295] The pharmaceutical composition described herein may be formulated for parenteral administration, e.g., by

bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative. The compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

[0296] Pharmaceutical compositions for parenteral administration include aqueous solutions of the active preparation in water-soluble form. Additionally, suspensions of the active ingredients may be prepared as appropriate oily or water based injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the active ingredients to allow for the preparation of highly concentrated solutions.

[0297] Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water based solution, before use.

[0298] The pharmaceutical composition of the present invention may also be formulated in rectal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.

[0299] Pharmaceutical compositions suitable for use in context of the present invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount means an amount of active ingredients (i.e. viral particles) effective to prevent, alleviate or ameliorate symptoms of a disorder (e.g., glioblastoma) or prolong the survival of the subject being treated.

[0300] Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

[0301] For any preparation used in the methods of the invention, the therapeutically effective amount or dose can be estimated initially from in vitro and cell culture assays. For example, a dose can be formulated in animal models to achieve a desired concentration or titer. Such information can be used to more accurately determine useful doses in humans.

[0302] Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures in vitro, in cell cultures or experimental animals. The data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl, et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p. 1).

[0303] Dosage amount and interval may be adjusted individually to provide brain levels of the active ingredient are sufficient to induce or suppress the biological effect (minimal effective concentration, MEC). The MEC will vary for each preparation, but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual

characteristics and route of administration. Detection assays can be used to determine plasma concentrations.

[0304] Depending on the severity and responsiveness of the condition to be treated, dosing can be of a single or a plurality of administrations, with course of treatment lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved.

[0305] The amount of a composition to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.

[0306] The therapeutically effective amount of the active ingredient can be formulated in a unit dose. As used herein "unit dose" refers to a physically discrete unit containing a predetermined quantity of an active material calculated to individually or collectively produce a desired effect such as an anti-cancer effect. A single unit dose or a plurality of unit doses can be used to provide the desired effect, such as an anti-cancer therapeutic effect.

[0307] According to one embodiment, about 10^3 to about 10^{16} virus particles are administered to the subject.

[0308] According to another embodiment, about 10^5 to about 10^{13} virus particles are administered to the subject.

[0309] According to one embodiment, about 10^7 to about 10^{12} virus particles are administered to the subject.

[0310] According to one embodiment, about 1×10^{12} to about 5×10^{12} virus particles are administered to the subject.

[0311] According to one embodiment, about 1×10^{13} to about 5×10^{13} virus particles are administered to the subject.

[0312] According to yet another embodiment the subject is administered intravenously with 1×10^{12} - 1×10^{13} viral particles of SEQ ID NO: 9. or SEQ ID NO: 10.

[0313] According to yet another embodiment the subject is administered intravenously with at least two doses of 1×10^{12} - 1×10^{13} viral particles of SEQ ID NO: 9. or SEQ ID NO: 10. According to yet another embodiment the subject is administered intravenously with at least three or more doses of 1×10^{12} - 1×10^{13} viral particles of SEQ ID NO: 9. or SEQ ID NO: 10. In a particular embodiment, the at least two doses are administered at least about 1 day, at least about 3 days, at least about 5 days, at least about 7 days, at least about 2 weeks, at least about 3 weeks, at least about 4 weeks, at least about 2 months, at least about 6 months, at least about 9 months, at least about 1 year, at least about 1.25 years, at least about 1.5 years, at least about 1.75 years, at least about 2 years, at least about 2.5 years, at least about 3 years or more apart.

[0314] Compositions of the present invention may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert. Compositions comprising a preparation of the invention formulated in a compatible pharma-

ceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition, as is further detailed above.

[0315] The vectors of the present invention may be administered with additional ingredients which may improve the uptake of the nucleic acid construct by the cells, expression of the chimeric polypeptide by the nucleic acid construct in the cells, or the activity of the expressed chimeric polypeptide.

[0316] For example, the uptake of adenoviral vectors into EC cells can be enhanced by treating the vectors with engineered antibodies or small peptides. Such "adenobody" treatment, was shown effective in directing adenovirus constructs to EGF receptors on cells (Watkins et al 1997, Gene Therapy 4:1004-1012). In addition, Nicklin et al have shown that a small peptide, isolated via phage display, increased specificity and efficiency of vectors in endothelial cells and decreased the expression in liver cells in culture (Nicklin et al 2000, Circulation 102:231-237). In a recent study, an FGF retargeted adenoviral vector reduced the toxicity of tk in mice (Printz et al 2000, Human Gene Therapy 11:191-204).

[0317] Low dose radiation has been shown to cause breaks in DNA strands primarily in the G2/M phase, cell membrane damage enhancing the bystander effect, and thus may potentiate other cytotoxic and anti-neoplastic therapies, when administered in combination. Vascular endothelial cells may be particularly suitable to such combination, or adjunct, therapies, since it has been demonstrated that low dose radiation specifically targets the apoptotic system of the microvascular endothelial cells (Kolesnick et al., Oncogene 2003; 22:5897-906). Angiostatin has been shown to potentiate the therapeutic effects of low dose radiation (Gorski et al. Can Res 1998; 58:5686-89). However, the effects of radiation are still poorly understood, since irradiation has also been shown to increase pro-angiogenic "tissue repair factors" (Itasaka et al., Am Assoc Canc Res, 2003; abstract 115). Similarly, certain chemotherapeutic agents have been shown to activate specific cytotoxic and apoptotic pathways [doxorubicin, cisplatin and mitomycin C induce accumulation of Fas receptor, FADD, and other proapoptotic signals in the FADD/MORT-1 pathway (Micheau et al., BBRC 1999 256:603-07)].

[0318] For example International Application WO/2008/132729 teaches combined doxorubicin and AdPPE-1 (3x)-Fas-c chimera construct administration in endothelial cells (BAEC). Thus, the viral vectors and the pharmaceutical compositions comprising same of the present invention can be used to treat malignant gliomas alone or in combination with one or more other established or experimental therapeutic regimen for such disorders. Therapeutic regimen for treatment of malignant gliomas suitable for combination with the viral vectors of the present invention include, but are not limited to chemotherapy, radiotherapy, phototherapy and photodynamic therapy, surgery, nutritional therapy, ablative therapy, combined radiotherapy and chemotherapy, brachiotherapy, proton beam therapy, immunotherapy, cellular therapy and photon beam radiosurgical therapy.

[0319] Anti-cancer drugs that can be co-administered with the compounds of the invention include, but are not limited to Acivicin; Aclarubicin; Acodazole Hydrochloride; Acronine; Adriamycin; Adozelesin; Aldesleukin; Altretamine; Ambo-mycin; Ametantrone Acetate; Aminoglutethimide; Amsacrine; Anastrozole; Anthramycin; Asparaginase; Asperlin; Azacitidine; Azetepa; Azotomycin; Batimastat; Benzodepa; Bicalutamide; Bisantrene Hydrochloride; Bisnafide Dimesylate; Bizelesin; Bleomycin Sulfate; Brequinar Sodium;

Bropiramine; Busulfan; Cactinomycin; Calusterone; Caraceamide; Carbetimer; Carboplatin; Carmustine; Carubicin Hydrochloride; Carzelesin; Cedefingol; Chlorambucil; Circlemycin; Cisplatin; Cladribine; Crisnatol Mesylate; Cyclophosphamide; Cytarabine; Dacarbazine; Dactinomycin; Daunorubicin Hydrochloride; Decitabine; Dexormaplatin; Dezaguanine; Dezaguanine Mesylate; Diaziquone; Docetaxel; Doxorubicin; Doxorubicin Hydrochloride; Droxifene; Droxifene Citrate; Dromostanolone Propionate; Duazomycin; Edatexate; Eflornithine Hydrochloride; Elsamitricin; Enloplatin; Enpromate; Epiropidine; Epirubicin Hydrochloride; Erbulozole; Erorubicin Hydrochloride; Estramustine; Estramustine Phosphate Sodium; Etanidazole; Etoposide; Etoposide Phosphate; Etoprine; Fadrozole Hydrochloride; Fazarabine; Fenretinide; Floxuridine; Fludarabine Phosphate; Fluorouracil; Flurocitabine; Fosquidone; Fostriecin Sodium; Gemcitabine; Gemcitabine Hydrochloride; Hydroxyurea; Idarubicin Hydrochloride; Ifosfamide; Ilmofofosine; Interferon Alfa-2a; Interferon Alfa-2b; Interferon Alfa-n1; Interferon Alfa-n3; Interferon Beta-1 a; Interferon Gamma-1 b; Iproplatin; Irinotecan Hydrochloride; Lanreotide Acetate; Letrozole; Leuprolide Acetate; Liarozole Hydrochloride; Lometrexol Sodium; Lomustine; Losoxantrone Hydrochloride; Masoprocol; Maytansine; Mechlorethamine Hydrochloride; Megestrol Acetate; Melengestrol Acetate; Melphalan; Menogaril; Mercaptopurine; Methotrexate; Methotrexate Sodium; Metoprine; Meturedopa; Mitindomide; Mitocarcin; Mitocromin; Mitogillin; Mitomalcin; Mitomycin; Mitosper; Mitotane; Mitoxantrone Hydrochloride; Mycophenolic Acid; Nocodazole; Nogalamycin; Ormaplatin; Oxisuran; Paclitaxel; Pegaspargase; Peliomycin; Pentamustine; Peplomycin Sulfate; Perfosfamide; Pipobroman; Pipsulfan; Piroxantrone Hydrochloride; Plicamycin; Plomestane; Porfimer Sodium; Porfiro-mycin; Prednimustine; Procarbazine Hydrochloride; Puro-mycin; Puromycin Hydrochloride; Pyrazofurin; Riboprine; Rogletimide; Safingol; Safingol Hydrochloride; Semustine; Simtrazene; Sparfosate Sodium; Sparsomycin; Spirogermanium Hydrochloride; Spiromustine; Spiroplatin; Streptonigrin; Streptozocin; Sulofenur; Talisomycin; Taxol; Tecogalan Sodium; Tegafur; Teloxantrone Hydrochloride; Temopofin; Teniposide; Teroxirone; Testolactone; Thiamiprine; Thioguanine; Thiotepa; Tiazofuirin; Tirapazamine; Topotecan Hydrochloride; Toremfene Citrate; Trestolone Acetate; Triciribine Phosphate; Trimetrexate; Temozolomide (Temo-dar™); Bevacizumab, Dorafinib, Sorafenib (Nexavar™), Sunitinib (Sutent™), Vandetanib (ZD6474; Zactima™), Pazopanib (GW786034), and Vatalanib (PTK787), Trimetrexate Glucuronate; Triptorelin; Tubulozole Hydrochloride; Uracil Mustard; Uredepia; Vapreotide; Verteporfin; Vinblastine Sulfate; Vincristine Sulfate; Vindesine; Vindesine Sulfate; Vinepidine Sulfate; Vinyglycinate Sulfate; Vinleurosine Sulfate; Vinorelbine Tartrate; Vinrosidine Sulfate; Vinzolidine Sulfate; Vorozole; Zeni-platin; Zinostatin; Zorubicin Hydrochloride. Additional antineoplastic agents include those disclosed in Chapter 52, Antineoplastic Agents (Paul Calabresi and Bruce A. Chabner), and the introduction thereto, 1202-1263, of Goodman and Gilman's "The Pharmacological Basis of Therapeutics", Eighth Edition, 1990, McGraw-Hill, Inc. (Health Professions Division).

[0320] The viral vectors of the present invention may also be administered with an agent that enhances expression of transgenes in adenoviral-mediated transient expression. For example International Application WO/2008/132729 teaches

administration of a corticosteroid (e.g. dexamethasone and/or N-Acetyl Cysteine (NAC) prior to AdPPE-1 (3x)-Fas-c chimera construct administration.

[0321] In addition, the viral vectors of the present invention may also be administered with an agent that brings about transient immunosuppression, such as for example deoxyspergualin (DSG) or cyclophosphamide (see for example Smith et al., Gene Ther. 1996 June; 3(6):496-502) in order to allow for repetitive dosing.

[0322] It is expected that during the life of a patent maturing from this application many relevant chemotherapeutic agents will be developed and the scope of the term chemotherapeutic agent is intended to include all such new technologies a priori.

[0323] As used herein the term "about" refers to $\pm 10\%$.

[0324] The terms "comprises", "comprising", "includes", "including", "having" and their conjugates mean "including but not limited to".

[0325] The term "consisting of means" "including and limited to".

[0326] The term "consisting essentially of" means that the composition, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.

[0327] As used herein, the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" may include a plurality of compounds, including mixtures thereof.

[0328] Throughout this application, various embodiments of this invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.

[0329] Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases "ranging/ranges between" a first indicate number and a second indicate number and "ranging/ranges from" a first indicate number "to" a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.

[0330] As used herein the term "method" refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.

[0331] As used herein, the term "treating" includes abrogating, substantially inhibiting, slowing or reversing the progression of a condition, substantially ameliorating clinical or

aesthetical symptoms of a condition or substantially preventing the appearance of clinical or aesthetical symptoms of a condition.

[0332] It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.

[0333] Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.

EXAMPLES

[0334] Reference is now made to the following examples, which together with the above descriptions illustrate some embodiments of the invention in a non limiting fashion.

[0335] Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, "Molecular Cloning: A laboratory Manual" Sambrook et al., (1989); "Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Md. (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988); Watson et al., "Recombinant DNA", Scientific American Books, New York; Birren et al. (eds) "Genome Analysis: A Laboratory Manual Series", Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; "Cell Biology: A Laboratory Handbook", Volumes I-III Cellis, J. E., ed. (1994); "Culture of Animal Cells—A Manual of Basic Technique" by Freshney, Wiley-Liss, N.Y. (1994), Third Edition; "Current Protocols in Immunology" Volumes Coligan J. E., ed. (1994); Stites et al. (eds), "Basic and Clinical Immunology" (8th Edition), Appleton & Lange, Norwalk, Conn. (1994); Mishell and Shiigi (eds), "Selected Methods in Cellular Immunology", W. H. Freeman and Co., New York (1980); available immunoassays are extensively described in the patent and scientific literature, see, for example, U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521; "Oligonucleotide Synthesis" Gait, M. J., ed. (1984); "Nucleic Acid Hybridization" Hames, B. D., and Higgins S. J., eds. (1985); "Transcription and Translation" Hames, B. D., and Higgins S. J., eds. (1984); "Animal Cell Culture" Freshney, R. I., ed. (1986); "Immobilized Cells and Enzymes" IRL Press, (1986); "A Practical Guide to Molecular Cloning" Perbal, B., (1984) and "Methods in Enzymology" Vol. 1-317, Academic Press; "PCR Protocols: A Guide To Methods And Applications", Academic Press, San Diego, Calif. (1990); Marshak et al., "Strategies for Protein Purification and Characterization—A Laboratory Course Manual" CSHL Press (1996); all of which are incorporated by refer-

ence as if fully set forth herein. Other general references are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the convenience of the reader. All the information contained therein is incorporated herein by reference.

Example 1

Effect of VB-111 in an Animal Model of Glioblastoma

[0336] Materials and Methods

[0337] Construction and Cloning of the Viral Vector:

[0338] The vector was constructed using a backbone containing most of the genome of adenovirus type 5, as well as partial homology to an adaptor plasmid, which enables recombination.

[0339] The E1 early transcriptional unit was deleted from the backbone plasmid, and further modified by deleting the pWE25 and the Amp resistance selection marker site.

[0340] The adaptor plasmid, containing sequences of the Ad5, CMV promoter, MCS, and SV40 polyA was modified to delete deleting the CMV promoter, and the PPE-1 promoter and Fas-c fragment were inserted by restriction digestion.

[0341] The modified PPE-1 promoter (PPE-1-3X, SEQ ID NO: 12) and the Fas-chimera transgene (Fas-c, SEQ ID NO: 4) were utilized for construction of the adenoviral vector. The PPE-1-(3X)-Fas-c element (2115 bp) was constructed from the PPE-1-(3X)-luc element. This element contains the 1.4 kb of the murine preproendothelin PPE-1-(3X) promoter, the Luciferase gene, the SV40 polyA site and the first intron of the murine ET-1 gene, originated from the pEL8 plasmid (8848 bp) used by Harats et al (Harats D. et al., JCI, 1995). The PPE-3-Luc cassette was extracted from the pEL8 plasmid using the BamHI restriction enzyme. The Luciferase gene was substituted by the Fas-c gene [composed of the extra cellular and intra membranal domains of the human TNF-R1 (Tumor Necrosis Factor Receptor 1, SEQ ID NO: 2) and of the Fas (p55) intracellular domain (SEQ ID NO: 3) (Boldin et al. JBC, 1995)] to obtain the PPE-1-3x-Fas-c cassette.

[0342] PPE-1(3x)-Fas-c Plasmid—The cassette was further introduced into the backbone plasmid by restriction digestion, resulting with the PPE-1(3x)-Fas-c plasmid.

[0343] Adaptor-PPE-1(3x)-Fas-c Plasmid—The PPE-1-3x-Fas-c element was extracted from the first generation construct PPE-1-3x-Fas-c plasmid, and was amplified with designated PCR primers introducing SnaBI and EcoRI restriction sites at the 5'-and-3'-end respectively. These sites were used to clone the PPE-Fas-c fragment into the adaptor plasmid digested with SnaBI and EcoRI, resulting in the adaptor-PPE-1-3x-Fas-c used for transfection of the host cells (for example, PER.C6 cells).

[0344] Xenografts:

[0345] 10⁶ U87 human glioma tumor cells expressing a biofluorescent/bioluminescent protein (luciferase) were implanted intracranially in the striatum of athymic nude rats (NxGen BioSciences). Animals were anesthetized with isoflurane prior to implantation. Briefly, glioma tumor cells expressing luciferase were implanted intracranially in the striatum of athymic nude rats (NxGen BioSciences). Animals were anesthetized with isoflurane prior to implantation and placed secured on a Just for Mice Stereotaxic (Stoelting) apparatus. A 1 cm incision was made in the scalp and the bregma identified. A small burr hole was made in the cranium using a mounted Micromotor drill (Stoelting) at the identified

position (1 mm forward and 4 mm lateral of the bregma). 1×10^6 cells in a volume of 5 ul were injected into the caudate over 5 minutes using a Quintessential Stereotaxic Injector (Stoelting) containing a 10 ul Hamilton syringe mounted to the stereotaxic device to assure appropriate placement. Animals were imaged following isoflurane sedation using an IVIS chemiluminescence system. The fluorescence/bioluminescence of these tumors are typically detectable within 7-10 days due to rapid growth and high expression of the marker. An alternative imaging modality, i.e. MRI, was also utilized to assist with tumor visualization. Animals received chemical anesthesia for MRI imaging. Once tumor establishment and growth was detected (variable depending on the rate of growth for the respective line), rats were treated with VB-111. The total dose was 10^{11} vp in a volume of 100 ul. Control groups received vehicle only. Animals were monitored for tumor growth or response through non-invasive imaging of fluorescence/luminescence—see FIG. 1 for a typical treatment and monitoring regimen.

[0346] Experimental Protocol:

[0347] Two types of tumor growth experiments were performed, tumor growth inhibition (TGI) and tumor growth delay (TGD). The TGI experiment was terminated when the animals showed clinical signs of tumor development i.e. become dull, listless, or moribund, usually prior to 4 weeks post-implantation, as median survival of 28-29 days has been typically observed in prior studies. Upon termination, all rats were weighed, sacrificed, and their tumors excised. For a TGD experiment, animals were sacrificed on an individual basis and tumor-related parameters (e.g. size) were measured. The average day of sacrifice was determined for all groups, and the tumor growth delay (TGD) for each treatment group compared to the control group was calculated.

[0348] MRI:

[0349] Magnetic resonance imaging has shown to be capable of demonstrating early changes within the tumor vasculature without any invasive measures. It is possible to generate maps of blood volume and blood flow, vascular permeability, white matter tracks, and apparent diffusion coefficient. These parameters offer clinically relevant physiological information that could help to characterize, stage tumor growth, and evaluate treatment efficacy. MRI was performed on a Bruker 7 Tesla scanner. Blood flow and blood volume was measured using dynamic contrast enhanced imaging technique following a bolus of gadopentetate-dimeglumine (GdDTPA). White matter tracks and apparent diffusion coefficient was measured using diffusion tensor imaging. Vascular permeability was measured using T1-weighted MRI obtained prior to and following contrast (Gd-DTPA) injection. For dynamic contrast enhanced MRI, single-shot gradient echo planar imaging (EPI) was used, resolution at $0.27 \times 0.27 \times 0.5$ mm, 5 slices (no gap), matrix= 96×96 , field of view= 25.6×25.6 mm, repetition time TR=0.5 s, echo time TE=20 ms. For diffusion tensor imaging, single-shot spin-echo echo-planar imaging was used, resolution be $0.27 \times 0.27 \times 0.5$ mm, 15 slices (no gap), matrix= 96×96 , field of view= 25.6×25.6 mm, repetition time TR=2 s, echo time TE=40 ms, b value=0 s/mm², and 6 diffusion direction of b=1100 s/mm². For T1-weighted MRI, conventional acquisition was used, resolution $0.27 \times 0.27 \times 0.5$ mm, 15 slices (no gap), matrix= 96×96 , field of view= 25.6×25.6 mm, repetition time TR=0.5 s, echo time TE=20 ms. The number of slices analyzed adequately covered the entire tumor region and roughly cover the entire cerebrum.

[0350] The maps described above were calculated using standard software. For permeability maps, the maps were processed using codes in Matlab to obtain maps of Ktrans (corresponding roughly to wash-in rates of the contrast agent). Ktrans can be influenced by flow, or by permeability, or both. In high-flow organs such as the brain, flow limitations are not usually a concern, but the blood-brain barrier severely limits permeability unless it is disrupted by disease. Even in such a state, Ktrans does not fully correspond to permeability, but it is related rather to the permeability*surface area product of the capillary bed (in nonflow-limited situations).

[0351] Histopathology:

[0352] To further characterize changes at the microscopic level, animals were sacrificed by cardiac puncture, followed by intracardiac saline and formalin irrigation. Necropsy was performed, and brains underwent standard H&E processing. The number of vessels per medium power field were counted.

[0353] Results

[0354] As illustrated in FIG. 2, animal death began at approximately day 32. The median survival for the control group was 39.25 (+/-3.8) days and for the treatment group was 45.8 days.

[0355] Luciferase Activity:

[0356] Luciferase activity was followed by ip injection of luciferin and optical imaging on a Xenogen system. The region of interest was generated automatically without manipulation and total photons recorded. As illustrated in FIG. 3, a clear separation in activity was observed at day 33 with a mean (SD) in the control group of $9.7 (2.9) \times 10^6$ versus $5.3 (6.2) \times 10^5$ in the treated group.

[0357] MRI:

[0358] As illustrated in FIG. 4, mean of the maximum diameters of tumors in the VB111 treated group was smaller than those for controls.

Example 2

Effect of VB-111 in Glioblastoma Patients

[0359] Treatment Plan:

[0360] VB-111 will be administered as a single intravenous infusion of 1×10^{12} or 3×10^{12} Dose.

[0361] Study consists of 2 cohorts.

[0362] Cohort 1a: 3-6 subjects, safety (1×10^{12} VPs);

[0363] Cohort 1b: 3-6 subjects, safety (3×10^{12} VPs);

[0364] Cohort 2: 23-26 subjects, efficacy & safety (3×10^{12} VPs)

[0365] Cohort 1a & Cohort 1b: Study subjects will be enrolled sequentially. The first subject of each cohort will be treated and observed for 14 days; if no dose-limiting toxicities (DLT) are observed, then another two subjects will be recruited to that cohort. All six subjects of cohort 1 need to be observed for a minimum of 14 days and show no DLT for the start of the next cohort. If a DLT is observed in one patient in a specific dosing cohort, three additional subjects will be accrued for the same dosing cohort, and safety will be reassessed. If DLT is confirmed, i.e. two out of six subjects experience a DLT, then the study will be discontinued. All subjects in cohorts 1a and 1b must be observed for a minimum of 28 days prior to commencing cohort 2.

[0366] The study will be conducted according to the Simon's 2 step method. A total of 29 subjects are anticipated to enroll at the 3×10^{12} VP dose level (3-6 from cohort 2 and 23-26 in cohort 3). Step one will include the first 10 patients at this dose level. A subject will be considered to have a

response if s/he has either 6 months progression free survival or at least a partial tumor response according to Rano criteria. An interim analysis will be performed after 10 patients from cohorts 2 and 3 have completed the study. If 2 or more responses occur in the step 1 subjects, step 2 will commence, enrolling an additional 19 subjects.

[0367] The following study stopping rule for halting the study will be applied:

[0368] A) If 3 out of 6 (or 5 out of 9 or 6 out of 12) subjects in the cohort 1a & 1b experience drug related DLT.

[0369] B) If 2 out of the subjects in cohort 1a experience a DLT.

[0370] C) If ANY death occurs within two weeks after the product is given, except death due to disease progression or clearly unrelated to study drug. Enrollment will be temporarily suspended for an ad hoc, emergency IDMC meeting to review the case and make a recommendation if enrollment can be reinstated.

[0371] When safety end point is achieved for cohorts 1a and 1b (day 28), eligible subjects will be enrolled into the study and commence cohort 2. It is expected that 26 GBM subjects will be enrolled into cohort 2 for additional safety and efficacy endpoints (or 23 patients if 6 were enrolled in cohort 2).

[0372] One dose of VB 111 (1×10^{12} , 3×10^{12} or 1×10^{13} VPs) administered within 3 weeks after the visit. Subjects will return to the clinic for follow up visits at days 4, 7, 14 and 28 and on monthly schedule on days 56, 84, 112, 140 and 168 if no disease progression has occurred prior to the visit.

[0373] On days 7, 14, 28, 56, 112 and 168, subjects will be assessed for response using contrast and non-contrast brain magnetic resonance imaging (MRI) with assessment based on the RANO criteria.

[0374] The post study follow up period will include telephone contacts every two months after day 168, early termination, or disease progression (whichever occurs earlier) to follow up on survival. Follow up will continue until patient expires. The study duration is 7 months (6 months post dose), thereafter the subjects will be followed by telephone for survival data every two months. Surveillance MRIs will be performed every 2 months until 1 year, and then every 3 months until 2 years post dosing (or until progression).

[0375] Population:

[0376] Up to 35 eligible subjects (cohort 1 & cohort 2) with relapsed GBM.

[0377] Main Inclusion Criteria:

[0378] 1. Ability to understand and the willingness to sign a written informed consent document.

[0379] 2. Subjects ≥ 18 years of age

[0380] 3. Subjects must have histologically confirmed diagnosis of primary malignant glioma (glioblastoma multiforme, gliosarcoma or anaplastic astrocytoma, or anaplastic oligodendroglioma). Subjects with recurrent disease whose diagnostic pathology confirmed malignant glioma (glioblastoma multiforme, gliosarcoma or anaplastic astrocytoma, or anaplastic oligodendroglioma) will not need re-biopsy.

[0381] 4. Evidence of measurable recurrent or residual primary CNS neoplasm on contrast-enhanced MRI, unless medically contraindicated (CT scan will then be used).

[0382] 5. Measurable disease by RANO criteria.

[0383] 6. Avastin and anti-angiogenic (TKIs such as sunitinib or sorafenib) naive subjects.

[0384] 7. Disease progression or recurrence following standard of care treatment with radiotherapy and temozolomide.

[0385] 8. An interval of at least 4 weeks between prior surgical resection and study enrolment.

[0386] 9. Completed radiotherapy ≥ 90 days before study starts.

[0387] 10. An interval of at least 12 weeks between prior radiotherapy or at least 4 weeks from prior chemotherapy, and enrolment on this protocol.

[0388] 11. Recovered to Grade 1 or less from the toxic effects of any earlier intervention.

[0389] 12. Karnofsky performance status a 60%.

[0390] 13. Adequate renal, liver, and bone marrow function according to the following criteria:

[0391] Absolute neutrophil count ≥ 1500 /mcL

[0392] Platelets $\geq 125\ 000$ /mcL

[0393] Total bilirubin within upper limit of normal (ULN)

[0394] Aspartate aminotransferase (AST) $\leq 2.5 \times$ institutional ULN

[0395] Creatinine within normal limits or creatinine clearance ≥ 50 mL/min for patients with creatinine levels above normal limits.

[0396] PT, PTT greater than 80% of the lower normal limits.

[0397] 13. Subjects must be treated with corticosteroids on day 0. Subjects will be on a stable dose for 1 week prior to entry, and is not anticipated to require increase in steroid dose throughout the study.

[0398] 14. No evidence of haemorrhage on the baseline MRI or CT scan.

[0399] 15. Males and Females of childbearing potential must utilize, throughout the course of the trial a standard contraception method.

[0400] Cohort 1a and 1b Additional Eligibility Criteria: Subjects without Major Mass Effect of Tumor.

[0401] Main Exclusion Criteria:

[0402] 1. Pregnant or breastfeeding subjects

[0403] 2. Co-medication that may interfere with study results; e.g. immuno-suppressive agents other than corticosteroids

[0404] 3. Active Infection.

[0405] 4. Greater than 3 prior recurrences.

[0406] 5. Evidence of CNS haemorrhage CTCAE on baseline MRI or CT scan.

[0407] 6. Requires therapeutic anti-coagulation.

[0408] 7. Prior anti-angiogenic therapy including VEGF-sequestering agents (e.g. bevacizumab, aflibercept) or VEGF inhibitors (e.g. cedirinib, pazopanib, sunitinib, sorafenib).

[0409] 8. Prior stereotactic radiotherapy.

[0410] 9. Known active secondary malignancy.

[0411] 10. Expected to have surgery during study period.

[0412] 11. Subjects, who suffered from an acute cardiac event within the last 12 months.

[0413] 12. Subjects with active vascular disease, either myocardial or peripheral

[0414] 13. Subjects with proliferative and/or vascular retinopathy

[0415] 14. Subjects with known liver disease (alcoholic, drug/toxin induced, genetic, or autoimmune).

[0416] 15. Subjects with known CNS metastatic disease (other than GBM).

[0417] 16. Subjects with known active second malignancy.

[0418] 17. Subjects testing positive to one of the following viruses: HIV, HBV and HCV

[0419] 18. Subjects that have undergone major surgery within the last 4 weeks before enrolment.

[0420] 19. Subjects may not have received any other investigational agent within 4 weeks before enrolment.

[0421] 20. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

[0422] Test Drug and Formulation:

[0423] VB-111 (SEQ ID NO: 9 or 10) is formulated as a sterile vector solution. The solution is supplied frozen (below -65° C.), in single use, plastic screw cap vials. Each vial contains 1.1 mL of vector solution at a viral titer of 1×10^{12} VP/ml. The vector solution should be thawed and maintained on ice during dilution and handling for a maximum of 3 hours.

[0424] Dosage and Administration:

[0425] Prior to infusion, the solution for injection should be brought to room temperature. Maximum time for drug in saline is 1 hour at room temperature. The vials should be opened in a biological safety cabinet and injected into 4 mL of normal saline for infusion for each 1 ml of drug. ie; for the 1×10^{12} viral particle (VP) dose 1 ml of drug+4 ml of saline, for the 3×10^{12} VP dose 3 ml of drug+12 ml of saline. A single infusion of approximately 5 mL/15 ml of diluted VB-111 should be administered 1 mL/minute.

[0426] Safety Evaluations:

[0427] Adverse events will be recorded on an ongoing basis and up to 2 months following the administration of the test drug. Adverse events will be assessed for seriousness, relatedness to study drug, and severity (according to CTCAE 4.0). Vital signs will be recorded at screening, prior to dosing, 30, 60 minutes, 4 and 6 hours after dosing and at all patient visits. A physical examination will be conducted at screening, days 14, 28, 56, 84, 112, 140, 168 and at the end of the study. A 12 lead ECG will be obtained at screening, prior to dosing and on days 28 and 168 (or ET). Safety laboratory assessment (blood

haematology and chemistry, urine analysis) will be conducted at screening, prior to dosing, and at all patient visits, starting from day 4 ± 1 to 168 ± 7 .

[0428] Distribution:

[0429] Blood and urine samples will be collected prior to dosing, at the end of the infusion, days 4, 7, 14, 28 and 56, for evaluation of levels of virus DNA (in whole blood and urine) and its transgene (in whole blood).

[0430] Tumor Response:

[0431] Tumor response will be assessed at screening, prior to dosing, days 14, 28, 56, 112, 140 and 168, and then every 2 months for 1 year and every 3 months for 2 years post dosing, using contrast and non-contrast brain magnetic resonance imaging (MRI) with assessment based on the RANO criteria, until progression of disease (local and central independent radiology review). For patients who do not progress or die, PFS will be censored at the time of initiation of alternative anticancer therapy, date of last radiologic assessment, or time of last contact.

[0432] Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.

[0433] All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 13

<210> SEQ ID NO 1

<211> LENGTH: 34350

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Empty Ad5 vector sequence without repeats

<400> SEQUENCE: 1

```

catcatcaat aatatacctt attttgatt gaagccaata tgataatgag ggggtggagt      60
ttgtgacgtg gcgcggggcg tgggaacggg gcgggtgacg tagtagtgtg gcggaagtgt      120
gatgttgcaa gtgtggcgga acacatgtaa gcgacggatg tggcaaaagt gacgtttttg      180
gtgtgcgccc gtgtcacacag gaagtgacaa ttttcgcgcg gttttaggcg gatgttgtag      240
taaatttggg cgtaaccgag taagatttgg ccattttcgc gggaaaactg aataagagga      300
agtgaaatct gaataatfff gtgttactca tagcgcgtaa tatttgtcta gggccgcggg      360
gactttgacc gtttactgtg agactcgcgc aggtgttttt ctcagggtgt ttccgcggtc      420
cgggtcaaaag ttggcgtttt attattatag tcagtagctc tcgagcatgc atctaggcgg      480

```

-continued

ccgcatggca gaaattcgcg aattcgctag cgттаacgga tcctctagac gagatccgaa	540
cttgtttatt gcagcttata atggttacaa ataaagcaat agcatcacia atttcacaaa	600
taaagcattt ttttcactgc attctagttg tggtttgtec aaactcatca atgtatctta	660
tcattgctag atctgtactg aaatgtgtgg gcgtggctta aggggtggaa agaatatata	720
aggtgggggt cttatgtagt tttgtatctg ttttgacgca gccgccgccc ccatgagcac	780
caactcgttt gatggaagca ttgtgagctc atatttgaca acgcgcatgc ccccatgggc	840
cgggggtgct cagaatgtga tgggtccag cattgatggt cggcccgtcc tgcccgcaaa	900
ctctactacc ttgacctacg agaccgtgtc tggaacgccc ttggagactg cagcctccgc	960
cgccgcttca gccgctgcag ccaccgcccg cgggattgtg actgactttg ctttctgag	1020
cccgcttgcg agcagtgtag cttccgctc atccgcccgc gatgacaagt tgacggctct	1080
tttggcacia ttggattctt tgaccggga acttaatgtc gtttctcagc agctgttggg	1140
ctcggccag caggtttctg ccctgaaggc ttctctcccet cccaatgccc tttaaaacat	1200
aaataaaaaa ccagactctg tttgatttg gatcaagcaa gtgtcttctg gtctttattt	1260
aggggttttg cgcgcgggtt agggccggga ccagcggctc cggtcgttga gggctcctgtg	1320
tattttttcc aggacgtggt aaaggtgact ctggatgttc agatacatgg gcataagccc	1380
gtctctgggg tggaggtagc accactgcag agcttcatgc tgcgggggtg tgtttagat	1440
gatccagtcg tagcaggagc gctgggctg gtgcctaaaa atgtcttca gtagcaagct	1500
gattgccagg gccagccctt tgggtgaagt gtttaciaag cggttaagct gggatgggtg	1560
catagctggg gatatgagat gcatcttggg ctgtattttt aggttggtca tgttcccagc	1620
catatccctc cggggattca tgttgtgcag aaccaccagc acagtgtatc cgggtgactt	1680
gggaaatttg tcatgtagct tagaaggaaa tgcgtggaag aacttgaga cgccttctg	1740
acctccaaga ttttccatgc attcgtccat aatgatggca atgggcccac gggcggcggc	1800
ctgggcgaag atatttctgg gatcaactaac gtcatagttg tgttccagga tgagatcgtc	1860
ataggccatt tttaciaaag cggggcggag ggtgccagac tgcggtataa tggttccatc	1920
cggcccaggg gcgtagttac cctcacagat ttaagggtgg gaaagaatat ataaggtggg	1980
ggctttatgt agttttgat ctgttttgca gcagccgccc cggccatgag caccaactcg	2040
ttgatggaa gcattgtgag ctcatatttg acaacgcgca tgccccatg gcccggggtg	2100
cgtcagaatg tgatgggctc cagcattgat ggtcgccccg tctgccccg aaactctact	2160
accttgacct acgagaccgt gtctggaacg ccgttggaga ctgcagcctc cgcgcggct	2220
tcagccgctg cagccaccgc ccgcccggatt gtgactgact ttgctttcct gagcccgtt	2280
gcaagcagtg cagcttcccc ttcacccgccc cgcgatgaca agttgacggc tcttttgga	2340
caattggatt ctttgaccgg ggaacttaat gtctgtttctc agcagctggt ggatctgcgc	2400
cagcaggttt ctgccctgaa ggcttctccc cctcccaatg cggtttaaaa cataaataaa	2460
aaaccagact ctgtttgat ttggatcaag caagtgtctt gctgtcttta tttaggggtt	2520
ttgcgcgcgc ggtaggcccc ggaccagcgg tctcggtcgt tgagggtcct gtgtattttt	2580
tcaggacgtt ggtaaaggtg actctggatg ttcagataca tgggcataag cccgtctctg	2640
gggtggaggt agcaccactg cagagcttca tgctgcgggg tgggtgtgta gatgatccag	2700
tcgtagcagg agcgcggggc gtggtgccta aaaatgtctt tcagtagcaa gctgattgcc	2760
aggggcaggc ccttggtgta agtgtttaca aagcgggtaa gctgggatgg gtgcatacgt	2820

-continued

ggggatatga gatgcatcct ggactgtatt tttaggttgg ctatgttccc agccatatcc	2880
ctccggggat tcatgtttgt cagaaccacc agcacagtgt atccggtgca cttgggaaat	2940
ttgtcatgta gcttagaagg aatgcgtgg aagaacttgg agacgccctt gtgacctcca	3000
agattttcca tgcattcgtc cataatgatg gcaatgggcc cacgggcggc ggcctgggcg	3060
aagatatttc tgggatcact aacgtcatag ttgtgttcca ggatgagatc gtcataggcc	3120
atttttacaa agcgcggggc gagggtgcca gactgcggtg taatggttcc atccggccca	3180
ggggcgtagt taccctcaca gatttgcatt tcccacgctt tgagttcaga tggggggatc	3240
atgtctacct gcggggcgat gaagaaaacg gtttccgggg taggggagat cagctgggaa	3300
gaaagcaggt tcctgagcag ctgcgactta ccgcagccgg tgggcccgta aatcacacct	3360
attaccggct gcaactggta gttaaagagag ctgcagctgc cgtcatcctt gagcaggggg	3420
gccacttcgt taagcatgtc cctgactcgc atgttttccc tgaccaaata cgcagaagg	3480
cgctcgcgc ccagcgatag cagttcttgc aaggaagcaa agtttttcaa cggtttgaga	3540
ccgtccgccc taggcatgct tttgagcgtt tgaccaagca gttccaggcg gtcccacagc	3600
tcggteacct gctctacgac atctcgtatc agcatatctc ctctgttctc gggttggggc	3660
ggctttcgtt gtacggcagt agtcgggtgt cgtccagacg ggccagggtc atgtctttcc	3720
acgggcgcag ggtcctcgtc agcgtagtct gggtcacggt gaaggggtgc gctccgggct	3780
gcgcgctggc cagggtgcgc ttgaggttgg tcctgctggt gctgaagcgc tgcggtctt	3840
cgccctcgc gtcggccagg tagcatttga ccattgggtc atagtccagc ccctccgagg	3900
cgtggccctt ggccgcagc ttgcccttgg aggaggcgc gcacgagggg cagtgcagac	3960
ttttgagggc gtagagcttg ggcgcgagaa ataccgatc cggggagtag gcatccgccc	4020
cgcaggcccc gcagacggtc tcgcattcca cgagccagggt gagctctggc cgttcggggt	4080
caaaaaacc gtttccccca tgccttttga tgcgtttctt acctctggtt tccatgagcc	4140
ggtgtccacg ctccggtgac aaaaggctgt ccgtgtcccc gtatacagac ttgagaggcc	4200
tgtctcgcag cgggttccg cggctcctct cgtatagaaa ctccggaccac tctgagacaa	4260
aggctcgcgt ccaggccagc acgaaggagg ctaagtggga ggggtagcgg tcgttgtcca	4320
ctagggggtc cactcgtctc aggggtgtgaa gacacatgct gccctcttcc gcatcaagga	4380
aggtgattgg tttgtaggtg tagggccagt gaccgggtgt tcctgaaggg gggctataaa	4440
aggggtggg ggcgcgttcc tcctcactct cttccgcac gctgtctgcg agggccagct	4500
gttgggggta gtactccctc tgaaaagcgg gcatgacttc tgcgctaaga ttgtcagttt	4560
ccaaaaaccg ggaggatttg atattcacct ggcccgcggg gatgcctttg aggggtggccg	4620
catccatctg gtcagaaaag acaatctttt tgttgtcaag cttggtggca aacgaccctg	4680
agagggcggt ggacagcaac ttggcgatgg agcgcagggt ttggtttttg tcgcatcgg	4740
cgcgctcctt ggccgcgatg tttagctgca cgtattcgcg cgcaacgcac cgccattcgg	4800
gaaagacggt ggtgcgctcg tcgggcacca ggtgcacgcg ccaaccgagg ttgtgcaggg	4860
tgacaaggtc aacgctgggt gtaacctctc cgcgtaggcg ctctgtggtc cagcagaggc	4920
ggccgccctt gcgcgagcag aatggcggta gggggtctag ctgcgtctcg tccggggggg	4980
ctgcgtccac ggtaaagacc ccgggcagca ggcgcgctc gaagtagtct atcttgcac	5040
cttgaagtc tagcgcctgc tgccatgcgc gggcggaag cgcgcgctc tatgggttga	5100

-continued

gtgggggacc	ccatggcatg	gggtgggtga	gcgcgaggc	gtacatgccg	caaatgtcgt	5160
aaacgtagag	gggctctctg	agtattccaa	gatatgtagg	gtagcatctt	ccaccgcgga	5220
tgctggcgcg	cacgtaatcg	tatagtctcg	gcgagggagc	gaggaggtcg	ggaccgaggt	5280
tgctacgggc	gggctgctct	gctcgggaaga	ctatctgcct	gaagatggca	tgtgagttgg	5340
atgatatggt	tggacgctgg	aagacgttga	agctggcgtc	tgtgagacct	accgcgtcac	5400
gcacgaagga	ggcgtaggag	tcgcgagct	tgttgaccag	ctcggcggtg	acctgcacgt	5460
ctagggcgca	gtagtccagg	gtttccttga	tgatgtcata	cttatcctgt	cccttttttt	5520
tccacagctc	gcggttgagg	acaaactctt	cgcggtcttt	ccagtaactct	tggatcggaa	5580
accgctcggc	ctccgaacgg	taagagccta	gcattgtaga	ctggttgacg	gcctggtagg	5640
cgcagcatcc	cttttctacg	ggtagcgcgt	atgcctgcgc	ggccttcgag	agcgaggtgt	5700
gggtgagcgc	aaaggtgtcc	ctgaccatga	ctttgaggta	ctggtatttg	aagtcagtgt	5760
cgctgcaccc	gcctctctcc	cagagcaaaa	agtcctgcgc	ctttttggaa	cgcggatttg	5820
gcagggcgaa	ggtgacatcg	ttgaagagta	tctttcccgc	gcgaggcata	aagttgcgtg	5880
tgatgcggaa	gggtcccggc	acctcggaac	ggttgtaaat	tacctgggcg	gcgagcacga	5940
tctcgtcaaa	gcccgtgatg	ttgtggccca	caatgtaaag	ttccaagaag	cgcgggatgc	6000
ccttgatgga	aggcaatttt	ttaagttcct	cgtaggtgag	ctcttcaggg	gagctgagcc	6060
cgtgctctga	aagggcccag	tctgcaagat	gagggttgga	agcgacgaat	gagctccaca	6120
ggtcacgggc	cattagcatt	tgcaggtggt	cgcgaaaggt	cctaaactgg	cgacctatgg	6180
ccattttttc	tggggtgatg	cagtagaagg	taagcgggtc	ttgttcccag	cggtcccac	6240
caaggttcgc	ggctaggtct	cgcgcggcag	tcaactagagg	ctcatctccg	ccgaacttca	6300
tgaccagcat	gaagggcacg	agctgcttcc	caaaggcccc	catccaagta	taggtctcta	6360
catcgtaggt	gacaaagaga	cgtcgggtgc	gaggatgcga	gccgatcggg	aagaactgga	6420
tctcccgcc	ccaattggag	gagtggtat	tgatgtggtg	aaagtagaag	tccctgcgac	6480
gggcccgaaca	ctcgtgctgg	cttttgtaaa	aacgtgcgca	gtactggcag	cggtgcacgg	6540
gctgtacatc	ctgcacgagg	ttgacctgac	gaccgcgcac	aaggaagcag	agtgggaatt	6600
tgagcccctc	gcctggcggg	tttggtggtg	ggtcttctac	tccggctgct	tgtccttgac	6660
cgtctggctg	ctcaggggga	gttacggtgg	atcggaccac	cacgccgcgc	gagccc aaag	6720
tccagatgtc	cgcgcgcggc	ggtcggagct	tgatgacaac	atcgcgcaga	tgggagctgt	6780
ccatggtctg	gagctcccgc	ggcgtcaggt	caggcgggag	ctcctgcagg	tttacctcgc	6840
atagacgggt	cagggcgcgg	gctagatcca	ggtgatacct	aatttccagg	ggctggttgg	6900
tggcgcgcgc	gatggcttgc	aagagggcgc	atccccgcgg	cgcgactacg	gtaccgcgcg	6960
gcgggcgggtg	ggccgcgggg	gtgtccttgg	atgatgcac	taaaagcggg	gacgcgggcg	7020
agcccccgga	ggtagggggg	gctccggacc	cgcggggaga	gggggcaggg	gcacgtcggc	7080
gccgcgcgcg	ggcaggagct	ggtgctgcgc	gcgtaggttg	ctggcgaacg	cgacgacgcg	7140
gcggttgatc	tccatgaact	ggcgcctctg	cgtgaagacg	acgggcccgg	tgagcttgaa	7200
cctgaaagag	agttcgcag	aatcaatttc	ggtgtcgttg	acggcggcct	ggcgcaaaat	7260
ctcctgcacg	tctcctgagt	tgtcttgata	ggcgatctcg	gccatgaact	gctcgtatct	7320
ttcctcctgg	agatctccgc	gtccggtctg	ctccacgggtg	gcggcgaggt	cgttggaat	7380
gcgggccatg	agctgcgaga	aggcgttgag	gocctcctcg	ttccagacgc	ggctgtagac	7440

-continued

cacgccccct	tgggcatcgc	gggcgcgcac	gaccacctgc	gcgagattga	gctccacgtg	7500
ccgggcgaag	acggcgtagt	ttcgcaggcg	ctgaaagagg	tagttgaggg	tggtggcggt	7560
gtgttctgce	acgaagaagt	acataacca	gcgtcgcaac	gtggattcgt	tgatatcccc	7620
caaggcctca	aggcgctcca	tggcctcgta	gaagtccacg	gcgaagtga	aaaactggga	7680
gttgcgcgcc	gacacggtta	actcctcctc	cagaagacgg	atgagctcgg	cgacagtgtc	7740
gcgcacctcg	cgctcaaagg	ctacaggggc	ctcttcttct	tcttcaatct	cctcttccat	7800
aagggcctcc	ccttcttctt	cttctggcgg	cggtggggga	ggggggacac	ggcggcgacg	7860
acggcgccac	gggaggcggg	cgacaaagcg	ctcgatcatc	tccccgcggc	gacggcgcat	7920
ggtctcgggtg	acggcgcggc	cgttctcgcg	ggggcgcgag	tggaagacgc	cgccccgtcat	7980
gtcccgggta	tgggttgggc	gggggctgcc	atgcggcagg	gatacggcgc	taacgatgca	8040
tctcaacaat	tgttgtgtag	gtactccgcc	gccgagggac	ctgagcgagt	ccgcatcgac	8100
cggatcggaa	aacctctcga	gaaaggcgtc	taaccagtca	cagtcgcaag	gtaggctgag	8160
cacggtggcg	ggcggcagcg	ggcggcggtc	ggggttggtt	ctggcggagg	tgctgctgat	8220
gatgtaatta	aagtaggcgg	tcttgagacg	gcggatggtc	gacagaagca	ccatgtcctt	8280
gggtccggcc	tgctgaaatg	gcaggcggtc	ggccatgccc	caggcttcgt	tttgacatcg	8340
gcgcaggctc	ttgtagtagt	cttgcatgag	cctttctacc	ggcacttctt	cttctccttc	8400
ctcttgctct	gcatctcttg	catctatcgc	tgcggcggcg	gcgagtttg	gccgtaggtg	8460
gcgccctctt	cctccccatg	gtgtgacccc	gaagcccctc	atcggtgaa	gcagggctag	8520
gtcggcgaca	acgcgctcgg	ctaataatgg	ctgctgcacc	tgcgtgaggg	tagactggaa	8580
gtcatccatg	tccacaaagc	ggtggtatgc	gcccggttg	atggtgtaag	tgcagttggc	8640
cataacggac	cagttaacgg	tctggtgacc	cggtcgcgag	agctcggtgt	acctgagacg	8700
cgagtaagcc	ctcgagtcaa	atacgtatgc	gttgcaagtc	cgcaccaggt	actggtatcc	8760
cacaaaaaag	tgcggcggcg	gctggcggta	gaggggccag	cgtagggtgg	ccggggctcc	8820
gggggcgaga	tcttccaaca	taaggcgatg	atatccgtag	atgtacctgg	acatccaggt	8880
gatgccggcg	gcggtggtgg	aggcgcgcgg	aaagtcgcgg	acgcggttcc	agatggtgcg	8940
cagcggcaaa	aagtgtctca	tggtcgggac	gctctggccg	gtcaggcgcg	cgcaatcggt	9000
gacgctctag	accgtgcaaa	aggagagcct	gtaagcgggc	actcttccgt	ggtctggtgg	9060
ataaattcgc	aagggtatca	tggcggacga	ccggggttcg	agccccgtat	ccggccgtcc	9120
gccgtgatcc	atgcggttac	cgccccgctg	tcgaaccacg	gtgtgcgacg	tcagacaacg	9180
ggggagtget	ccttttgget	tccttccagg	cgccggcggt	gctgcgctag	cttttttggc	9240
cactggccgc	gcgcagcgta	agcggttagg	ctggaaagcg	aaagcattaa	gtggctcgct	9300
ccctgtagcc	ggagggttat	tttccaaggg	ttgagtcgcg	ggacccccgg	ttcgagtctc	9360
ggaccggccg	gactgcggcg	aacggggggt	tgctccccg	tcatgcaaga	ccccgcttgc	9420
aaatctctcc	ggaacaggg	acgagcccct	tttttgcttt	tcccagatgc	atccggtgct	9480
gcggcagatg	cgccccctc	ctcagcagcg	gcaagagcaa	gagcagcggc	agacatgcag	9540
ggcaccctcc	cctcctccta	ccgcgtcagg	agggggcgaca	tccgcggttg	acgcggcagc	9600
agatggtgat	tacgaacccc	cgcggcgcgc	ggccccgcac	tacctggact	tggaggaggg	9660
cgagggcctg	gcgcggctag	gagcgcctc	tcctgagcgg	cacccaaggg	tgcagctgaa	9720

-continued

gcbtgatagc	cgtagggcgt	acgtgcccgc	gcagaacctg	tttcgagacc	gcbgaggaga	9780
ggagcccag	gagatgcccg	atcgaaagt	ccacgcaggg	cgagagctgc	ggcatggcct	9840
gaatcgcag	cggttgctgc	gcbgaggaga	ctttgagccc	gacgcgcgaa	ccgggattag	9900
tcccgcgcg	gcacacgtg	cgcccgcga	cctggtaacc	gcatacagc	agacggtgaa	9960
ccaggagatt	aactttcaaa	aaagcttta	caaccacgtg	cgtacgcttg	tggcgcgcga	10020
ggaggtggct	ataggactga	tgcatctgtg	ggactttgta	agcgcgctgg	agcaaaacc	10080
aaatagcaag	ccgctcatgg	cgagctgtt	ccttatagtg	cagcacagca	gggacaacga	10140
ggcattcagg	gatgagctgc	taaacatagt	agagcccag	ggcgcgctgg	tgctcgattt	10200
gataaacatc	ctgcagagca	tagtggtgca	ggagcgcagc	ttgagcctgg	ctgacaaggt	10260
ggccgccatc	aactattcca	tgcttagcct	gggcaagttt	taccccgcga	agatatacca	10320
taccocctac	gttcccatag	acaaggaggt	aaagatcgag	gggttctaca	tgcgcatggc	10380
gctgaaggtg	cttaccttga	gcbgagacct	ggcgctttat	cgcaacgagc	gcatccaaa	10440
ggccgtgagc	gtgagccg	ggcgcgagct	cagcagccgc	gagctgatgc	acagcctgca	10500
aaaggccctg	gctggcacgg	gcagcggcga	tagagaggcc	gagtcctact	ttgagcgggg	10560
cgctgacctg	cgctgggccc	caagccgagc	cgccctggag	gcagctgggg	ccggacctgg	10620
gctggcgggtg	gcacccgcgc	gcbgctggcaa	cgccggcggc	gtggaggaat	atgacgagga	10680
cgatgagtac	gagccagagg	acggcgagta	ctaagcgggtg	atgtttctga	tcagatgatg	10740
caagacgcaa	cgaccgccgc	ggtgcccggc	gcbgctgcaga	gccagccgtc	cgccctaac	10800
tccacggagc	actggcgcca	ggtcatggac	cgcatcatgt	cgctgactgc	gcbgcaatcct	10860
gagcgttcc	ggcagcagcc	gcaggccaac	cggtctctcg	caattctgga	agcgggtggc	10920
ccggcgcgcg	caaacccca	gcacgagaag	gtgctggcga	tcgtaaacgc	gctggccgaa	10980
aacagggccca	tccggcccga	cgaggccg	ctggtctacg	acgcgctgct	tcagcgcgtg	11040
gctcgttaca	acagcggcaa	cgtgcagacc	aacctggacc	ggctgggtggg	ggatgtgcgc	11100
gagggcgtgg	cgagcgtgca	gcbgcccag	cagcagggca	acctgggctc	catggttgca	11160
ctaaacgcct	tctgagtac	acagcccgc	aacgtgccc	gggacagga	ggactacacc	11220
aactttgtga	gcbgactcgc	gctaattggtg	actgagacac	cgcaaatgga	ggtgtaccag	11280
tctgggcccag	actatTTTTT	ccagaccagt	agacaaggcc	tgacagccgt	aaacctgagc	11340
caggtttca	aaaacttgca	ggggtgtgg	ggggtgccc	ctcccacagg	cgaccgcgcg	11400
accgtgtcta	gcttgtgtac	gcccactcg	cgctgttg	tgtgtctaat	agcgccttc	11460
acggacagtg	gcagcgtg	ccgggacaca	tacctagtc	acttgtgtac	actgtaccgc	11520
gagggccatag	gtcagggcga	tgtggacgag	catactttcc	aggagattac	aagtgtcagc	11580
cgccgcctgg	ggcagaggga	cacgggcagc	ctggaggcaa	ccctaaacta	cctgctgacc	11640
aaccggcggc	agaagatccc	ctcgtgac	agtttaaca	gcbgaggaga	gcbgattttg	11700
cgctacgtgc	agcagagcgt	gagcctaac	ctgatgccc	acggggtaac	gcccagcgtg	11760
gcbgctggaca	tgaccgcgcg	caacatggaa	ccgggcatgt	atgcctcaaa	ccggccgctt	11820
atcaaccgcc	taatggacta	cttgcatcgc	gcbgcccgcg	tgaacccgca	gtatttcacc	11880
aatgccatct	tgaacccgca	ctggctaccg	ccccctggtt	tctacaccgg	gggattcagag	11940
gtgcccagag	gtaacgatgg	attcctctgg	gacgacatag	acgacagcgt	gttttccccg	12000
caaccgcaga	ccctgctaga	gttgcaacag	cgagcagcag	cagaggcggc	gctgcaaaag	12060

-continued

gaaagcttcc gcaggccaag cagcttgctc gatctaggcg ctgcggcccc gcggtcagat 12120
gctagtagcc cattieccaag cttgataggg tctcttacca gcactcgcac caccgcgccg 12180
cgctgctgg gcgaggagga gtacctaaac aactcgctgc tgcagccgca gcgcaaaaa 12240
aacctgcctc cggcatttcc caacaacggg atagagagcc tagtgacaa gatgagtaga 12300
tggaagacgt acgcgagga gcacaggac gtgccaggcc cgcgcccgc caccgcctgt 12360
caaaggcagc accgtcagcg gggctcgtg tgggaggacg atgactcggc agacgacagc 12420
agcgtcctgg atttgggagg gactggcaac cgtttgcgc accttcgccc caggctgggg 12480
agaatgtttt aaaaaaaaa aaagcatgat gcaaaataaa aaactacca aggccatggc 12540
accgagcgtt ggttttcttg tattccccctt agtatgcggc gcgcgccgat gtatgaggaa 12600
ggctcctcct cctcctacga gactgtggtg agcgcggcgc cagtggcggc ggcgctgggt 12660
tctcccttcg atgctcccct ggaccgcgc tttgtgcctc cgcggtacct gcggcctacc 12720
ggggggagaa acagcatccg ttactctgag ttggcaccct tattcgacac caccctgtgt 12780
tactggtgg acaacaagtc aacggatgtg gcaccctga actaccagaa cgaccacagc 12840
aactttctga ccacggtcat tcaaaacaat gactacagcc cgggggaggc aagcacacag 12900
accatcaate ttgacgaccg gtcgcactgg ggcggcgacc tgaaaacct cctgcatacc 12960
aacatgcca atgtgaacga gttcatgtt accaataagt ttaaggcgcg ggtgatggtg 13020
tcgctcttc ctactaagga caatcagtg gagctgaaat acgagtggtt ggagttcacg 13080
ctgcccagg gcaactactc cgagaccatg accatagacc ttatgaacaa cgcgatcgtg 13140
gagcactact taaaagtggg cagacagaac ggggttctgg aaagcgacat cggggtaaag 13200
ttgacaccc gcaacttcag actggggtt gaccccgta ctggtcttgt catgcctggg 13260
gtatatacaa acgaagcctt ccatccagac atcattttgc tgcaggatg cggggtggac 13320
ttaccccaca gccgcctgag caactgttg ggcacccga agcggcaacc cttccaggag 13380
ggcttagga tcacctacga tgatctggag ggtggtaaca tccccgact gttggatgtg 13440
gagcctacc aggcgagcct gaaagatgac accgaacagg gcgggggtgg cgcaggcggc 13500
agcaacagca gtggcagcgg cgcggaagag aactccaacg cgcgagccgc ggcgatgcag 13560
ccggtggagg acatgaacga tcatgccatt cgcggcgaca cctttgccac acgggctgag 13620
gagaagcgcg ctgagccga agcagcggcc gaagctgccc ccccgctgc gcaaccggag 13680
gtcgagaagc ctcaagaag accggtgatc aaaccctga cagaggacag caagaaacgc 13740
agttacaacc taataagcaa tgacagcacc ttcaccagt accgcagctg gtacctgca 13800
tacaactacg gcgacctca gaccggaatc cgctcatgga ccctgcttg cactcctgac 13860
gtaacctgcg gctcggagca ggtctactgg tcggtgccag acatgatgca agacccctg 13920
accttcgct ccacgcgcca gatcagcaac tttccggtgg tggcgccga gctggtgcc 13980
gtgcaactca agagcttcta caacgaccag gccgtctact cccaactcat ccgccagttt 14040
acctctctga cccacgtgtt caatcgcttt cccgagaacc agattttggc gcgcccgcca 14100
gccccacca tcaccacgt cagtgaaaac gttcctgctc tcacagatca cgggacgcta 14160
ccgctgcgca acagcatcgg aggagtcag cgagtgacca ttactgacgc cagacgccgc 14220
acctgcccct acgtttaca gccctgggc atagtctgc cgcgctcct atcgagccgc 14280
actttttgag caagcatgct catccttata tcgcccagca ataacacagg ctggggcctg 14340

-continued

cgcttcccaa gcaagatggt tggcggggcc aagaagcgcct cgcaccaaca cccagtgcgc 14400
gtgcgcgggc actaccgcgc gccctggggc gcgcacaaac gcggccgcac tgggcgcacc 14460
accgtcgatg acgccatcga cgcggtggtg gaggaggcgc gcaactacac gccccacgcg 14520
ccaccagtgt ccacagtgga cgcggccatt cagaccgtgg tgcgcgagc ccggcgctat 14580
gctaaaaatga agagacggcg gaggcgcgta gcacgtcgcc accgccgccc acccggaact 14640
gccgcccaac gcgcgggcgc ggccctgctt aaccgcgcac gtcgcaccgg ccgacggggc 14700
gccatgcggg ccgctcgaag gctggccgcg ggtattgtca ctgtgcccc caggtccagg 14760
cgacgagcgg ccgccgcgc agccgcggcc attagtgcta tgactcaggg tcgcaggggc 14820
aacgtgtatt ggggtgcgca ctcggttagc ggctgcgcg tgcctgcgc caccgcccc 14880
ccgcgcaact agattgcaag aaaaaactac ttagactcgt actgttctat gtatccagcg 14940
gcggcgggcgc gcaacgaagc tatgtccaag cgcaaatca aagaagagat gctccaggtc 15000
atcgcgccgg agatctatgg cccccgaag aaggaagagc aggattacaa gcccccgaag 15060
ctaaagcggg tcaaaaaaa aaagaagat gatgatgatg aacttgacga cgaggtgga 15120
ctgctgcacg ctaccgcgc caggcgacgc gtacagtgga aaggtcgacg cgtaaaacgt 15180
gttttgcgac ccggcaccac cgtagtctt acgcccggtg agcctccac ccgcacctac 15240
aagcgcgtgt atgatgaggt gtacggcgac gaggacctgc ttgagcaggc caacgagcgc 15300
ctcggggagt ttgcctacgg aaagcggcat aaggacatgc tggcgttgcc gctggacgag 15360
ggcaacccaa cactagcct aaagcccgt aactgcgcgc aggtgctgcc cgcgcttgca 15420
ccgtccgaag aaaagcgcgc cctaaagcgc gactctggtg acttggcacc caccgtgcag 15480
ctgatggtac ccaagcgcca gcgactggaa gatgtcttgg aaaaaatgac cgtggaacct 15540
gggtgagc ccgaggtccg cgtgcggcca atcaagcagg tggcgccggg actggcgctg 15600
cagaccgtgg acgttcagat acccactacc agtagacca gtattgccac cgcacagag 15660
ggcatggaga cacaaacgtc cccggttgc tcagcgggtg cggatgccc ggtgcaggcg 15720
gtcgtgcgcg ccgctccaa gacctctac gaggtgcaaa cggaccctg gatgttctgc 15780
gtttcagccc ccggcgccc gcgccgttc aggaagtac gcgccgcag cgcgctactg 15840
cccgaatatg ccctacatcc ttccattgcg cctaccccc gctatcgtgg ctacacctac 15900
cgcccagaa gacgagcaac taccgcgcgc cgaaccacca ctggaacccg ccgccgcct 15960
cgccgtgcgc agcccgtgct ggccccgatt tccgtgcgca ggggtgctcg cgaaggaggc 16020
aggaccctgg tgctgccaac agcgcgctac caccacagca tcgttataaa gccggtcttt 16080
gtggttcttg cagatatggc cctcaactgc cgcctccgtt tcccgggtgcc gggattccga 16140
ggaagaatgc accgtaggag gggcatggcc ggccacggcc tgacgggccc catgcctcgt 16200
gcgcaccacc ggccggggcg cgcgtgcac cgtcgcctgc gcggcggtat cctgccccctc 16260
cttattccac tgatgcgccg gcgcatggc gccgtgccc gaattgcatc cgtggccttg 16320
caggcgcaga gactcgtatt aaaaacaagt tgcattgga aaaatcaaaa taaaaagtct 16380
ggactctcac gctcgttgg tccgttaact atttttaga atggaagaca tcaactttgc 16440
gtctctggcc ccgcgacgc gctcgcgcc gttcatggga aactggcaag atatcgccac 16500
cagcaatatg agcggtgggc cctcagctg gggctcctg tggagcggca ttaaaaattt 16560
cggttccacc gttaaagact atggcagcaa ggctggaac agcagcacag gccagatgct 16620
gagggataag ttgaaagagc aaaatttcca acaaaagggt gtagatggcc tggcctctgg 16680

-continued

cattagcggg gtggtggacc tggccaacca ggcagtgcaa aataagatta acagtaagct 16740
tgatccccgc cctcccgtag aggagcctcc accggccgtg gagacagtgt ctccagaggg 16800
gcgtggcgaa aagcgtccgc gccccgacag ggaagaaact ctggtgacgc aaatagacga 16860
gcctccctcg tacgaggagg cactaaagca aggctgccc accaccgctc ccatcgcgcc 16920
catggctacc ggagtgtggt gccagcacac acccgtaacg ctggacctgc ctccccccgc 16980
cgacaccag cagaaacctg tgctgccagg cccgaccgcc gttgtttaa cccgtcctag 17040
ccgcgcgtcc ctgcccgcgc ccgcccagcg tccgcgatcg ttgcccgcgc tagccagtgg 17100
caactggcaa agcacactga acagcatcgt gggctctgggg gtgcaatccc tgaagcgcgc 17160
acgatgcttc tgatagctaa cgtgtcgtat gtgtgtcatg tatgcgtcca tgcgcgcgc 17220
agaggagctg ctgagccgcc gcgcgcccgc tttccaagat ggctaccctc tcgatgatgc 17280
cgcagtggtc ttacatgcac atctcgggcc aggacgcctc ggagtacctg agccccgggc 17340
tggtgcagtt tgcccgcgc accgagacgt acttcagcct gaataacaag tttagaaacc 17400
ccacggtggc gcctacgcac gacgtgacca cagaccgctc ccagcgttg acgctgcggt 17460
tcatccctgt ggaccgtgag gatactgcgt actcgtacaa ggcgcggttc accctagctg 17520
tggtgataa ccgtgtgctg gacatggctt ccacgtactt tgacatccgc ggcgtgctgg 17580
acaggggccc tacttttaag ccctactctg gcaactgccta caacgcccctg gctcccagg 17640
gtccccaaa tccttgcgaa tgggatgaag ctgctactgc tcttgaataaacctagaag 17700
aagaggacga tgacaacgaa gacgaagtag acgagcaagc tgagcagcaa aaaactcacg 17760
tatttgggca ggcgccttat tctggtataa atattacaaa ggagggtatt caaataggtg 17820
tcgaaggta aacacctaaa tatgcccata aacatttca acctgaacct caaataggag 17880
aatctcagtg gtacgaaaca gaaattaatc atgcagctgg gagagtcta aaaaagacta 17940
ccccaatgaa accatgttac ggttcataatg caaaaccac aatgaaaat ggagggcaag 18000
gcattcttgt aaagcaacaa aatggaaagc tagaaagtca agtggaaatg caatttttct 18060
caactactga ggcagccgca ggcaatggtg ataacttgac tcctaaagtg gtattgtaca 18120
gtgaagatgt agatatagaa accccagaca ctcatatttc ttacatgcc actattaagg 18180
aaggtaactc acgagaacta atgggccaac aatctatgcc caacaggcct aattacattg 18240
cttttaggga caattttatt ggtctaattg attacaacag cacgggtaat atgggtgttc 18300
tggcgggcca agcatcgag ttgaatgctg ttgtagattt gcaagacaga aacacagagc 18360
ttcatacca gcttttgctt gattccattg gtgatagaac caggtacttt tctatgtgga 18420
atcaggctgt tgacagctat gatccagatg ttagaattat tgaaaatcat ggaactgaag 18480
atgaacttcc aaattactgc tttccactgg gaggtgtgat taatacagag actcttacca 18540
aggtaaaacc taaaacaggt caggaaaatg gatgggaaaa agatgctaca gaattttcag 18600
ataaaaatga aataagagtt ggaataatt ttgccatgga aatcaatcta aatgccaacc 18660
tgtggagaaa tttcctgtac tccaacatag cgctgtattt gcccgacaag ctaaagtaca 18720
gtccttccaa cgtaaaaatt tctgataacc caaacaccta cgactacatg aacaagcgag 18780
tggtggctcc cgggctagtg gactgctaca ttaaccttgg agcacgctgg tcccttgact 18840
atatggacaa cgtcaaccca ttaaacacc accgcaatgc tggcctgcgc taccgctcaa 18900
tgttgcgtgg caatggctgc tatgtgcctc tccacatcca ggtgcctcag aagttctttg 18960

-continued

ccattaaaaa	cctccttctc	ctgcccgggt	catacaccta	cgagtggaac	ttcaggaagg	19020
atgttaacat	ggttctgcag	agctccctag	gaaatgacct	aagggttgac	ggagccagca	19080
ttaagtttga	tagcatttgc	ctttaogcca	ccttcttccc	catggcccac	aacaccgcct	19140
ccacgcttga	ggccatgctt	agaaacgaca	ccaacgacca	gtcctttaac	gactatctct	19200
ccgcccga	catgctctac	cctataccgg	ccaacgctac	caacgtgccc	atatccatcc	19260
cctcccga	ctgggcccgt	ttcccgggt	gggccttcac	gcgcttaag	actaaggaaa	19320
ccccatcact	gggctggg	tacgaccctt	attacaccta	ctctggctct	ataccctacc	19380
tagatggaac	cttttacctc	aaccacacct	ttaagaagg	ggccattacc	tttgactctt	19440
ctgtcagctg	gcctggcaat	gaccgctgc	ttaccccaa	cgagttttaa	attaagcgtc	19500
cagttgacgg	ggagggttac	aacgttgccc	agtgtaacat	gaccaaagac	tggttcctgg	19560
tacaaatgct	agtaactat	aacattggct	accagggtct	ctatatccca	gagagctaca	19620
aggaccgcat	gtactccttc	tttagaaact	tccagcccat	gagccgtcag	gtgggggatg	19680
atactaaata	caaggactac	caacagggtg	gcctcctaca	ccaacacaac	aactctggat	19740
ttgttggtta	ccttgccccc	accatgccc	aaggacaggc	ctaccctgct	aacttcccct	19800
atccgcttat	aggcaagacc	gcagttgaca	gcattaccca	gaaaaagttt	ctttgcgac	19860
gcaccctttg	gcgcatccca	ttctccagta	actttatgtc	catgggccc	ctcacagacc	19920
tgggcaaaa	ccttctctac	gccaaactcc	cccacgccc	agacatgact	tttgaggtgg	19980
atcccatgga	cgagcccacc	cttctttatg	ttttgtttga	agtctttgac	gtggccctg	20040
tgaccagcc	gcaccgccc	gtcatcgaaa	ccgtgtacct	gcgcacgccc	ttctcgccc	20100
gcaacgccac	aacataaaga	agcaagcaac	atcaacaaca	gctgccgcca	tgggctccag	20160
tgagcaggaa	ctgaaagcca	ttgtcaaaga	tcttggttgt	gggcatatt	tttgggcac	20220
ctatgacaag	cgctttccag	gctttgttcc	tccacacaag	ctgcctgccc	ccatagtcaa	20280
tacggccggt	cgcgagactg	ggggcgta	ctggatggcc	tttgccctgga	accgcactc	20340
aaaaacatgc	tacctctttg	agccctttgg	ctttctgac	cagcgactca	agcaggttta	20400
ccagtttgag	tacgagtcac	tcctgccc	tagcccatt	gcttctccc	ccgaccctg	20460
tataacgctg	gaaaagtcca	cccaaagcgt	acaggggccc	aactcggccc	cctgtggact	20520
attctgctgc	atgtttctcc	acgcctttgc	caactggccc	caactccca	tggatcaca	20580
ccccaccatg	aaccttatta	ccgggttacc	caactccatg	ctcaacagtc	cccaggtaca	20640
gcccaccctg	cgtcgcaacc	aggaacagct	ctacagcttc	ctggagcgc	actcgccta	20700
cttccgcagc	cacagtgcgc	agattaggag	cgccacttct	ttttgtcact	tgaaaaacat	20760
gtaaaaataa	tgactagag	acactttcaa	taaaggcaaa	tgcttttatt	tgtacactct	20820
cggttgatta	tttaccacca	cccttgccgt	ctgcgcccgt	taaaaatcaa	aggggttctg	20880
ccgcccacgc	ctatgcgcca	ctggcaggga	cacgttgcga	tactggtgtt	tagtgcctca	20940
cttaaacctc	ggcacaacca	tccgcccag	ctcgggtgaag	tttcaactcc	acaggtcgc	21000
caccatcacc	aacgcgttta	gcaggtcggg	cgccgatatc	ttgaagtcgc	agttggggcc	21060
tccgcccctg	gcccgcgag	tgcgatacac	agggttgcag	cactggaaca	ctatcagcgc	21120
cggttggtgc	acgctggcca	gcacgctctt	gtcggagatc	agatcccgt	ccaggtcctc	21180
cgcttgctc	agggcgaaag	gagtcaactt	tggtagctgc	cttcccaaaa	agggcgcgtg	21240
cccagcttt	gagttgcact	cgcacogtag	tggcatcaaa	aggtgaccgt	gcccgtctg	21300

-continued

ggcgtagga tacagcgcct gcataaaagc cttgatctgc ttaaaagcca cctgagcctt 21360
tgcgccctca gagaagaaca tgcccaaga cttgccgaa aactgattgg cgggacaggc 21420
cgcgctgtgc acgcagcacc ttgcgtcggg gttggagatc tgcaccacat ttcggcccca 21480
ccggttcttc acgatcttgg ccttgcctga ctgctccttc agcgcgcgct gcccgtttcc 21540
gctcgtcaca tccatttcaa tcacgtgctc cttatttata ataagtcttc cgtgtagaca 21600
cttaagctcg ccttcgatct cagcgcagcg gtgcagccac aacgcgcagc cctggggctc 21660
gtgatgcttg taggtcact ctgcaaacga ctgcaggtac gcctgcagga atcgcccat 21720
catcgtcaca aaggtcttgt tgctgggtaa ggctcagctgc aaccgcggg gctcctcgtt 21780
cagccaggtc ttgcatacgg ccgccagagc ttccacttgg tcaggcagta gtttgaagt 21840
cgctttaga tcggtatcca cgtggtaact gtccatcagc gcgcgcgcag cctccatgcc 21900
cttctccacc gcagacacga tcggcacact cagcgggttc atcacgtaa tttcacttcc 21960
cgcttcgctg ggtcttctct cttctctctg cgtccgcata ccaecgcaca ctgggtcgtc 22020
ttcattcagc cgcgcactg tgccgttacc tctttgcca tgcttgatta gcaaccggtg 22080
ggtgctgaaa cccaccatt gtacgcacc atcttctctt tcttctctgc tgtccacgat 22140
tacctctggt gatggcgggc gctcgggctt gggagaaggc cgcttctttt tcttcttggg 22200
cgcaatggcc aaatccgcgc ccgaggtcga tggccgcggg ctgggtgtgc gcggcaccag 22260
cgctcttgt gatgagtctt cctcgtctcc ggactcgata cgcgcctca tccgcttttt 22320
tgggggcgcc cggggaggcg gcggcgacgg ggacggggac gacacgtcct ccatggttgg 22380
gggacgtcgc gccgcaccgc gtccgcgctc ggggggtggt tcgcgctgct cctcttccc 22440
actggccatt tcttctctct ataggcagaa aaagatcatg gagtcagtcg agaagaagga 22500
cagcctaacc gccccctctg agttcgcacc caccgcctcc accgatgccg ccaacgcgcc 22560
taccaccttc cccgtcgagg ccccccgct tgaggaggag gaagtgatta tcgagcagga 22620
cccaggtttt gtaagcgaag acgacagga ccgctcagta ccaacagagg ataaaaagca 22680
agaccaggac aacgcagagg caaacagga acaagtctgg cggggggacg aaaggcatgg 22740
cgactaccta gatgtgggag acgacgtgct gttgaagcat ctgcagcgc agtgcccat 22800
tatctcgcag gcgttgcaag agcgcagcga tgtgcccctc gccatagcgg atgtcagcct 22860
tgctacgaa cgcacactat tctcaccgcg cgtaccccc aaacgccaag aaaacggcac 22920
atgcgagccc aaccgcgcgc tcaacttcta ccccgattt gccgtgccag aggtgcttgc 22980
cacctatcac atctttttcc aaaactgcaa gataccccta tctgcccgtg ccaaccgcag 23040
ccgagcggac aagcagctgg ccttgcggca gggcgtgctc ataactgata tcgctcgtct 23100
caacgaagtg ccaaaaatct ttgaggtctc tggacgcgac gagaagcgcg cggcaaacgc 23160
tctgcaacag gaaaacagcg aaaatgaaag tcaactctga gtgttggtgg aactcgaggg 23220
tgacaacgcg cgcttagccg tactaaaaag cagcatcgag gtcaccactc ttgctaccc 23280
ggacttaac ctacccccca aggtcatgag cacagtcag agtgagctga tctgcccgc 23340
tgcgagccc ctggagaggg atgcaaat tcaagaacaa acagaggagg gcctacccgc 23400
agttggcgac gagcagctag cgcgctggct tcaaacgcgc gagcctgccg acttgaggga 23460
gcgacgcaaa ctaatgatgg ccgcagtgct cgttaccgtg gagcttgagt gcatgcagcg 23520
gttcttctgct gaccgggaga tgcagcgcga gctagaggaa acattgcact acaccttctg 23580

-continued

acagggctac	gtacgccagg	cctgcaagat	ctccaacgtg	gagctctgca	acctggctc	23640
ctaccttga	atthttgcacg	aaaacgcct	tgggcaaac	gtgcttcatt	ccacgctcaa	23700
ggggagggcg	cgccgcgact	acgtccgcga	ctgcgtttac	ttatttctat	gctacacctg	23760
gcagacggcc	atggggcgtt	ggcagcagtg	cttgaggag	tgcaacctca	aggagctgca	23820
gaaactgcta	aagcaaaact	tgaaggacct	atggacggcc	ttcaacgagc	gctccgtggc	23880
cgcgacctg	gcgacatca	ttttccccga	acgcctgctt	aaaaccctgc	aacagggtct	23940
gccagacttc	accagtcaaa	gcatgttgca	gaactttagg	aactttatcc	tagagcgctc	24000
aggaatcttg	cccgcacct	gctgtgact	tcttagcgac	tttgtgcca	ttaagtaccg	24060
cgaatgccct	cgcccgctt	ggggccactg	ctaccttctg	cagctagcca	actaccttgc	24120
ctaccactct	gacataatgg	aagacgtgag	cggtgacggt	ctactggagt	gtcactgtcg	24180
ctgcaacct	tgcacccgc	accgctccct	ggtttgcaat	tcgcagctgc	ttaacgaaag	24240
tcaaattatc	ggtaccttgg	agctgcaggg	tcctcgcct	gacgaaaagt	ccgcggtccc	24300
ggggttgaaa	ctcactccgg	ggctgtggac	gtcggcttac	cttcgcaaat	ttgtacctga	24360
ggactaccac	gcccacgaga	ttaggttcta	cgaagaccaa	tcccgcgccg	ctaatgcgga	24420
gcttaccgcc	tgcgtcatta	cccagggcca	cattcttggc	caattgcaag	ccatcaaaa	24480
agcccgccaa	gagtttctgc	tacgaaagg	acggggggtt	tacttgacc	cccagtcgg	24540
cgaggagctc	aacccaatcc	cccgcgccg	gcagccctat	cagcagcagc	cgcgggccct	24600
tgcttccag	gatggcacc	aaaaagaagc	tgcagctgcc	gccgccacc	acggacgagg	24660
aggaatctg	ggacagtcag	gcagaggagg	ttttggacga	ggaggaggag	gacatgatgg	24720
aagactggga	gagcctagac	gaggaagctt	ccgaggtcga	agaggtgtca	gacgaaacac	24780
cgccaccctc	ggtcgcattc	ccctcgcgg	cgcccagaa	atcggaacc	ggtccagca	24840
tggctacaac	ctccgctcct	caggcgcgc	cggcactgcc	cgttcgcga	cccaaccgta	24900
gatgggacac	caactggaacc	agggcggta	agtccaagca	gccgccgccg	ttagcccaag	24960
agcaacaaca	gcgccaagge	taccgctcat	ggcgcgggca	caagaacgcc	atagttgctt	25020
gcttgcaaga	ctgtgggggc	aacatctcct	tcgcccgcg	ctttcttctc	taccatcag	25080
gcgtggcctt	ccccgtaac	atcctgcatt	actaccgtca	tctctacagc	ccatactgca	25140
ccggcgccag	cggcagcaac	agcagcgcc	acacagaagc	aaaggcgacc	ggatagcaag	25200
actctgacaa	agcccagaag	atccacagcg	gcggcagcag	caggaggagg	agcgtgcgt	25260
ctgggcccc	acgaaccctg	atcgaccgcg	gagcttagaa	acaggattht	tcccactctg	25320
tatgctatat	ttcaacagag	caggggccc	gaacaagagc	tgaaaataaa	aaacaggtct	25380
ctcgatccc	tcaccgcag	ctgcctgtat	cacaaaagcg	aagatcagct	tcggcgcaag	25440
ctggaagacg	cggaggtctt	cttcagtaaa	tactgcgcgc	tgactcttaa	ggactagtht	25500
cgcgccctt	ctcaattta	agcgcgaaaa	ctacgtcatc	tccagcgcc	acaccggcg	25560
ccagcacctg	ttgtcagcgc	cattatgagc	aaggaaatc	ccacgccta	catgtggagt	25620
taccagccac	aatgggact	tgccgctgga	gctgcccaag	actactcaac	ccgaataaac	25680
tacatgagcg	cgggacccca	catgatatcc	cgggtcaacg	gaatacgcgc	ccaccgaaac	25740
cgaattctcc	tggaacagcg	ggctattacc	accacacctc	gtaataacct	taatccccgt	25800
agttggccc	ctgccctggt	gtaccaggaa	agtcgcctc	ccaccactgt	ggtacttccc	25860
agagacgccc	agccgaagt	tcagatgact	aactcagggg	cgagcttgc	ggcggtctt	25920

-continued

cgtcacaggg	tgcggtcgcc	cgggcagggt	ataactcacc	tgacaatcag	agggcgaggt	25980
atlcagctca	acgacgagtc	ggtgagctcc	tcgcttggtc	tccgtccgga	cgggacattt	26040
cagatcggcg	gcccggcgcc	ctcttcattc	acgcctcgtc	aggcaatcct	aactctgcag	26100
acctcgtcct	ctgagccgcg	ctctggaggc	attggaactc	tgcaatttat	tgaggagttt	26160
gtgccatcgg	tctactttaa	ccccttctcg	ggacctcccg	gccactatcc	ggatcaattt	26220
attcctaact	ttgacgcggt	aaaggactcg	gcggacggct	acgactgaat	gttaagtgga	26280
gaggcagagc	aactgcgcct	gaaacacctg	gtccactgtc	gcccgcacaa	gtgctttgcc	26340
cgcgactccg	gtgagttttg	ctactttgaa	ttgcccggag	atcatatcga	gggcccggcg	26400
caaggcgtcc	ggcttaccgc	ccagggagag	cttgcccgta	gcctgattcg	ggagtttacc	26460
cagcgcctcc	tgctagttag	gcgggacagg	ggacctgtg	ttctcactgt	gatttgcaac	26520
tgctctaacc	ctggattaca	tcaagatctt	tggtgccatc	tctgtgctga	gtataataaa	26580
tacagaaatt	aaaatatact	ggggtcctca	tcgccatcct	gtaaacgcca	ccgtcttcac	26640
ccgccaagc	aaaccaaggc	gaaccttacc	tggtactttt	aacatctctc	cctctgtgat	26700
ttacaacagt	ttcaaccag	acggagttag	tctacgagag	aacctctccg	agctcagcta	26760
ctccatcaga	aaaaacacca	ccctccttac	ctgcccggaa	cgtacgagtg	cgtcaccggc	26820
cgctgcacca	caactaccgc	ctgaccgtaa	accagacttt	ttccggacag	acctcaataa	26880
ctctgtttac	cagaacagga	ggtgagctta	gaaaaccctt	agggatttag	gccaaaggcg	26940
cagctactgt	ggggtttatg	aacaattcaa	gcaactctac	gggctattct	aattcagggt	27000
tctctagaat	cggggttggg	gttattctct	gtcttgtgat	tctctttatt	cttatactaa	27060
cgcttctctg	cctaaggctc	gccgcctgct	gtgtgcacat	ttgcatttat	tgctcagctt	27120
ttaaacgctg	gggtcgccac	ccaagatgat	taggtacata	atcctagggt	tactcaccct	27180
tgctgcagcc	caeggtacca	cccaaaaggt	ggattttaag	gagccagcct	gtaatgttac	27240
atcgcagct	gaagctaata	agtgcaccac	tcttataaaa	tgaccacag	aacatgaaaa	27300
gctgcttatt	cgccacaaaa	acaaaattgg	caagtatgct	gtttatgcta	tttggcagcc	27360
aggtgacact	acagagtata	atgttacagt	ttccagggt	aaaagtcata	aaacttttat	27420
gtatactttt	ccattttatg	aaatgtgcga	cattaccatg	tacatgagca	aacagtataa	27480
gttgtggccc	ccacaaaatt	gtgtggaaaa	cactggcact	ttctgctgca	ctgctatgct	27540
aattacagt	ctcgtcttgg	tctgtaccct	actctatatt	aaatacaaaa	gcagacgcag	27600
ctttattgag	gaaaagaaaa	tgcccttaatt	tactaagtta	caaagctaata	gtcaccacta	27660
actgctttac	tcgctgcttg	caaaacaaat	tcaaaaagtt	agcattataa	ttagaatagg	27720
atttaaacc	cccggctcatt	tcctgctcaa	taccattccc	ctgaacaatt	gactctatgt	27780
gggatatgct	ccagcgtcac	aacctggaag	tcaggcttcc	tgatgtcag	catctgactt	27840
tgccagcac	ctgtcccgcg	gatttgttcc	agtccaacta	cagcgaccca	ccctaacaga	27900
gatgaccaac	acaaccaacg	cggccgcgcg	taccggactt	acatctacca	caaatacacc	27960
ccaagtttct	gcctttgtca	ataactggga	taacttgggc	atgtggtggt	tctccatagc	28020
gcttatgttt	gtatgcctta	ttattatgtg	gctcatctgc	tgctaaagc	gcaaacgcgc	28080
ccgaccacc	atctatagtc	ccatcattgt	gctacacca	aacaatgatg	gaatccatag	28140
attgacgga	ctgaaacaca	tgttcttttc	tcttacagta	tgattaaatg	agacatgatt	28200

-continued

cctcgagttt ttatattact gacccttggt ggcctttttt tgtgcgtgct ccacattggc 28260
tgcggtttct cacatcgaag tagactgcat tocagccttc acagtctatt tgctttacgg 28320
atttgcacc ctcacgctca tctgcagcct catcactgtg gtcacgcct ttatccagt 28380
cattgactgg gtctgtgtgc gctttgcata tctcagacac catccccagt acagggacag 28440
gactatagct gagcttctta gaattcttta attatgaaat ttactgtgac ttttctgctg 28500
attatttgca ccctatctgc gttttgttcc cgcacctcca agcctcaaag acatatatca 28560
tgcagattca ctcgatatg gaatattcca agttgctaca atgaaaaaag cgatctttcc 28620
gaagcctggt tatatgcaat catctctggt atgggtgtct gcagtagcat cttagcccta 28680
gctatatatc cctaccttga cattggctgg aacgcaatag atgccatgaa ccaoccaact 28740
ttccccgcgc ccgctatgct tccactgcaa caagtgttg cggcggtctt tgtcccagcc 28800
aatcagcctc gcccaccttc tcccaccccc actgaaatca gctactttaa tctaacagga 28860
ggagatgact gacaccctag atctagaat ggacggaatt attacagagc agcgcctgct 28920
agaaagacgc agggcagcgg ccgagcaaca gcgcatgaat caagagctcc aagacatggt 28980
taacttgca cagtgcacaaa ggggtatctt ttgtctggta aagcaggcca aagtcaccta 29040
cgacagtaat accaccggac accgccttag ctacaagttg ccaaccaagc gtcagaaatt 29100
gggtgcatg gtgggagaaa agcccattac cataactcag cactcggtag aaaccgaag 29160
ctgcattcac tcacctgtc aaggacctga ggatctctgc acccttatta agaccctgtg 29220
cggctctcaa gatcttattc cctttaacta ataaaaaaaa ataataaagc atcacttact 29280
taaaatcagt tagcaaattt ctgtccagtt tattcagcag cacctccttg cctcctccc 29340
agetctggta ttgcagcttc ctccctggctg caaactttct ccacaatcta aatggaatgt 29400
cagtttctct ctgttctctg ccacccgcac ccaactatct catgttgttg cagatgaagc 29460
gcgcaagacc gtctgaagat accttcaacc ccgtgtatcc atatgacacg gaaaccggtc 29520
ctccaaactg gccttttctt actcctcctt ttgtatcccc caatggggtt caagagagtc 29580
ccctgggggt actctctttg cgcctatccg aacctctagt tacctccaat ggcagcttg 29640
cgctcaaat gggcaacgac ctctctctgg acgaggccgg caaccttacc tcccaaatg 29700
taaccactgt gagcccact ctcaaaaaa ccaagtcaaa cataaacctg gaaatatctg 29760
caccctcac agttacctca gaagccctaa ctgtggctgc cgcgcacct ctaatggctg 29820
cgggcaacac actcaccatg caatcacagg ccccgctaac cgtgcacgac tccaaactta 29880
gcattgccac ccaaggacc ctcacagtgt cagaaggaaa gctagccttg caaacatcag 29940
gccccctcac caccaccgat agcagtaccc ttactatcac tgctcacc cctctaacta 30000
ctgccactgg tagcttgggc attgacttga aagagcccat ttatacacia aatggaaaac 30060
taggactaaa gtacggggct cctttgcatg taacagacga cctaaacact ttgaccgtag 30120
caactgggtc aggtgtgact attaataata ctctcttga aactaaagt actggagcct 30180
tgggttttga ttcacaagac aatatgcaac ttaatgtagc aggaggacta aggattgatt 30240
ctcaaaaacag acgccttata ctgtatgta gttatcgtt tgatgctcaa aaccaactaa 30300
atctaagact aggacaggc cctctttta taaactcagc ccacaacttg gatattaact 30360
acaacaaag cctttacttg tttacagctt caaacaattc caaaaagctt gaggttaacc 30420
taagcactgc caaggggtg atgtttgac ctacagccat agccattaat gcaggagatg 30480
ggcttgaatt tggttcacct aatgcaccaa acacaaatcc cctcaaaaaca aaaattggcc 30540

-continued

atggcctaga atttgattca aacaaggcta tggttcctaa actaggaact ggccttagtt 30600
ttgacagcac aggtgccatt acagtaggaa acaaaaataa tgataagcta actttgtgga 30660
ccacaccage tccatctcct aactgtagac taaatgcaga gaaagatgct aaactcactt 30720
tggctctaac aaaatgtggc agtcaaatc tggctacagt ttcagttttg gctgttaaag 30780
gcagtttggc tccaatatct ggaacagttc aaagtgtcca tcttattata agatttgacg 30840
aaaaatggagt gctactaaac aattccttcc tggaccaga atattggaac tttagaatg 30900
gagatcttac tgaaggcaca gcctatacaa acgctgttgg atttatgctt aacctatcag 30960
cttatccaaa atctcacggt aaaactgcca aaagtaacat tgtcagtcaa gtttacttaa 31020
acggagacaa aactaaacct gtaacactaa ccattacact aaacggtaca caggaaacag 31080
gagacacaac tccaagtgca tactctatgt cattttcatg ggactggtct ggccacaact 31140
acattaatga aatatttggc acatcctctt acactttttc atacattgcc caagaataaa 31200
gaatcgtttg tgttatgttt caacgtgttt atttttcaat tgcagaaaat ttcaagtcatt 31260
ttttcattca gtagtatagc cccaccacca catagcttat acagatcacc gtaocttaat 31320
caaaactcaca gaacctagtt attcaacctg ccacctcctt cccaacacac agagtacaca 31380
gtcctttctc cccggtggc cttaaaaagc atcatatcat gggtaacaga catattctta 31440
ggtgttatat tccacacggt ttctgtcga gccaaacgct catcagtgat attaataaac 31500
tccccgggca gctcacttaa gttcatgtcg ctgtccagct gctgagccac aggctgctgt 31560
ccaacttgcg gttgcttaac gggcgcgcaa ggagaagtcc acgctacat gggggtagag 31620
tcataatcgt gcatcaggat agggcggtgg tggctgcagca gcgcgcgaat aaactgctgc 31680
cgccgcgct ccgctctgca ggaatacaac atggcagtggt tctctcagc gatgattcgc 31740
accgcccga gcataaggcg ccttgtctc cgggcacagc agcgcacctt gatctcactt 31800
aaatcagcac agtaactgca gcacagcacc acaatattgt tcaaaatccc acagtgcagg 31860
gcgctgtatc caaagctcat ggcggggacc acagaacca cgtggccatc ataccacaag 31920
cgcaggtaga ttaagtggcg accctcata aacacgctgg acataaacat tacctctttt 31980
ggcatgttgt aattcaccac ctcccgttac catataaac tctgattaaa catggcgcca 32040
tccaccacca tctaaacca gctggccaaa acctgcccgc cggctataca ctgcagggaa 32100
ccgggactgg aacaatgaca gtggagagcc caggactcgt aacctggat catcatgctc 32160
gtcatgatat caatgttggc acaacacagc cacacgtgca tacacttctt caggattaca 32220
agctcctccc gcgttagaac catatcccag ggaacaacc attcctgaat cagcgtaaat 32280
cccacactgc agggaagacc tgcacgtaa ctcacgttgt gcattgtcaa agtggtacat 32340
tcgggcagca gcgatgatc ctccagtatg gtagcggggg tttctgtctc aaaaggaggt 32400
agacgatccc tactgtacgg agtgcgcgga gacaaccgag atcgtgttgg tcgtagtgct 32460
atgccaaatg gaacgccgga cgtagtcata tttctgaag caaaaccagg tgcgggctgt 32520
acaaacagat ctgctctccc ggtctcggc cttagatcgc tctgtgtagt agttgtagta 32580
tatccactct ctcaaagcat ccaggcgcct cctggcttgc ggttctatgt aaactccttc 32640
atgcgccgct gccctgataa catccaccac cgcagaataa gccacacca gccaacctac 32700
acattcgttc tgcgagtcac acacgggagc agcgggaaga gctggaagaa ccatgttttt 32760
ttttttatc caaaagatta tccaaaacct caaaatgaag atctattaag tgaacgcgct 32820

-continued

```

ccctccggt ggcgtggtca aactctacag ccaaagaaca gataatggca tttgtaagat 32880
gttgcacaat ggcttccaaa aggcaaacgg ccctcacgtc caagtggacg taaaggctaa 32940
acccttcagg gtgaatctcc tctataaaca ttccagcacc ttcaaccatg cccaaataat 33000
tctcatctcg ccaccttctc aatatacttc taagcaaatc ccgaatatta agtccggcca 33060
ttgtaaaaat ctgctccaga gcgccctcca ccttcagcct caagcagcga atcatgattg 33120
caaaaattca ggttctctac agacctgtat aagattcaaa agcggaaat taacaaaaat 33180
accgcatcc cgtaggtccc ttcgaggggc cagctgaaca taatcgtgca ggtctgcacg 33240
gaccagcgcg gccacttccc cgccaggaac catgacaaaa gaaccacac tgattatgac 33300
acgcatactc ggagctatgc taaccagcgt agccccgatg taagcttgtt gcatggggcg 33360
cgatataaaa tgcaaggtgc tgctcaaaaa atcaggcaaa gcctcgcgca aaaaagaaag 33420
cacatcgtag tcatgctcat gcagataaag gcaggtaagc tccggaacca ccacagaaaa 33480
agacaccatt tttctctcaa acatgtctgc gggtttctgc ataaacacaa aataaaataa 33540
caaaaaaaca tttaaacatt agaagcctgt cttacaacag gaaaaacaac ccttataagc 33600
ataagacgga ctacggccat gccggcgtga ccgtaaaaa actggtcacc gtgattaataa 33660
agcaccaccg acagctcctc ggtcatgtcc ggagtcataa tgtaagactc ggtaaacaca 33720
tcaggttgat tcacatcggt cagtgcataa aagcgaccga aatagcccgg gggaatacat 33780
accgcagggc gtagagacaa cattacagcc cccataggag gtataacaaa attaatagga 33840
gagaaaaaca cataaacacc tgaaaaacc tctgccttag gcaaaatagc accctcccgc 33900
tccagaacaa catacagcgc ttccacagcg gcagccataa cagtcagcct taccagtaaa 33960
aaagaaaacc tattaataaa acaccactcg acacggcacc agctcaatca gtcacagtgt 34020
aaaaaagggc caagtgcaga gcgagtatat ataggactaa aaaatgacgt aacggttaa 34080
gtccacaaaa aacaccgaga aaaccgacg cgaacctacg cccagaaacg aaagccaaaa 34140
aaccacaaac ttctctaaat cgtcacttcc gttttccac gttacgtcac ttcccatttt 34200
aagaaaacta caattccaa cacatacaag ttactccgcc ctaaaccta cgtcaccgc 34260
ccggttccca cgccccgcg cagctcacia actccacccc ctattatca tattggcttc 34320
aatccaaaat aaggtatatt attgatgatg 34350

```

<210> SEQ ID NO 2

<211> LENGTH: 590

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: TNFR portion of the TNFR-Fas chimera (Fas-c)

<400> SEQUENCE: 2

```

atgggcctct ccaccgtgcc tgacctgctg ctgccgctgg tgetcctgga gctggtggg 60
ggaaataacc cctcaggggt tattggactg gtcctcacc taggggacag ggagaagaga 120
gatagtgtgt gtccccaaag aaaatataat cacctcaaa ataattgat ttgctgtacc 180
aagtgccaca aaggaacctt cttgtacaat gactgtccag gcccggggca ggatacggac 240
tgacgggagt gtgagagcgg ctccttcacc gcttcagaaa accacctcag aactgcctc 300
agctgtccca aatgccgaaa ggaaatgggt caggtggaga tctctcttg cacagtggac 360
cgggacaccg tgtgtggctg caggaagaac cagtaccggc attattggag tgaaaacctt 420
ttccagtgct tcaattgcag cctctgcctc aatgggaccg tgcacctctc ctgccaggag 480

```

-continued

```

aacagaaca ccgtgtgac ctgccatgca ggtttcttc taagagaaaa cgagtgtgtc 540
tcctgtagta actgtaagaa aagcctggag tgcacgaagt tgtgcctacc 590

```

```

<210> SEQ ID NO 3
<211> LENGTH: 511
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Fas portion of the TNFR-Fas chimera (Fas-c)

```

```

<400> SEQUENCE: 3
aacgttagga tccagatcta acttggggtg gctttgtctt cttcttttgc caattccact 60
aattgtttgg gtgaagagaa aggaagtaca gaaaacatgc agaaagcaca gaaaggaaaa 120
ccaagttct catgaatctc caaccttaaa tcctgaaaca gtggcaataa atttatctga 180
tgttgacttg agtaaatata tcaccactat tgctggagtc atgacactaa gtcaagttaa 240
aggctttggt cgaaagaatg gtgtcaatga agccaaaata gatgagatca agaatgacaa 300
tgtccaagac acagcagaac agaaagtta actgcttcgt aattggcatc aacttcatgg 360
aaagaaagaa gcgtatgaca cattgattaa agatctcaaa aaagccaatc tttgtactct 420
tgcagagaaa attcagacta tcactcctcaa ggacattact agtgactcag aaaattcaaa 480
cttcagaaat gaaatccaaa gcttgggtcta g 511

```

```

<210> SEQ ID NO 4
<211> LENGTH: 1101
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: TNFR1-Fas chimera (Fas-c) coding sequence

```

```

<400> SEQUENCE: 4
atgggcctct ccaccgtgac tgacctgctg ctgccgctgg tgcctcctgga gctgttggtg 60
ggaatatacc cctcaggggt tattggactg gtcctcacc taggggacag ggagaagaga 120
gatagtgtgt gtcccaaggg aaaatatact caccctcaaa ataattgat ttgctgtacc 180
aagtgccaca aaggaacctc cttgtacaat gactgtccag gccccgggca ggataccgac 240
tgcagggagt gtgagagcgg ctccttcacc gcttcagaaa accacctcag acactgcctc 300
agctgctcca aatgccgaaa ggaaatgggt caggtggaga tctcttcttg cacagtggac 360
cgggacaccg tgtgtggctg caggaagaac cagtaccggc attattggag tgaaaacctt 420
ttccagtgct tcaattgcag cctctgcctc aatgggaccg tgcacctctc ctgccaggag 480
aacagaaca ccgtgtgac ctgccatgca ggtttcttc taagagaaaa cgagtgtgtc 540
tcctgtagta actgtaagaa aagcctggag tgcacgaagt tgtgcctacc aagcttagga 600
tccagatcta acttgggggt gctttgtctt cttcttttgc caattccact aattgtttgg 660
gtgaagagaa aggaagtaca gaaaacatgc agaaagcaca gaaaggaaaa ccaagttct 720
catgaatctc caaccttaaa tcctgaaaca gtggcaataa atttatctga tgttgacttg 780
agtaaatata tcaccactat tgctggagtc atgacactaa gtcaagttaa aggctttggt 840
cgaaagaatg gtgtcaatga agccaaaata gatgagatca agaatgacaa tgtccaagac 900
acagcagaac agaaagtta actgcttcgt aattggcatc aacttcatgg aaagaaagaa 960
gcgtatgaca cattgattaa agatctcaaa aaagccaatc tttgtactct tgcagagaaa 1020

```

-continued

 attcagacta tcatcctcaa ggacattact agtgactcag aaaattcaaa cttcagaat 1080

gaaatccaaa gcttggctca g 1101

<210> SEQ ID NO 5
 <211> LENGTH: 6
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Hypoxia responsive element - E-box
 <400> SEQUENCE: 5

gcacgt 6

<210> SEQ ID NO 6
 <211> LENGTH: 44
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Murine endothelial specific enhancer elemet
 <400> SEQUENCE: 6

gtacttcata cttttcattc caatgggggtg actttgcttc tgga 44

<210> SEQ ID NO 7
 <211> LENGTH: 143
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: A triplicate copy of a murine enhancer sequence originated from the PPE-1 promoter
 <400> SEQUENCE: 7

gtacttcata cttttcattc caatgggggtg actttgcttc tggagggtga ctttgcttct 60

ggagccagta cttcatactt ttcattgtac ttcatacttt tcattccaat ggggtgactt 120

tgcttctgga ggctagctgc cag 143

<210> SEQ ID NO 8
 <211> LENGTH: 47
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: EDC fragment
 <400> SEQUENCE: 8

ctggagggtg actttgcttc tggagccagt acttcatact tttcatt 47

<210> SEQ ID NO 9
 <211> LENGTH: 36460
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: PPE-1-3X-FasC v1rl construct including repeat sequences
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (460)..(1437)
 <223> OTHER INFORMATION: A modified murine pre-proendothelin-1 promoter (PPE-1-3X)
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (1438)..(1468)
 <223> OTHER INFORMATION: Linker containing Restriction sites (NotI, PstI, BamHI)
 <220> FEATURE:
 <221> NAME/KEY: misc_feature

-continued

```

<222> LOCATION: (1469)..(2058)
<223> OTHER INFORMATION: TNFR portion of the Fas-TNFR-1 chimera (Fas-c)
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2059)..(2569)
<223> OTHER INFORMATION: FAS portion of the Fas-TNFR-1 chimera (Fas-c)
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2801)..(4062)
<223> OTHER INFORMATION: Duplication - copy 1
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (4063)..(5315)
<223> OTHER INFORMATION: Duplication - copy 2

<400> SEQUENCE: 9

catcatcaat aatatacctt attttggatt gaagccaata tgataatgag ggggtggagt    60
ttgtgacgtg gcgcgggggc tgggaacggg gcgggtgacg tagtagtggt gcggaagtgt    120
gatgttgcaa gtgtggcggg acacatgtaa gcgacggatg tggcaaaagt gacgtttttg    180
gtgtgcgccg gtgtacacag gaagtgacaa ttttcgcgcg gttttaggcg gatgtttag    240
taaatattgg cgtaaccgag taagatttgg ccattttcgc gggaaaactg aataagagga    300
agtgaaatct gaataathtt gtgttactca tagcgcgtaa tatttgtcta gggccgcggg    360
gactttgacc gtttaactgg agactcgccc aggtgttttt ctcagggtgt tccgcggttc    420
cgggtcaaag ttggcgtttt attattatag tcagtacgta cgtgtacttc tgatcggcga    480
tactagggag ataaggatgt acctgacaaa accacattgt tgttgttacc attattattt    540
agttttcctt ccttgetaac tcctgacgga atctttctca cctcaaatgc gaagtacttt    600
agtttagaaa agacttgggt gaaggggtgg tgggtgaaaa gtaggggtgat cttccaaact    660
aatctgggtc cccgcccgcc ccagtagctg ggattcaaga gcgaagagtg gggatcgtcc    720
ccttgtttga tcagaaagac ataaaaggaa aatcaagtga acaatgatca gccccacctc    780
caccaccacc ccctgcgcgc gcacaataca atctatttaa ttgtacttca tacttttcat    840
tccaatgggg tgactttgct tctggagaaa ctcttgatc ttgaactctg gggctggcag    900
ctagcctcca gaagcaaagt caccocattg gaatgaaaag tatgaagtac aatgaaaagt    960
atgaagtact ggctccagaa gcaaagtcac cctccagaag caaagtcacc ccattggaat   1020
gaaaagtatg aagtagccta gcaaaagggg aagcgggctg ctgctctctg caggttctgc   1080
agcggctctc gtctagtggg tgttttcttt ttcttagccc tgcccctgga ttgtcagacg   1140
gcgggcgtct gcctctgaag ttagccgtga tttcctctag agccgggtct tatctctggc   1200
tgacggttgc ctgtgggtga ctaatcacac aataacattg tttagggtct gaataaagtc   1260
agagctgttt acccccactc tataggggtt caatataaaa aggcggcgga gaactgtccg   1320
agtcagaagc gttcctgcac cggcctgtag agcctgaccc ggtctgctcc gctgtccttg   1380
cgcgctgect cccgctgcc cgcgacgctt tcgccccagt ggaagggcca cttgctgceg   1440
ccgctaatte tgcagatcgg gatccggcat gggcctctcc accgtgctg acctgctgct   1500
gccgctggtg ctcttgagc tgttggtggg aatatacccc tcaggggtta ttggactggt   1560
ccctcaccta ggggacaggg agaagagaga tagtgtgtgt cccaaggaa aatatacca   1620
ccctcaaaat aattcgatgt gctgtaccaa gtgccacaaa ggaacctact tgtacaatga   1680
ctgtccaggc cggggcagg atacggactg cagggagtgt gagagcggct ccttcaccgc   1740
ttcagaaaac cacctcagac actgcctcag ctgctccaaa tgccgaaagg aatgggtca   1800

```

-continued

ggtggagatc	tcttcttgca	cagtggaccg	ggacaccgtg	tgtggctgca	ggaagaacca	1860
gtaccggcat	tattggagtg	aaaacctttt	ccagtgtctc	aattgcagcc	tctgcctcaa	1920
tgggaccgtg	cacctctcct	gccaggagaa	acagaacacc	gtgtgcacct	gccatgcagg	1980
tttctttcta	agagaaaacg	agtgtgtctc	ctgtagtaac	tgtaagaaaa	gcctggagtg	2040
cacgaagttg	tgectaccaa	gcttaggatc	cagatctaac	ttgggggtggc	tttgtcttct	2100
tcttttgcca	attccactaa	ttgtttgggt	gaagagaaag	gaagtacaga	aaacatgcag	2160
aaagcacaga	aaggaaaacc	aaggttctca	tgaatctcca	accttaaatc	ctgaaacagt	2220
ggcaataaat	ttatctgatg	ttgacttgag	taaatataac	accactattg	ctggagtcac	2280
gacactaagt	caagttaaag	gctttgtctg	aaagaatggt	gtcaatgaag	ccaaaataga	2340
tgagatcaag	aatgacaatg	tccaagacac	agcagaacag	aaagttcaac	tgcttcgtaa	2400
ttggcatcaa	cttcatggaa	agaaaagaagc	gtatgacaca	ttgattaaag	atctcaaaaa	2460
agccaatctt	tgtactcttg	cagagaaaat	tcagactatc	atcctcaagg	acattactag	2520
tgactcagaa	aattcaaact	tcagaaatga	aatccaaagc	ttggtctagc	tcgagcatgc	2580
atctaggcgg	ccgatggca	gaaattcgcg	aattcgctag	cgtaaacgga	tcctctagac	2640
gagatccgaa	cttgtttatt	gcagcttata	atggttacia	ataaagcaat	agcatcacia	2700
atctcaciaa	taaagcattt	tttccactgc	attctagtgg	tggtttgtcc	aaactcatca	2760
atgtatctta	tcattgtctag	atctgtactg	aaatgtgtgg	gcgtggctta	aggggtggaa	2820
agaatatata	aggtgggggt	cttattgtagt	tttgtatctg	ttttgcagca	gccgccgccc	2880
ccatgagcac	caactcgttt	gatggaagca	ttgtgagctc	atatttgaca	acgcgcatgc	2940
ccccatgggc	cggggtgcgt	cagaatgtga	tgggtccag	cattgatggg	cgccccgtcc	3000
tgccccgaaa	ctctactacc	ttgacctacg	agaccgtgtc	tggaacgccg	ttggagactg	3060
cagcctccgc	cgccgcttca	gccgctgcag	ccaaccgccg	cgggattgtg	actgactttg	3120
ctttctctgag	cccgcttgca	agcagtgcag	cttcccgttc	atccgccgcg	gatgacaagt	3180
tgacggctct	tttggcacia	ttggattctt	tgaccgggga	acttaatgtc	gtttctcagc	3240
agctgttgga	tctgcccag	caggtttctg	ccctgaaagg	ttctcccct	cccaatgcgg	3300
tttaaaacat	aaataaaaaa	ccagactctg	tttggatttg	gatcaagcaa	gtgtcttget	3360
gtctttatct	aggggttttg	cgcgcgcggg	aggcccggga	ccagcggctc	cggtcgttga	3420
gggtcctgtg	tattttttcc	aggacgtggg	aaaggtgact	ctggatgttc	agatacatgg	3480
gcataagccc	gtctctgggg	tggaggtagc	accactgcag	agcttcatgc	tgcgggggtgg	3540
tgtttagat	gatccagtcg	tagcaggagc	gctgggcgtg	gtgcctaaaa	atgtctttca	3600
gtagcaagct	gattgccagg	ggcaggccct	tggtgtaagt	gtttaciaag	cggttaaagc	3660
gggatgggtg	catagctggg	gatatgagat	gcactcttgg	ctgtattttt	aggttggtca	3720
tgttcccagc	catatccctc	cggggattca	tgttgtgcag	aaccaccagc	acagtgtatc	3780
cgggtcactt	gggaaatttg	tcattgtagct	tagaaggaaa	tgctggaag	aacttggaga	3840
cgcctctgtg	acctccaaga	ttttccatgc	attcgtccat	aatgatggca	atgggcccac	3900
ggggcggcggc	ctgggcgaag	atatttctgg	gatcactaac	gtcatagtgg	tgttccagga	3960
tgagatcgtc	ataggccatt	tttaciaaagc	gcgggcggag	gggtccagac	tgcggtataa	4020
tggttccatc	cggcccaggg	gcgtagttag	cctcacagat	ttaaggggtg	gaaagaatat	4080
ataaggtggg	ggtcttatgt	agttttgtat	ctgttttgca	gcagccgccg	ccgccatgag	4140

-continued

caccaactcg	tttgatgaa	gcattgtgag	ctcatatttg	acaacgcgca	tgccccatg	4200
ggcgggggtg	cgtcagaatg	tgatgggctc	cagcattgat	ggcggccccg	tcctgccccg	4260
aaactctact	accttgacct	acgagaccgt	gtctggaacg	ccgttgagga	ctgcagcctc	4320
cgccggcctg	tcagccgctg	cagccaccgc	ccgcccggatt	gtgactgact	ttgctttcct	4380
gagcccgcct	gcaagcagtg	cagcttcccc	ttcatccgcc	cgcgatgaca	agttgacggc	4440
tcttttggca	caattggatt	ctttgaccgg	ggaacttaac	gtcgtttctc	agcagctggt	4500
ggatctgcgc	cagcaggttt	ctgccctgaa	ggcttccctc	cctcccaatg	cggtttaaaa	4560
cataaataaa	aaaccagact	ctgtttggat	ttggatcaag	caagtgtctt	gctgtcttta	4620
tttagggggt	ttgcgcgcgc	ggtaggcccg	ggaccagcgg	tctcggctgt	tgagggtcct	4680
gtgtatTTTT	tccaggacgt	ggtaaagggtg	actctggatg	ttcagataca	tgggcataag	4740
cccgtctctg	gggtggagggt	agcaccactg	cagagcttca	tgctgcgggg	tggtgttgta	4800
gatgatccag	tcgtagcagg	agcctggggc	gtggtgccta	aaaatgtctt	tcagtagcaa	4860
gctgattgcc	aggggcagcg	ccttggtgta	agtgtttaca	aagcggtaa	gctgggatgg	4920
gtgcatacgt	gggatatga	gatgcatctt	ggactgtatt	tttaggttgg	ctatgttccc	4980
agccatatcc	ctccggggat	tcatgttgtg	cagaaccacc	agcacagtgt	atccggtgca	5040
cttgggaaat	ttgtcatgta	gcttagaagg	aatgctgtgg	aagaacttgg	agacgccctt	5100
gtgacctcca	agattttcca	tgcatctctc	cataatgatg	gcaatgggcc	cacgggcggc	5160
ggcctggggc	aagatatttc	tgggatcact	aacgtcatag	ttgtgttcca	ggatgagatc	5220
gtcatagccc	atTTTTaaca	agcgcggggc	gagggtgcca	gactgcggta	taatggttcc	5280
atccggccca	ggggcgtagt	taccctcaca	gatttgcatt	tcccacgctt	tgagttcaga	5340
tggggggatc	atgtctacct	gcggggcgat	gaagaaaacg	gtttccgggg	taggggagat	5400
cagctgggaa	gaaagcaggt	tcctgagcag	ctgcgactta	ccgcagccgg	tgggcccgtg	5460
aatcacacct	attaccggct	gcaactggta	gttaagagag	ctgcagctgc	cgctcatcct	5520
gagcaggggg	gccacttctg	taagcatgtc	cctgactcgc	atgttttccc	tgaccaaate	5580
cgccagaagg	cgctccggcg	ccagcagatg	cagttcttgc	aaggaagcaa	agtttttcaa	5640
cggtttgaga	ccgtccggcg	taggcatgct	tttgagcgtt	tgaccaagca	gttccagggc	5700
gtcccacage	tcggtcacct	gctctacggc	atctcgatcc	agcatatctc	ctcgtttcgc	5760
gggttggggc	ggctttcgtc	gtacggcagt	agtcgggtct	cgtccagacg	ggccagggtc	5820
atgtctttcc	acggggcgcg	ggctctctgc	agcgtagtct	gggtcacggg	gaaggggtgc	5880
gctccgggct	gcgcgctggc	caggggtgcgc	ttgaggettg	tcctgctggt	gctgaagcgc	5940
tgccggctct	cgccctgcgc	gtcggcccag	tagcatttga	ccatggtgtc	atagtccagc	6000
ccctccggcg	cgtggccctt	ggcgcgcagc	tgcccttgg	aggaggcgc	gcacgagggg	6060
cagtgacagc	ttttgagggc	gtagagcttg	ggcgcgagaa	ataccgattc	cggggagtag	6120
gcatccggcg	cgcagggccc	gcagacggtc	tcgcattcca	cgagccaggt	gagctctggc	6180
cgttcggggg	caaaaaccag	gtttccccca	tgcttttga	tgcttttctt	acctctgggt	6240
tccatgagcc	ggtgtccacg	ctcggtgacg	aaaaggctgt	ccgtgtcccc	gtatacagac	6300
ttgagaggcc	tgtcctcgag	cggtgttccg	cggtcctcct	cgtatagaaa	ctcggaccac	6360
tctgagacaa	aggctcgcgt	ccaggccagc	acgaaggagg	ctaagtggga	ggggtagcgg	6420

-continued

tcgttgcca	ctagggggc	cactcgctcc	agggtgtgaa	gacacatgtc	gcoctcttcg	6480
gcatcaagga	aggtgattgg	ttttaggtg	taggccacgt	gaccgggtgt	tectgaagg	6540
gggtataaa	aggggtggg	ggcgcgttcg	tctcactct	cttcgcate	gctgtctcg	6600
agggccagct	gttgggtga	gtactccctc	tgaaaagcgg	gcatgacttc	tgcgctaaga	6660
ttgtcagttt	ccaaaaacga	ggaggatttg	atattcaect	ggcccgcggt	gatgcctttg	6720
agggtggccg	catccatctg	gtcagaaaag	acaatctttt	tgttgtaag	cttgggtggca	6780
aacgaccctg	agagggcgtt	ggacagcaac	ttggcgatgg	agcgcagggt	ttggtttttg	6840
tcgcatcgg	cgcgctcctt	ggcgcgatg	tttagctgca	cgtattcgcg	cgaacgcac	6900
cgcattcgg	gaaagacggt	ggtgcgctcg	tcgggacca	ggtgcacgcg	ccaaccgcg	6960
ttgtgcagg	tgacaaggtc	aacgctggtg	gctacctctc	cgcgtaggcg	ctcgttggtc	7020
cagcagaggc	ggcgcctt	gcgcgagcag	aatggcggtg	gggggtctag	ctcgcctcgc	7080
tccgggggtg	ctgctccac	ggtaaagacc	cggggcagca	ggcgcgctc	gaagtagctt	7140
atctgcatc	cttgcaagtc	tagcgcctgc	tgccatgcgc	ggcggcaag	cgcgcgctc	7200
tatgggtga	gtgggggacc	ccatggcatg	gggtgggtga	gcgcgaggc	gtacatgccg	7260
caaatgctg	aaacgtagag	gggctctctg	agtattccaa	gatatgtagg	gtagcatctt	7320
ccaccgcgga	tgctggcgcg	cacgtaactc	tatagttcgt	gaggggagc	gaggaggctc	7380
ggaccgaggt	tgtaacgggc	gggctgctct	gctcggaaga	ctatctgcct	gaagatggca	7440
tgtgagttg	atgatatggt	tggacgctgg	aagacgttga	agctggcgtc	tgtgagacct	7500
accgctcac	gcacgaagga	ggcgtaggag	tcgcgagct	tgttgaccag	ctcggcggtg	7560
acctgcacgt	ctagggcgca	gtagtccagg	gtttccttga	tgatgtcata	cttatcctgt	7620
ccctttttt	tccacagctc	gcggttgagg	acaaactctt	cgcggtcttt	ccagtactct	7680
tgatcggaa	accctgcgcg	ctccgaacgg	taagagccta	gcatgtagaa	ctggttgacg	7740
gcctggtagg	cgcagcatcc	ctttctacg	ggtagcgcgt	atgcctgcgc	ggccttcggg	7800
agcaggtgt	gggtgagcgc	aaaggtgtcc	ctgaccatga	ctttgaggtg	ctggatattg	7860
aagtcaagt	cgtcgcaccc	gccctgctcc	cagagcaaaa	agtcctgctc	ctttttggaa	7920
cgcggatttg	gcagggcgaa	ggtgacatcg	ttgaagagta	tctttcccgc	gagaggcata	7980
aagtgcgctg	tgatcgggaa	gggtcccgcg	acctcggaac	ggttgtaaat	tacctgggcg	8040
gagagcacga	tctcgtcaaa	gccgttgatg	ttgtggccca	caatgtaaag	ttccaagaag	8100
cgcgggatgc	ccttgatgga	aggcaatttt	ttaagttcct	cgtagggtgag	ctcttcaggg	8160
gagctgagcc	cgtgctctga	aagggcccag	tctgcaagat	gagggttgga	agcagcgaat	8220
gagctccaca	ggtcacgggc	cattagcatt	tgcaggtggt	cgcgaaaggt	cctaaactgg	8280
cgacctatgg	ccattttttc	tggggtgatg	cagtagaagg	taagcgggtc	ttgttcccag	8340
cgttcccac	caaggtctgc	ggctaggtct	cgcgcggcag	tactagagg	ctcatctccg	8400
ccgaacttca	tgaccagcat	gaagggcacg	agctgcttcc	caaaggcccc	catccaagta	8460
taggtctcta	catcgtaggt	gacaaagaga	cgctcgggtc	gaggatgcga	gccgatccgg	8520
aagaactgga	tctcccgcga	ccaattggag	gagtggtctat	tgatgtggtg	aaagtagaag	8580
tccctcgcac	gggcccgaaca	ctcgtgctgg	cttttgtaaa	aacgtgcgca	gtactggcag	8640
cgtgacagc	gctgtacatc	ctgcacgagg	ttgacctgac	gaccgcgcac	aaggaagcag	8700
agtggaatt	tgagcccctc	gcctggcggg	ttggctggt	ggtcttctac	ttcggctgct	8760

-continued

tgtccttgac cgtctggctg ctcgagggga gttacggtgg atcggaccac cacgccgcgc 8820
gagcccaaaag tccagatgtc cgcgcgcgcg ggctcggagct tgatgacaac atcgcgcaga 8880
tgggagctgt ccatggtctg gagctcccgc ggctcaggt caggcgggag ctctgcagg 8940
ttacctcgc atagacgggt cagggcgcg gctagatcca ggtgatacct aatttccagg 9000
ggctggttg tggcggcgc gatggcttg aagaggccgc atccccgcg cgcgactacg 9060
gtaccgcgc ggcggcgggt ggccgcgggg gtgtccttg atgatgcac taaaagcgg 9120
gacgcgggag agccccgga ggtaggggg gctccggacc cgcgggaga gggggcagg 9180
gcacgtcgc gccgcgcgc gccaggagct ggtgtcgc gcctaggttg ctggcgaacg 9240
cgacgacgc gcggtgatc tcttgaatc ggccctctg cgtgaagac acgggcccg 9300
tgagcttga cctgaaagag agttcgcag aatcaattc ggtgtcgttg acggcgcct 9360
ggcgcaaat ctctgcacg tctctgagt tgtcttgata ggcatctcg gccatgaac 9420
gtcgcgctc tctctctgg agatctccgc gtccggtcg ctccacggg gcggcgagg 9480
cgttggaat gggggccatg agctcgcaga aggcgttgag gcctccctc ttcagacgc 9540
ggctgtagc cacgccccct tcggcatcgc gggcgcgat gaccacctg gcgagattga 9600
gtccacgct cggggcgaag acggcgtagt ttcgcaggc ctgaaagag tagttgagg 9660
tggtggcgg gtgttctgc acgaagaag acataacca gcgtcgaac gtggattcgt 9720
tgatcccc caagcctca aggcctcca tggcctcgt gaagtccac gcgaagtga 9780
aaaactggga gttgcgcgc gacacggta actcctctc cagaagacg atgagctcg 9840
cgacagtgc gcgcacctc cgtcaaaag ctacagggg ctctctctc tctcaatc 9900
cctctccat aaggcctcc ccttctctt cttctggcg cgggtgggga gggggacac 9960
ggcggcgcg acggcgcacc gggaggcgg cgacaaaag ctcgatcac tccccgcgc 10020
gacggcgcg ggtctcggg acggcgcgc cgttctcgc ggggcgcagt tggaaagac 10080
cgcccgcat gtcccggta tgggttggc gggggctgc atcggcagg gatacggcgc 10140
taacgatga tctcaaat tggtgttag gtactccgc gccaggggac ctgagcaggt 10200
ccgatcgc cgatcggaa aacctctca gaaaggcgc taaccagtca cagtcgaag 10260
gtagctgag caccgtggc gccgcgcgc gggcgggtc ggggtgttt ctggcggag 10320
tgctgctgat gatgtaata aagtaggcg tcttgagac gcggatggtc gacagaagca 10380
ccatgtcctt ggtccggcc tctgtaatg gcaggcgtc ggccatgcc caggttcgt 10440
ttgacatcg gcgcaggct ttgtagtag cttgcatgag ccttctacc ggcactctt 10500
cttctcttc ctcttctct geatctctg catctatgc tgcggcggc gcggagtgt 10560
gccgtaggt gcgccctct cctccatgc gtgtgaccc gaagccctc atcggctgaa 10620
gcaggcctag gtcggcgaca acgcgctcg ctaatatgg ctgctgcacc tgcgtgagg 10680
tagactgga gtcacccatg tccacaaag ggtggtatg gcccggttg atggtgtaag 10740
tcagttggc cataacggac cagttaacg tctggtgacc cggctcgcag agctcgggt 10800
acctgagac cgagtaagcc ctcgagtca atacgtatg gttcaagtc cgcaccagg 10860
actggtatc caccaaaaag tgcggcggc gctggcggtg gaggggccc cgtagggtg 10920
ccgggctcc gggggcgaga tcttccaaca taaggcgtg atatccgtg atgtacctg 10980
acatccagg gatgcggcg gcggtggtg aggcgcgcg aaagtccgc acgcggttc 11040

-continued

agatgttgcg	cagcggcaaa	aagtgtctcca	tggtcgggac	gctctggccg	gtcaggcgcg	11100
cgcaatcggt	gacgctctag	accgtgcaaa	aggagagcct	gtaagcgggc	actcttccgt	11160
ggtctgggtg	ataaattcgc	aagggatca	tggcggacga	ccggggttcg	agccccgtat	11220
ccggccgtcc	gccgtgatcc	atgcggttac	cgccccgctg	tcgaaccag	gtgtgcgacg	11280
tcagacaacg	ggggagtgtc	ccttttggtc	tccttccagg	cgcgccggct	gctgcgctag	11340
cttttttggc	cactggccgc	gcgagcgtg	agcggttagg	ctggaaagcg	aaagcattaa	11400
gtggctcgct	ccctgtagcc	ggagggttat	ttccaaggg	ttgagtcgcg	ggaccccccg	11460
ttcagagtctc	ggaccggccg	gactgcggcg	aacgggggtt	tgctccccg	tcatgcaaga	11520
ccccgcttgc	aaattctcc	ggaacaggg	acgagcccct	tttttgcttt	tcccagatgc	11580
atccggtgct	gcggcagatg	cgccccctc	ctcagcagcg	gcaagagcaa	gagcagcggc	11640
agacatgcag	ggcaccctcc	cctctccta	ccgcgtcagg	agggggcaca	tccgcggttg	11700
acggcgcagc	agatggtgat	tacgaacccc	cgcgccgccc	ggccccgcac	tacctggact	11760
tggaggaggg	cgaggccctg	gcgcggctag	gagcgccctc	tcctgagcgg	caccaaggg	11820
tgcagctgaa	gctgatacgc	cgtgaggcgt	acgtgccgcg	gcagaacctg	tttcgcgacc	11880
gcgagggaga	ggagcccag	gagatgcggg	atcgaaagt	ccacgcaggg	cgcgagctgc	11940
ggcatggcct	gaatcgcgag	cggttgctgc	gcgaggagga	ctttgagccc	gacgcgcgaa	12000
ccgggattag	tccccgcg	gcacacgtgg	cgcccgccga	cctggtaacc	gcatacgagc	12060
agacggtgaa	ccaggagatt	aactttcaaa	aaagcttaa	caaccacgtg	cgtacgcttg	12120
tggcgcgcga	ggaggtggct	ataggactga	tgcactctgtg	ggactttgta	agcgcgctgg	12180
agcaaaaccc	aaatagcaag	ccgctcatgg	cgcagctggt	ccttatagtg	cagcacagca	12240
gggacaacga	ggcattcagg	gatgcgctgc	taaacatagt	agagcccag	ggccgctggc	12300
tgctcgattt	gataaacatc	ctgcagagca	tagtgggtgca	ggagcgcagc	ttgagcctgg	12360
ctgacaaggt	ggccgccatc	aactattcca	tgcttagcct	gggcaagttt	tacgcccgca	12420
agatatacca	tacccttac	gttcccatag	acaaggaggt	aaagatcgag	gggttctaca	12480
tgcgcatggc	gctgaagggt	cttaccttga	gcgacgacct	ggcggtttat	cgcaacgagc	12540
gcatccacaa	ggccgtgagc	gtgagccggc	ggcgcgagct	cagcgaccgc	gagctgatgc	12600
acagcctgca	aagggccctg	gctggcacgg	gcagcggcga	tagagaggcc	gagtcctact	12660
ttgacgcggg	cgctgacctg	cgctgggccc	caagccgacg	cgccctggag	gcagctgggg	12720
ccggacctgg	gctggcggtg	gcaccgcgcg	gcgctggcaa	cgtcggcggc	gtggaggaat	12780
atgacgagga	cgatgagtac	gagccagagg	acggcgagta	ctaagcggtg	atgtttctga	12840
tcagatgatg	caagacgcaa	cggacccggc	ggtgcgggcg	gcgctgcaga	gccagccgtc	12900
cggccttaac	tccacggagc	actggcgcca	ggtcatggac	cgcacatgt	cgctgactgc	12960
gcgcaatcct	gacgcgttcc	ggcagcagcc	gcaggccaac	cggtctccg	caattctgga	13020
agcgggtggtc	ccggcgcgcg	caaaccccc	gcacgagaag	gtgctggcga	tcgtaaacgc	13080
gctggccgaa	aacagggcca	tccggccccg	cgaggccggc	ctggtctacg	acgcgctgct	13140
tcagcgcgctg	gctcgttaca	acagcggcaa	cgtgcagacc	aacctggacc	ggctggtggg	13200
ggatgtgcgc	gagggcgtgg	cgcagcgtga	gcgcgcgag	cagcagggca	acctgggctc	13260
catggttgca	ctaaacgcct	tcctgagtac	acagcccccc	aacgtgccgc	ggggacagga	13320
ggactacacc	aacttttgta	gcgcaotgcg	gctaattggtg	actgagacac	cgcaaatgta	13380

-continued

ggtgtaccag tctgggccag actatTTTTT ccagaccagt agacaaggcc tgcagaccgt 13440
aaacctgagc caggctttca aaaacttgca ggggctgtgg ggggtgcggg ctcccacagg 13500
cgaccgcegc accgtgtcta gcttgctgac gcccactcg cgctgttgcc tgetgctaata 13560
agcgccttc acggacagt gcagcgtgtc cggggacaca tacctaggtc acttctgac 13620
actgtaccgc gaggccatag gtcaggcgca tgtggacgag catactttcc aggagattac 13680
aagtgtcagc cgcgcctgg ggcaggagga cacgggcagc ctggaggcaa cctaaacta 13740
cctgtgacc aaccggcggc agaagatccc ctgctgac agtttaaca gcgaggagga 13800
gcgcattttg cgctacgtgc agcagagcgt gagcctaac ctgatgcgcg acggggtaac 13860
gcccagcgtg gcgctggaca tgaccgcgcg caacatgaa cggggcatgt atgcctcaaa 13920
ccggcgttt atcaaccgc taatggacta cttgcatcgc gcggccgcg tgaacccga 13980
gtatttcacc aatgccatct tgaacccgca ctggctaccg cccctgggt tctacaccg 14040
gggattcgag gtgcccagg gtaacgatgg attcctctgg gacgacatag acgacagcgt 14100
gttttcccc caaccgaga cctgctaga gttgcaacag cgcgagcagg cagaggcggc 14160
gctgcgaaag gaaagcttc gcaggccaag cagctgtcc gatctaggcg ctgcccgc 14220
gcggtcagat gctagtagcc ctttccaag cttgataggg tctcttacc gactcgcac 14280
caccgcccc cgctgctgg gcgaggagga gtacctaac aactcgctgc tgcagccgca 14340
gcgcgaaaaa aacctgcctc cggcatttc caacaacggg atagagagcc tagtggacaa 14400
gatgagtaga tggaagcgt acgcgcagga gcacaggac gtgccaggcc cgcgcccgc 14460
caccgctcgt caaaggcagc accgtcagc gggctctggtg tgggaggac atgactcggc 14520
agacgacagc agcgtcctgg atttgggag gagtggcaac cgtttgccc acctcgc 14580
caggctgggg agaatgttt aaaaaaaaaa aaagcatgat gcaaaataaa aaactacca 14640
aggccatggc accgagcgtt ggtttcttg tattcccctt agtatgcggc gcgcccgat 14700
gtatgaggaa ggtcctcctc cctcctacga gagtgggtg agcgcggcgc cagtggcggc 14760
ggcgctgggt tctccctcg atgctcccct ggaccgcggc tttgtgctc cgcggtacct 14820
gcggcctacc ggggggagaa acagcatccg ttactctgag ttggcaccct tattcgacac 14880
caccgctgtg tacctggtgg acaacaagtc aacggatgtg gcacccctga actaccagaa 14940
cgaccacagc aactttctga ccacggctcat tcaaaacaat gactacagcc cgggggaggc 15000
aagcacacag accatcaate ttgacgaccg gtcgcactgg ggcggcgacc tgaaaacct 15060
cctgcatacc aacatgcaa atgtgaacga gttcatgttt accaataagt ttaaggcgcg 15120
ggtgatggtg tcgcttgc ctactaagga caatcagggt gagctgaaat acgagtggtt 15180
ggagttcacg ctgcccagg gcaactactc cgagaccatg accatagacc ttatgaacaa 15240
cgcgatcgtg gagcactact tgaagtgagg cagacagaac ggggttctgg aaagcgacat 15300
cggggtaaag tttgacacc gcaacttcag actggggtt gaccccgta ctggtcttgt 15360
catgcctggg gtatataca acgaagcctt ccacccagac atcatcttgc tgcaggatg 15420
cggggtggac ttcaccaca gccgcctgag caactgttg ggcatccgca agcggcaacc 15480
cttcaggag ggctttagga tcacctacga tgatctggag ggtggtaaca tccccgact 15540
gttgatgtg gacgcctacc aggcgagctt gaaagatgac accgaacagg gcgggggtg 15600
cgcaggcggc agcaacagca gtggcagcgc cgcggaagag aactccaacg cggcagccc 15660

-continued

ggcaatgcag	ccggtggag	acatgaacga	tcatgccatt	cgcggcgaca	cctttgccac	15720
acgggctgag	gagaagcgcg	ctgaggccga	agcagcggcc	gaagctgccg	ccccgctgc	15780
gcaacccgag	gtcgagaagc	ctcagaagaa	accggtgatc	aaacccctga	cagaggacag	15840
caagaaacgc	agttacaacc	taataagcaa	tgacagcacc	ttcaccagct	accgcagctg	15900
gtaccttgca	tacaactacg	gcgaccctca	gaccggaatc	cgctcatgga	cctgctttg	15960
cactcctgac	gtaacctgcg	gctcggagca	ggtctactgg	tcgttgccag	acatgatgca	16020
agaccccgty	accttcgct	ccacgcgcca	gatcagcaac	tttcggtgg	tgggcgcca	16080
gctgttgccc	gtgactcca	agagcttcta	caacgaccag	gccgtctact	cccaactcat	16140
ccgcagttt	acctctctga	cccacgtggt	caatcgcttt	cccgagaacc	agattttggc	16200
gcgcccgcga	gccccacca	tcaccacgt	cagtgaanaac	gttctctctc	tcacagatca	16260
cgggacgcta	ccgctgcgca	acagcatcgg	aggagtccag	cgagtgaacca	ttactgacgc	16320
cagacgcgcg	acctgccct	acgtttataa	ggcctgggg	atagtctcgc	cgcgctcct	16380
atcgagccgc	actttttgag	caagcatgtc	catccttata	tcgcccagca	ataacacagg	16440
ctggggcctg	cgcttccca	gcaagatggt	tggcggggcc	aagaagcgt	ccgaccaaca	16500
cccagtgccg	gtgcgcgggc	actacgcgc	gccctgggg	gcgcacaaac	gcggccgcac	16560
tgggcgcacc	accgtcgtg	acgccatcga	cgcggtggtg	gaggaggcgc	gcaactacac	16620
gcccacgcgc	ccaccagtgt	ccacagtgga	cgcgccatt	cagaccgtgg	tgcgaggagc	16680
ccggcgctat	gctaaaaatga	agagacggcg	gaggcgcgta	gcacgtcgc	accgccgccc	16740
accgcgcact	gcgcaccaac	gcgcggcgcc	ggcctgctt	aaccgcgcac	gtcgaccg	16800
ccgacggggc	gcccacgggg	ccgctogaag	gctggccgcg	ggtattgtca	ctgtgcccc	16860
caggtcagg	cgacgagcgg	ccgccgcagc	agccgcggcc	attagtgtca	tgaactcagg	16920
tcgcaggggc	aacgtgtatt	gggtgcgcga	ctcggttagc	ggcctgcgcg	tgcccgctgc	16980
caccgcgcgc	ccgcgcaact	agattgcaag	aaaaaactac	ttagactcgt	actgttgat	17040
gtatccagcg	gcggcgccgc	gcaacgaagc	tatgtccaag	cgcaaatca	aagaagagat	17100
gtctcaggtc	atcgcccgcg	agatctatgg	ccccccgaag	aaggaagagc	aggattacaa	17160
gccccgaaag	ctaaaacggg	tcaaaaagaa	aaagaaagat	gatgatgatg	aacttgacga	17220
cgaggtgaa	ctgctgcacg	ctaccgcgcc	caggcgacgg	gtacagtgga	aaggtcgcag	17280
cgtaaaacgt	gttttgcgac	ccggcaccac	cgtagtcttt	acgcccggtg	agcgctccac	17340
ccgcacctac	aagcgcgtgt	atgatgaggt	gtacggcgac	gaggacctgc	ttgagcagge	17400
caacgagcgc	ctcggggagt	ttgcctacgg	aaagcggcat	aaggacatgc	tggcgtgccc	17460
gctggacgag	ggcaacccaa	cacctagcct	aaagcccgta	acactgcagc	aggtgctgccc	17520
cgcgcttgca	ccgtccgaag	aaaagcgcgg	cctaaagcgc	gagctcgttg	acttggcacc	17580
caccgtgcag	ctgatggtac	ccaagcgcca	gcgactggaa	gatgtcttgg	aaaaaatgac	17640
cgtagaacct	gggctggagc	ccgaggtccg	cgtgcggcca	atcaagcagg	tggcgcggg	17700
actgggcgty	cagaccgtgg	acgttcagat	accactacc	agtagcacca	gtattgccac	17760
cgccacagag	ggcatggaga	cacaaacgtc	cccggttgcc	tcagcggtgg	cggatgccgc	17820
ggtgcagggc	gtcgctgcgg	ccgcgtccaa	gacctctacg	gaggtgcaaa	cggaccgty	17880
gatgtttcgc	gtttcagccc	cccggcgcgc	gcgcggttcg	aggaagtacg	gcgcccag	17940
cgcgctactg	cccgaatatg	ccctaatccc	ttcattgcy	cctaccccg	gctatcgtgg	18000

-continued

ctacacctac cgccccagaa gacgagcaac taccgcgacgc cgaaccacca ctggaacccg 18060
ccgcgcgccgt cgccgtcgcc agcccggtgct ggccccgatt tccgtgcgca ggggtggtcg 18120
cgaaggaggc aggacctgg tgctgccaac agcgcgctac caccagca tcgtttaaaa 18180
gccggtcttt gtggttcttg cagatatggc cctcacctgc cgcctccgtt tcccggtgcc 18240
gggattccga ggaagaatgc accgtaggag gggcatggcc ggccacggcc tgacgggagg 18300
catgctgctg gcgcaccacc ggccggcgcg cgcgtcgcc cgtcgcatgc gggcggtat 18360
cctgcccctc cttattccac tgatcgccgc gggcattggc gccgtgccc gaattgcac 18420
cgtggccttg caggcgagca gacactgatt aaaaacaagt tgcatgtgga aaaatcaaaa 18480
taaaaagtct ggactctcac gctcgcttg tctgtaact atttttaga atggaagaca 18540
tcaactttgc gtctctggcc ccgcgacacg gctcgccccc gttcatggga aactggcaag 18600
atatcgccac cagcaatag agcgggtggc ccttcagctg gggctcgctg tggagcggca 18660
ttaaaaaatt cggttccacc gtaagaact atggcagcaa ggctggaac agcagcacag 18720
gccagatgct gagggataag ttgaaagagc aaaatttcca aaaaagggtg gtagatggcc 18780
tggcctctgg cattagcggg gtggtggacc tggccaacca ggcagtgcaa aataagatta 18840
acagtaagct tgatccccgc cctccgtag agggagcctcc accggcgtg gagacagtgt 18900
ctccagaggg gcgtggcgaa aagcgtccgc gcccgcagc ggaagaaact ctggtgacgc 18960
aaatagacga gcctccctcg tacgaggagg cactaaagca aggcctgccc accaccgctc 19020
ccatcgccgc catggtacc ggagtgtg ggcagcacac accgtaacg ctggacctgc 19080
ctccccccgc cgacaccag cagaaacctg tgctgccagg cccgaccgcc gttgtttaa 19140
cccgtcctag ccgcgcgtcc ctgcccgcgc ccgcccagg tccgcgatcg ttgcccgcg 19200
tagccagtgg caactggcaa agcacactga acagcatcgt gggctctggg gtgcaatccc 19260
tgaagcggcc acgatgcttc tgatagctaa cgtgtcgtat ggtgtcatg tatgctcca 19320
tgtcgcgcc agaggagctg ctgagccgc gcgcgcccgc tttccaagat ggtaccct 19380
tcgatgatgc cgcagtggc ttacatgac atctcgggccc aggcgctc ggagtacctg 19440
agccccgggc tgggtgagtt tgcccgcgc accgagacgt acttcagcct gaataacaag 19500
tttagaaaacc ccacggtg gcctacgcac gacgtgacca cagaccggtc ccagcgtttg 19560
acgctgaggc tcatccctgt ggaccgtgag gatactgct actcgtaca ggcgagggtc 19620
accctagctg tgggtgataa ccgtgtgctg gacatggct ccacgtaact tgacatccgc 19680
ggcgtgctg acaggggccc tacttttaag ccctactctg gactgccta caacgcctg 19740
gctccaagg gtgccccaaa tccctgcaa tgggatgaag ctgctactgc tcttgaata 19800
aacctagaag aagaggacga tgacaacgaa gacgaagtag acgagcaagc tgagcagcaa 19860
aaaactcacg tatttgggca ggcgccttat tctggtataa atattacaaa ggagggtatt 19920
caaataggty tcgaaggta aacacctaaa tatgccgata aaacattca acctgaacct 19980
caaataggag aatctcagt gtacgaaaca gaaattaatc atgcagctgg gagagtcta 20040
aaaaagacta ccccaatgaa accatgttac ggttcatatg caaaaccac aatgaaaat 20100
ggagggcaag gcattcttgt aaagcaaca aatggaaagc tagaaagtca agtggaaatg 20160
caattttct caactactga ggcagccgca ggcaatggtg ataactgac tcctaaagt 20220
gtattgtaca gtgaagatgt agatatagaa accccagaca ctcatattc ttacatgcc 20280

-continued

actattaagg aaggtaactc acgagaacta atgggccaac aatctatgcc caacaggcct 20340
aattacattg cttttagggg caattttatt ggtctaattg attacaacag cacgggtaat 20400
atgggtgttc tggcggggcca agcatcgcag ttgaatgctg ttgtagattt gcaagacaga 20460
aacacagagc tttcatacca gcttttgctt gattccattg gtgatagaac caggactctt 20520
tctatgtgga atcaggctgt tgacagctat gatccagatg ttagaattat tgaatatcat 20580
ggaactgaag atgaacttcc aaattactgc tttccactgg gaggtgtgat taatacagag 20640
actcttacca aggtaaaacc taaaacaggt caggaaaatg gatgggaaaa agatgctaca 20700
gaattttcag ataaaaatga aataagagtt ggaaataatt ttgccatgga aatcaatcta 20760
aatgcccaacc tgtggagaaa tttcctgtac tccaacatag cgctgtatct gcccgacaag 20820
ctaaagtaca gtccttccaa cgtaaaaatt tctgataacc caaacaccta cgactacatg 20880
aacaagcgag tgggtgctcc cgggctagtg gactgctaca ttaaccttgg agcacgctgg 20940
tcccttgact atatggacaa cgtcaaccca ttaaccacc accgcaatgc tggcctgccc 21000
taccgctcaa tgttctgtgg caatggctgc tatgtgcctt tccacatcca ggtgcctcag 21060
aagttctttg ccattaaaaa cctccttctc ctgcccgggt catabaccta cgagtgggaa 21120
ttcaggaagg atgtaacat ggttctgcag agctccctag gaaatgaact aagggttgac 21180
ggagccagca ttaagtttga tagcatttgc ctttacgcca ccttcttccc catggcccac 21240
aacaccgctt ccacgcttga ggccatgctt agaaacgaca ccaacgacca gtcctttaac 21300
gactatctct ccgccgcaa catgctctac cctataccog ccaacgctac caacgtgccc 21360
atatccatcc cctcccgcaa ctggcgggct tcccgcggtt gggccttccac ggccttaag 21420
actaaggaaa ccccatcact gggctcgggc tacgaccctt attacaccta ctctggtctt 21480
ataccctacc tagatgggaa cttttacctc aaccacacct ttaagaaggt ggcattacc 21540
ttgactctt ctgtcagctg gcctggcaat gaccgctgc ttaccccaa cgagtttga 21600
attaagcgtt cagttgacgg ggagggttac aacgttccc agtgtaacat gaccaaagac 21660
tggttcctgg tacaatgct agctaactat aacattggtt accagggtt ctatatcca 21720
gagagctaca aggaccgat gtaactcttc tttagaaact tccagcccat gagccgtcag 21780
gtggtggatg atactaaata caaggactac caacaggtgg gcatcctaca ccaacacaac 21840
aactctggtt ttgttggtta ccttgcccc accatgcgog aaggacaggg ctaccctgct 21900
aacttcccc atccgcttat aggcaagacc gcagttgaca gcattacca gaaaaagttt 21960
ctttgcgatc gcacccttg gcgcatcca ttctccagta actttatgtc catggggcga 22020
ctcacagacc tgggcaaaaa ccttctctac gccaactccg cccacgcgct agacatgact 22080
tttaggtgg atcccatgga cgagcccacc cttctttatg tttgtttga agtctttgac 22140
gtggtccgtg tgcaccagcc gcaccggggc gtcacgaaa ccgtgtacct ggcacgccc 22200
ttctcggccg gcaacgccac aacataaaga agcaagcaac atcaacaaca gctgccgcca 22260
tgggtccag tgagcaggaa ctgaaagcca ttgtcaaaga tcttggttgt gggccatatt 22320
ttttgggac ctatgacaag cgctttccag gctttgttcc tccacacaag ctgcctgctg 22380
ccatagtcaa tacggccggt cgcgagactg ggggcgtaca ctggatggcc tttgcctgga 22440
accgcactc aaaaacatgc tacctctttg agccctttgg cttttctgac cagcgactca 22500
agcaggttta ccagtttgag tacgagctac tctgcgccc tagcgcatt gcttcttccc 22560
ccgaccgctg tataacgctg gaaaagtcca cccaagcgtt acaggggccc aactcggccc 22620

-continued

cctgtggact attctgctgc atgtttctcc acgcctttgc caactggccc caaactccca 22680
tggatcacia ccccaccatg aaccttatta cgggggtacc caactccatg ctcaacagtc 22740
cccaggta ca gcccaccctg cgtcgcaacc aggaacagct ctacagcttc ctggagcgcc 22800
actcgccta cttccgcagc cacagtgcgc agattaggag cgcaacttct tttgtcact 22860
tgaaaaacat gtaaaaaata tgtactagag acactttcaa taaaggcaaa tgcttttatt 22920
tgtacactct cgggtgatta tttaccccca cccttgccgt ctgcgccgtt taaaaatcaa 22980
aggggttctg ccgcgcctcg ctatcgccca ctggcagggc cacgttgcca tactggtgtt 23040
tagtgctcca cttaactca ggcacaacca tccgcggcag ctccgtgaag ttttactcc 23100
acaggctgcg caccatcacc aacgcgttta gcaggtcggg cgccgatatc ttgaagtcgc 23160
agttggggcc tccgccctgc gcgcgcaggt tgcgatacac agggttgcag cactggaaca 23220
ctatcagcgc cgggtggtgc acgctggcca gcacgctctt gtcggagatc agatcccgct 23280
ccaggctctc cgcgttctc agggcgaaag gagtcaactt tggtagctgc cttcccaaaa 23340
agggcgcgtg cccaggcttt gagttgcact cgcaccgtag tggcatcaaa aggtgaccgt 23400
gcccgtctg gcggttagga tacagcgct gcataaaaagc cttgatctgc ttaaaagcca 23460
cctgagcctt tgcgcctca gagaagaaca tgccgcaaga cttgccgaa aactgattgg 23520
ccggacaggc cgcgtctgac acgcagcacc ttgcgtcggg gttggagatc tgcaccacat 23580
ttcggcccca ccggttctc acgatcttg ccttgctaga ctgctcctc agcgcgcgct 23640
gcccgtttc gctcgtcaca tccatttcaa tcacgtctc cttatttacc ataagcttc 23700
cgtgtagaca cttaagctcg ccttcgatct cagcgcagcg gtgcagccac aacgcgcagc 23760
ccgtgggctc gtgatcttg taggtcacc ctgcaaacga ctgcaggtac gcctgcagga 23820
atcgcacct catcgtcaca aaggtcttgt tgctgggtgaa ggtcagctgc aaccgcgggt 23880
gctcctcgt cagccaggtc ttgcatacgg ccgccagagc ttccacttg tcaggcagta 23940
gtttgaagtt cgccttaga tgcgtatcca cgtggtactt gtcctcagc gcgcgcgcag 24000
cctccatgcc cttctccac gcagacacga tggcacact cagcgggttc atcaccgtaa 24060
ttcacttcc cgttcgctg ggctcttct cttcctctg cgtccgata ccaagcgcga 24120
ctgggtcgtc ttcattcagc cgcgcactg tgcgcttacc tctttgcca tgettatta 24180
gcaccgggtg gttgctgaaa cccaccatt gtacgcacc atcttctct tcttctcgc 24240
tgtccacgat taactctggt gatggcgggc gctcgggctt gggagaaggc cgttctttt 24300
tcttcttgg cgcaatggcc aaatccgcg ccgaggtcga tggccgcggg ctgggtgtgc 24360
gcggcaccag cgcgtcttgt gatgagtct cctcgtctc ggaactgata cgcgcctca 24420
tccgctttt tggggggccc cggggaggcg gcggcgacgg ggcggggac gacacgtcct 24480
ccatggttg gggacgtcgc gccgcaccgc gtccgcctc ggggtggtt tgcgctgct 24540
cctcttccc actggccatt tcttctct ataggcagaa aaagatcatg gagtcagtcg 24600
agaagaagga cagcctaacc gcccctctg agttcgcac caccgcctcc accgatgccg 24660
ccaacgcgc taccacctc ccgctcaggg caccctcct tgaggaggag gaagtatta 24720
tcgagcagga cccaggtttt gtaagcgaag acgacgagga ccgctcagta ccaacagagg 24780
ataaaaagca agaccaggac aacgcagagg caaacgagga acaagtcggg cggggggagc 24840
aaaggcatg cgactaccta gatgtgggag acgacgtgct gttgaagcat ctgcagcgc 24900

-continued

agtgcgccat	tatctgcgac	gcgttgcaag	agcgcagcga	tgtgcccctc	gccatagcgg	24960
atgtcagcct	tgectacgaa	cgccacctat	tctcaccgcg	cgtaccccc	aaacgccaag	25020
aaaaaggcac	atgcgagccc	aacccgcgcc	tcaacttcta	ccccgtat	gccgtgccag	25080
aggtgcttgc	cacctatcac	atctttttcc	aaaactgcaa	gataccccta	tcctgcccgtg	25140
ccaaccgcag	ccgagcggac	aagcagctgg	ccttgccgca	ggcgctgtc	atacctgata	25200
tcgectcgct	caacgaagtg	ccaaaaatct	ttgagggctc	tggacgcgac	gagaagcgcg	25260
cggcaaacgc	tctgcaacag	gaaaacagcg	aaaatgaaag	tcactctgga	gtgttggtgg	25320
aactcgaggg	tgacaacgcg	cgcctagccg	tactaaaaag	cagcatcgag	gtcaccact	25380
ttgectaccc	ggcacttaac	ctacccccca	aggtcatgag	cacagtcag	agtgagctga	25440
tcgtgcgccc	tcgagcggcc	ctggagaggg	atgcaaat	tcaagaacaa	acagaggagg	25500
gcctacccgc	agttggcgac	gagcagctag	cgcgctggct	tcaaacgcgc	gagcctgccc	25560
acttgaggga	gagcagcaaa	ctaatgatgg	ccgcagtgct	cgttacctgtg	gagcttgagt	25620
gcatgcagcg	gttctttgct	gacccggaga	tgacgcgcaa	gctagaggaa	acattgcact	25680
acacctttcg	acagggttac	gtacgccagg	cctgcaagat	ctccaacgtg	gagctctgca	25740
acctggtctc	ctaccttgga	atcttgcacg	aaaaccgcct	tgggcaaac	gtgcttcatt	25800
ccacgctcaa	ggcgagggcg	cgcgcgact	acgtccgca	ctgcgtttac	ttatttctat	25860
gctacacctg	gcagacggcc	atggcgcttt	ggcagcagtg	cttgaggagg	tgcaacctca	25920
aggagctgca	gaaactgcta	aagcaaaact	tgaaggacct	atggacggcc	ttcaacgagc	25980
gctccgtggc	cgcgcacctg	gcggacatca	ttttcccga	acgcctgctt	aaaaccctgc	26040
aacaggggtc	gccagacttc	accagtcaaa	gcatgttgca	gaactttagg	aactttatcc	26100
tagagcgctc	aggaatcttg	cccgcacct	gctgtgcact	tcctagcgac	ttgtgccc	26160
ttaagtaccg	cgaatgccct	ccgccgctt	ggggccactg	ctacctctg	cagctagcca	26220
actaccttgc	ctaccactct	gacataatgg	aagacgtgag	cggtgacggg	ctactggagt	26280
gtcactgtcg	ctgcaacctc	tgacccccg	accgctccct	ggtttgcaat	tcgagctgc	26340
ttaacgaaag	tcaaatatc	ggtaccttg	agctgcaggg	tcctcgccct	gacgaaaagt	26400
cccggtctcc	ggggttgaaa	ctcactccgg	ggctgtggac	gtcggcttac	cttcgcaaat	26460
ttgtacctga	ggactaccac	gcccacgaga	ttaggttcta	cgaagaccaa	tcccggcccgc	26520
ctaatacgga	gcttaccgcc	tgcgctatta	cccagggcca	cattcttggc	caattgcaag	26580
ccatcaacaa	agcccgccaa	gagtttctgc	tacgaaaggg	acgggggggt	tacttgacc	26640
cccagtcggg	cgaggagctc	aacccaatcc	ccccggccgc	gcagccctat	cagcagcagc	26700
cgcgggcccct	tgcttcccag	gatggcacc	aaaaagaagc	tgacgctgcc	gcccaccacc	26760
acggacgagg	aggaatactg	ggacagtcag	gcagaggagg	ttttggacga	ggaggaggag	26820
gacatgatgg	aagactggga	gagcctagac	gaggaagctt	ccgaggtcga	agaggtgtca	26880
gacgaaacac	cgtcaccctc	ggtcgcatc	ccctcgccgg	cgcccagaa	atcggaacc	26940
ggttccagca	tggtacaaac	ctccgctcct	caggccgcgc	cggcactgcc	cgttcgccga	27000
cccaaccgta	gatgggacac	cactggaacc	agggccggta	agccaagca	gcccggcccg	27060
ttagcccaag	agcaacaaca	gcgccaaggg	taccgctcat	ggcgccggca	caagaacgcc	27120
atagttgctt	gcttgcaaga	ctgtgggggc	aacatctcct	tcgcccggcg	ctttcttctc	27180
taccatcacg	gcgtggcctt	ccccgtaac	atcctgcatt	actaccgtca	tctctacagc	27240

-continued

ccatactgca cggcgccag cggcagcaac agcagcggcc acacagaagc aaaggcgacc 27300
ggatagcaag actctgacaa agcccaagaa atccacagcg gcggcagcag caggaggagg 27360
agcgtgcgct ctggcgccca acgaaccctg atcgaccctg gagcttagaa acaggatfff 27420
tcccactctg tatgctatat ttcaacagag caggggcccga gaacaagagc tgaaaataaa 27480
aaacaggtct ctgcatccc tcaccgcag ctgcctgtat cacaaaagcg aagatcagct 27540
tcggcgcaag ctggaagagc cggaggctct cttcagtaaa tactgcgcgc tgactcttaa 27600
ggactagttt cgcgcccttt ctcaaattta agcgcgaaaa ctacgtcctc tccagcggcc 27660
acaccggcgc ccagcacctg ttgtcagcgc cattatgagc aaggaaattc ccacgcctta 27720
catgtggagt taccagccac aaatgggact tgcggctgga gctgcccaag actactcaac 27780
ccgaataaac tacatgagcg cgggaaccca catgatatcc cgggtcaacg gaatacgcgc 27840
ccaccgaaac cgaattctcc tggaacagcg ggctattacc accacacctc gtaataacct 27900
taatccccgt agttggcccc ctgccctggg gtaccaggaa agtcccctc ccaccactgt 27960
ggtaactccc agagacgccc aggccgaagt tcagatgact aactcagggg cgcagcttgc 28020
ggcgcgcttt cgtcacaggg tgcggtcgcc cgggcagggt ataactcacc tgacaatcag 28080
agggcgagggt attcagctca acgacagctc ggtgagctcc tcgcttggtc tccgtccgga 28140
cgggacattt cagatcggcg gcgccggcgc ctcttcattc acgctcctc aggcaatcct 28200
aactctgcag acctcgtcct ctgagccgcg ctctggaggc attggaactc tgcaatttat 28260
tgaggagttt gtgccatcgg tctactttaa ccccttctcg ggacctcccg gccactatcc 28320
ggatcaattt attcctaact ttgacgcggg aaaggactcg gcggacggct acgactgaat 28380
gttaagtgga gaggcagagc aactgcgcct gaaacacctg gtccactgct gccgccacaa 28440
gtgctttgcc cgcgactcgg gtgagttttg ctactttgaa ttgcccaggg atcatatcga 28500
gggccccggc cagcggctcc ggcttaccgc ccaggagag cttgccgta gcctgattcg 28560
ggagtttacc cagcgcccc tgctagttag gcgggacagg ggaccctgtg ttctcactgt 28620
gatttgcaac tgtcctaacc ctggattaca tcaagatctt tgttgccatc tctgtgctga 28680
gtataataaa tacagaaatt aaaatatact ggggctccta tcgccatcct gtaaacgcca 28740
cgtctctcac ccgcccaagc aaaccaagcg gaaccttacc tggtactttt aacatctctc 28800
cctctgtgat ttacaacagt ttcaaccag acggagttag tctacgagag aacctctccg 28860
agctcagcta ctccatcaga aaaaacacca cctccttac ctgccgggaa cgtacgagtg 28920
cgtcacccgc cgctgcacca cacctaccgc ctgaccgtaa accagacttt tcccgacag 28980
acctcaataa ctctgtttac cagaacagga ggtgagctta gaaaaccctt agggatttag 29040
gccaaaggcg cagctactgt ggggtttatg aacaattcaa gcaactctac gggctattct 29100
aattcaggtt tctctagaat cggggttggg gttattctct gtcttgatgat tctctttatt 29160
cttatactaa cgcttctctg cctaaggctc gccgcctgct gtgtgcacat ttgcatttat 29220
tgtcagcttt ttaaaccgctg gggctgcacc ccaagatgat taggtacata atcctaggtt 29280
tactaccctt tgcgtcagcc cacggtacca cccaaaagggt ggattttaag gagccagcct 29340
gtaatgttac attcgcagct gaagctaattg agtgcaccac tcttataaaa tgcaccacag 29400
aacatgaaaa gctgcttatt cgccacaaaa acaaaattgg caagtatgct gtttatgcta 29460
tttggcagcc aggtgacact acagagtata atgttacagt tttccagggt aaaagtcaata 29520

-continued

aaacttttat	gtatactttt	ccattttatg	aaatgtgcga	cattaccatg	tacatgagca	29580
aacagtataa	gttgtggccc	ccacaaaatt	gtgtggaaaa	cactggcact	ttctgctgca	29640
ctgctatgct	aattacagtg	ctcgctttgg	tctgtaccct	actctatatt	aaatacaaaa	29700
gcagacgcag	ctttattgag	gaaaagaaaa	tgccttaatt	tactaagtta	caaagcta	29760
gtcaccacta	actgctttac	tcgctgcttg	caaaaacaat	tcaaaaagtt	agcattataa	29820
ttagaatag	atttaaacc	cccggtcatt	tctgtctcaa	taccattccc	ctgaacaatt	29880
gactctatgt	gggatatgct	ccagcgtac	aaccttgaag	tcaggcttcc	tggatgtcag	29940
catctgactt	tggccagcac	ctgtcccgcg	gatttgctcc	agtccaacta	cagcgacca	30000
ccctaacaga	gatgaccaac	acaaccaacg	cggccgccgc	taccggactt	acatctacca	30060
caaatacacc	ccaagtttct	gcctttgtca	ataactggga	taacttgggc	atgtggtggt	30120
tctccatagc	gcttatgttt	gtatgcttta	ttattatgtg	gctcatctgc	tgctaaagc	30180
gcaaacgcgc	ccgaccacc	atctatagtc	ccatcattgt	gctacacca	acaatgatg	30240
gaatccatag	attggacgga	ctgaaacaca	tgttcttttc	tcttacagta	tgattaaatg	30300
agacatgatt	cctcgagttt	ttatattact	gacccttgtt	gcgctttttt	tgtgcgtgct	30360
ccacattggc	tgcggtttct	cacatogaag	tagactgcat	tccagccttc	acagtctatt	30420
tgctttacg	atgtgtcacc	ctcacgctca	tctgcagcct	catcactgtg	gctcatgcct	30480
ttatccagtg	cattgactgg	gtctgtgtgc	gctttgcata	tctcagacac	catcccagt	30540
acagggacag	gactatagct	gagctcttta	gaattcttta	attatgaaat	ttactgtgac	30600
ttttctgctg	attatttgca	ccctatctgc	gttttgttcc	ccgacctcca	agcctcaaag	30660
acatatatca	tgcagattca	ctcgtatatg	gaatattcca	agttgctaca	atgaaaaaag	30720
cgatctttcc	gaagcctggt	tatatgcaat	catctctgtt	atggtgttct	gcagtaccat	30780
cttagcccta	gctatatatc	cctacctga	cattggctgg	aacgcaatag	atgccatgaa	30840
ccaccaact	ttccccgcgc	ccgctatgct	tccactgcaa	caagttgttg	ccggcggett	30900
tgtcccagcc	aatcagcctc	gcccaccttc	tcccaccccc	actgaaatca	gctactttaa	30960
tctaacagga	ggagatgact	gacaccctag	atctagaaat	ggacggaatt	attacagagc	31020
agcgcctgct	agaaaagcgc	agggcagcgg	ccgagcaaca	gcgcatgaat	caagagctcc	31080
aagacatggt	taacttgca	cagtgcacaaa	ggggtatctt	ttgtctggta	aagcaggcca	31140
aagtaccta	cgacagtaat	accaccggac	accgccttag	ctacaagttg	ccaaccaagc	31200
gtcagaaaat	ggtggtcatg	gtgggagaaa	agccattac	cataactcag	cactcggtag	31260
aaaccgaag	ctgcattcac	tcacctgtgc	aaggacctga	ggatctctgc	acccttatta	31320
agacctgtg	cggctctcaa	gatcttattc	cctttaacta	ataaaaaaaaa	ataataaagc	31380
atcacttact	taaaatcagt	tagcaaat	ctgtccagtt	tattcagcag	cacctccttg	31440
ccctcctccc	agctctggta	ttgcagcttc	ctcctggctg	caaactttct	ccacaatcta	31500
aatggaatgt	cagtttctcc	ctgttctctg	ccatccgcac	ccactatctt	catggtgttg	31560
cagatgaagc	gcgcaagacc	gtctgaagat	accttcaacc	ccgtgtatcc	atatgacacg	31620
gaaaccggtc	ctccaactgt	gccttttctt	actcctcctt	ttgtatcccc	caatggggtt	31680
caagagagtc	cccctggggt	actctctttg	cgctatccg	aacctctagt	tacctccaat	31740
ggcatgcttg	cgctcaaaat	gggcaacggc	ctctctctgg	acgaggccgg	caaccttacc	31800
tcccaaatg	taacctgt	gagcccacct	ctcaaaaaaa	ccaagtcaaa	cataaacttg	31860

-continued

gaaatatctg caccctcac agttaoctca gaagccctaa ctgtggctgc cgccgcacct	31920
ctaattggtcg cgggcaaac actcaccatg caatcacagc ccccgctaac cgtgcacgac	31980
tccaaactta gattgcccac ccaaggacc ctcacagtgt cagaaggaaa gctagccctg	32040
caaacatcag gccccctcac caccaccgat agcagtacc ttactatcac tgcctcacc	32100
cctctaacta ctgccactgg tagcttgggc attgacttga aagagcccat ttatacacia	32160
aatggaaaac taggactaaa gtacggggct cctttgcatg taacagacga cctaaacct	32220
ttgaccgtag caactggtcc aggtgtgact attaataata cttccttga aactaaagt	32280
actggagcct tgggttttga ttcacaaggc aatatgcaac ttaatgtagc aggaggacta	32340
aggattgatt ctcaaacag acgccttata cttgatgtta gttatccgtt tgatgctcaa	32400
aaccaactaa atctaagact aggacagggc cctcttttta taaactcagc ccacaacttg	32460
gatattaact acaacaaagg cctttacttg tttacagctt caaacaattc caaaaagctt	32520
gaggtaaac taagcactgc caaggggtg atgtttgacg ctacagccat agccattaat	32580
gcaggagatg ggcttgaatt tggttocct aatgcaccaa acacaaatcc cctcaaaaca	32640
aaaattggcc atggcctaga atttgattca aacaaggcta tggttcctaa actaggaact	32700
ggccttagtt ttgacagcac aggtgccatt acagtaggaa acaaaaataa tgataagcta	32760
actttgtgga ccacaccagc tccatctcct aactgtagac taaatgcaga gaaagatgct	32820
aaactcactt tggcttaaac aaaatgtggc agtcaaacac ttgctacagt ttcagttttg	32880
gctgttaaag gcagtttggc tccaatatct ggaacagttc aaagtgtca tcttattata	32940
agatttgacg aaaatggagt gctactaac aattccttc tggaccaga atattggaac	33000
ttagaatg gagatcttac tgaaggcaca gcctatacaa acgctgttg atttatgcct	33060
aacctatcag cttatccaaa atctcaggt aaaactgcca aaagtaacat tgtcagtcaa	33120
gtttacttaa acggagacaa aactaacct gtaacactaa ccattacact aaacggtaca	33180
caggaaacag gagacacaac tccaagtgca tactctatgt cattttcatg ggactggtct	33240
ggccacaact acattaatga aatatttggc acatcctctt acactttttc atacattgce	33300
caagaataaa gaatcgtttg tgttatgttt caacgtgttt atttttcaat tgcagaaaat	33360
ttcaagtcat ttttcattca gtagtatagc cccaccacca catagcttat acagatcacc	33420
gtacctaat caaactcaca gaaccctagt attcaacctg ccacctccct cccaacacac	33480
agagtacaca gtcccttctc cccggtggc cttaaaaagc atcatatcat gggtaacaga	33540
catattctta ggtgttatat tccacacggt ttcctgtcga gccaaacgct catcagtgat	33600
attaataaac tccccgggca gctcacttaa gttcatgtcg ctgtccagct gctgagccac	33660
aggctgctgt ccaacttgcg gttgctaac gggcgcgcaa ggagaagtcc acgcctacat	33720
gggggtagag tcataatcgt gcatcaggat agggcggtgg tgcgtcagca gcgcgcgaat	33780
aaactgctgc cgcgccgct ccgtcctgca ggaatacaac atggcagtggt tctcctcagc	33840
gatgattcgc accgcccga gcataaggcg ccttgtctc cgggcacagc agcgcacct	33900
gatctcactt aaatcagcac agtaactgca gcacagcacc acaatattgt tcaaaatccc	33960
acagtgcaag gcgctgtatc caaagctcat ggccgggacc acagaacca cgtggccatc	34020
ataccacaag cgcaggtaga ttaagtggcg acccctcata aacacgctgg acataaacat	34080
tacctctttt ggcattgtgt aatcaccac ctcccggtac catataaac tctgattaaa	34140

-continued

catggcgcca	tccaccacca	tccataacca	gctggccaaa	acctgcccgc	cggtatata	34200
ctgcaggaa	ccgggactgg	aacaatgaca	gtggagagcc	caggactcgt	aaccatggat	34260
catcatgctc	gtcatgatat	caatgttggc	acaacacagg	cacacgtgca	tacacttctc	34320
caggattaca	agctcctccc	gcgttagaac	catatcccag	ggaacaaccc	attcctgaat	34380
cagcgtaaat	cccacactgc	agggagacc	tcgcacgtaa	ctcacgttgt	gcattgtcaa	34440
agtgttacat	tcgggcagca	gcggatgatc	ctccagtatg	gtagcggggg	ttctgtctc	34500
aaaaggaggt	agacgatccc	tactgtaccg	agtgcccgca	gacaaccgag	atcgtgttgg	34560
tcgtagtgtc	atgccaaatg	gaacgccgga	cgtagtata	tttctgaag	caaaaccagg	34620
tcggggcgtg	acaaacagat	ctgcgtctcc	ggctcgcgcg	cttagatcgc	tctgtgtagt	34680
agttttagta	tatccactct	ctcaaagcat	ccaggcgcgc	cctggcttcg	ggttctatgt	34740
aaactccttc	atgcgcgctc	gccctgataa	catccaccac	cgcagaataa	gccacacca	34800
gccaacctac	acattcgttc	tcggagtcac	acacgggagg	agcgggaaga	gctggaagaa	34860
ccatgttttt	ttttttatcc	caaaagatta	tccaaaacct	caaaatgaag	atctattaag	34920
tgaacgcgct	cccctccggt	ggcgtggcca	aactctacag	ccaaagaaca	gataatggca	34980
tttgaagat	gttgcaaat	ggcttccaaa	aggcaaacgg	ccctcacgtc	caagtggacg	35040
taaaggctaa	acccttcagg	gtgaatctcc	tctataaaca	ttccagcacc	ttcaacctatg	35100
cccaataat	tctcatctcg	ccacctctc	aatatctctc	taagcaaatc	ccgaatatta	35160
agtcgggcca	ttgtaaaat	ctgctccaga	gcccctcca	ccttcagcct	caagcagcga	35220
atcatgattg	caaaaattca	ggttctctac	agacctgtat	aagattcaaa	agcggaacat	35280
taacaaaaat	accgcgatcc	cgtaggtccc	ttcgcagggc	cagctgaaca	taatcgtgca	35340
ggtctgcacg	gaccagcgcg	gccacttccc	cgccaggaac	catgacaaaa	gaaccacac	35400
tgattatgac	acgcatactc	ggagctatgc	taaccagcgt	agccccgatg	taagcttgtt	35460
gcatggggcg	cgatataaaa	tgcaaggctc	tgctcaaaaa	atcaggcaaa	gcctcgcgca	35520
aaaaagaaa	cacatcgtag	tcatgctcat	gcagataaag	gcaggtaagc	tccggaacca	35580
ccacagaaaa	agaccaccatt	tttctctcaa	acatgtctgc	gggtttctgc	ataaacacaa	35640
aataaaaaaa	caaaaaaaca	tttaaacatt	agaagcctgt	cttacaacag	gaaaaacaac	35700
ccttataagc	ataagacgga	ctacggccat	gccggcgtga	ccgtaaaaaa	actggtcacc	35760
gtgattaaaa	agcaccaccg	acagctctcc	ggctatgtcc	ggagtcataa	tgtaagactc	35820
ggtaaacaca	tcaggttgat	tcacatcggg	cagtgcataa	aagcgaccga	aatagcccgg	35880
gggaatacat	acccgcagcg	gtagagacaa	cattacagcc	cccataggag	gtatacaaaa	35940
attaatagga	gagaaaaaca	cataaacacc	tgaaaaaccc	tcctgcctag	gcaaaatagc	36000
accctcccgc	tccagaacaa	catacagcgc	ttccacagcg	gcagccataa	cagtcagcct	36060
taccagtaaa	aaagaaaacc	tattaaaaaa	acaccactcg	acacggcacc	agctcaatca	36120
gtcacagtgt	aaaaaagggc	caagtgcaga	gcgagtatat	ataggactaa	aaaatgacgt	36180
aacggttaaa	gtccacaaaa	aacaccacga	aaaccgcacg	cgaacctacg	cccagaaacg	36240
aaagccaaaa	aaccacaaac	ttcctcaaat	cgctcactcc	gttttcccac	gttacgtcac	36300
ttccattttt	aagaaaaacta	caattcccaa	cacatacaag	ttactccgcc	ctaaaaccta	36360
cgtcacccgc	cccgttccca	cgccccgcgc	cacgtcacia	actccacccc	ctcattatca	36420
tattggcttc	aatccaaaat	aaggtatatt	attgatgatg			36460

-continued

```

<210> SEQ ID NO 10
<211> LENGTH: 35203
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: PPE-1-3X-FasC vir1 construct (lacking repeats)
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (460)..(1437)
<223> OTHER INFORMATION: A modified murine pre-proendothelin-1 promoter
(PPE-1-3X)
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1438)..(1468)
<223> OTHER INFORMATION: Linker
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1469)..(2058)
<223> OTHER INFORMATION: TNFR portion of the Fas-TNFR-1 chimera (Fas-c)
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2059)..(2569)
<223> OTHER INFORMATION: FAS portion of the Fas-TNFR-1 chimera (Fas-c)

<400> SEQUENCE: 10

catcatcaat aatatacctt attttgatt gaagccaata tgataatgag ggggtggagt    60
ttgtgacgtg gcgcggggcg tgggaacggg gcgggtgacg tagtagtggtg gcggaagtgt    120
gatgttgcaa gtgtggcgga acacatgtaa gcgacggatg tggcaaaagt gacgtttttg    180
gtgtgcgccc gtgtacacag gaagtgacaa ttttcgcgcg gttttaggcg gatgtttag    240
taaatattgg cgtaaccgag taagatttgg ccattttcgc gggaaaactg aataagagga    300
agtgaaatct gaataatatt gtgttactca tagcgcgtaa tatttgtcta gggccgcggg    360
gactttgacc gtttactgtg agactcgccc aggtgttttt ctcaggtgtt ttcgcgcttc    420
cgggtcaaa gttggcgtttt attattatag tcagtagta cgtgtacttc tgatcgcgga    480
tactagggag ataaggatgt acctgacaaa accacattgt tgttggtatc attattattt    540
agttttcctt ccttgctaac tcctgacgga atctttctca cctcaaatgc gaagtacttt    600
agtttagaaa agacttggtg gaagggggtg tgggtgaaaa gtaggggat cttccaaact    660
aatctgggtc cccgcccgcc ccagtagctg ggattcaaga gcgaagagt gggatcgctc    720
cctgttttga tcagaagac ataaaaggaa aatcaagtga acaatgatca gccccactc    780
caccaccacc ccctgcgcgc gcacaataca atctatttaa ttgtacttca tacttttcat    840
tccaatgggg tgactttgct tctggagaaa ctcttgatc ttgaactctg gggctggcag    900
ctagcctcca gaagcaaagt caccocattg gaatgaaaag tatgaagtac aatgaaaagt    960
atgaagtact ggctccagaa gcaaagtcac cctccagaag caaagtcacc ccattggaat   1020
gaaaagtatg aagtacgcta gcaaaagggg aagcgggctg ctgctctctg caggttctgc   1080
agcggctctc gtctagtggt tgttttcttt ttcttagccc tgcccctgga ttgtcagacg   1140
gcgggcgtct gcctctgaag ttagecgtga tttcctctag agcgggtctc tatctctggc   1200
tgcacgttgc ctgtgggtga ctaatcacac aataacattg tttagggtctg gaataaagtc   1260
agagctgttt acccccactc tataggggtt caatataaaa aggcggcgga gaactgtccg   1320
agtcagaagc gttcctgcac cggcgctgag agcctgaccc ggtctgctcc gctgtccttg   1380
cgcgctgcct cccggctgcc cgcgaagctt tcgccccagt ggaagggcca cttgctgctg   1440
ccgtaattc tcagatcgg gatccggcat gggcctctcc accgtgctg acctgctgct   1500

```

-continued

gccgctggtg	ctcctggagc	tgttggtggg	aatatacccc	tcaggggtta	ttggactggt	1560
ccctcaccta	ggggacaggg	agaagagaga	tagtgtgtgt	ccccaaggaa	aatatatcca	1620
ccctcaaaat	aattcgattt	gctgtaccaa	gtgccacaaa	ggaacctact	tgtacaatga	1680
ctgtccaggc	ccggggcagg	ataccggactg	cagggagtgt	gagagcggt	ccttcaccgc	1740
ttcagaaaac	cacctcagac	actgcctcag	ctgctccaaa	tgccgaaagg	aaatgggtca	1800
ggtggagatc	tcttctgca	cagtggaccg	ggacaccgtg	tgtggctgca	ggaagaacca	1860
gtaccggcat	tattggagtg	aaaacctttt	ccagtgcttc	aattgcagcc	tctgcctcaa	1920
tgggaccgtg	cacctctcct	gccaggagaa	acagaacacc	gtgtgcacct	gccatgcagg	1980
tttctttcta	agagaaaacg	agtgtgtctc	ctgtagtaac	tgtaagaaaa	gcctggagtg	2040
cacgaagtgtg	tgctaccaa	gcttaggatc	cagatctaac	ttgggggtggc	tttgtcttct	2100
tcttttgcca	attccactaa	ttgtttgggt	gaagagaaag	gaagtacaga	aaacatgcag	2160
aaagcacaga	aagggaaaacc	aaggttctca	tgaatctcca	accttaaatc	ctgaaaacagt	2220
ggcaataaat	ttatctgatg	ttgacttgag	taaatatatac	accactattg	ctggagtcac	2280
gacactaagt	caagttaaag	gctttgttcg	aaagaatggt	gtcaatgaag	ccaaaataga	2340
tgagatcaag	aatgacaatg	tccaagacac	agcagaacag	aaagttcaac	tgttctgtaa	2400
ttggcatcaa	cttcatggaa	agaaagaagc	gtatgacaca	ttgattaaag	atctcaaaaa	2460
agccaatctt	tgtactcttg	cagagaaaat	tcagactatc	atcctcaagg	acattactag	2520
tgactcagaa	aattcaaact	tcagaaatga	aatccaaagc	ttggtctagc	tcgagcatgc	2580
atctaggcgg	ccgatggca	gaaatctcgc	aattcgctag	cgtaaacgga	tcctctagac	2640
gagatccgaa	cttgtttatt	gcagcttata	atggttacia	ataaagcaat	agcatcacia	2700
atctcaciaa	taaagcattt	tttctactgc	attctagtgt	tggtttgtcc	aaactcatca	2760
atgtatctta	tcagtcttag	atctgtactg	aaatgtgtgg	gcgtggctta	agggtgggaa	2820
agaatatata	agggtgggggt	cttatgtagt	tttgtatctg	ttttgcagca	gccgccggcg	2880
ccatgagcac	caactcgttt	gatggaagca	ttgtgagctc	atatttgaca	acgcgcatgc	2940
ccccatgggc	cgggggtcgt	cagaatgtga	tgggctccag	cattgatggt	cgccccgtcc	3000
tgcccgcaaa	ctctactacc	ttgacctacg	agaccgtgtc	tggaacgccg	ttggagactg	3060
cagcctccgc	cgccgcttca	gccgctgcag	ccaccgcccg	cgggattgtg	actgactttg	3120
ctttcctgag	cccgcttgca	agcagtgcag	cttcccgttc	atccgcccg	gatgacaagt	3180
tgacgctct	ttggcaciaa	ttggattctt	tgaccgggga	acttaatgtc	gtttctcagc	3240
agetgttgg	tctgcgccag	caggtttctg	ccctgaaggc	ttctcccct	cccaatggcg	3300
tttaaaacat	aaataaaaa	ccagactctg	tttggatttg	gatcaagcaa	gtgtcttgct	3360
gtctttat	aggggtttg	cgccgcgggt	aggccgggga	ccagcggct	cggtcgttga	3420
gggtcctgtg	tattttttcc	aggacgtgg	aaaggtgact	ctggatgttc	agatacatgg	3480
gcataagccc	gtctctgggg	tggaggtagc	accactgcag	agcttcatgc	tgcgggggtg	3540
tgtttagat	gatccagtcg	tagcaggagc	gctgggctg	gtgcctaaaa	atgtctttca	3600
gtagcaagct	gattgccagg	ggcaggccct	tggtgtaagt	gtttacaaag	cggttaagct	3660
gggatgggtg	catacgtggg	gatatgagat	gcactcttga	ctgtattttt	aggttggcta	3720
tgttcccagc	catatccctc	cggggattca	tggtgtgcag	aaccaccagc	acagtgtatc	3780

-continued

cgggtgcactt	gggaaatttg	tcatgtagct	tagaaggaaa	tgcgtggaag	aacttggaga	3840
cgcccttggtg	acctccaaga	ttttccatgc	attcgtccat	aatgatggca	atgggcccac	3900
ggggggcggc	ctgggcgaag	atatttctgg	gatcactaac	gtcatagtgtg	tgttccagga	3960
tgagatcgctc	ataggccatt	tttacaagc	gcgggcggag	ggtgccagac	tgcggtataa	4020
tggttccatc	cggcccaggg	gcgtagttag	cctcacagat	ttgcatttcc	cacgctttga	4080
gttcagatgg	ggggatcatg	tctacctgcg	gggcgatgaa	gaaaacggtt	tccgggtag	4140
gggagatcag	ctgggaagaa	agcaggttcc	tgagcagctg	cgacttaccc	cagccggtgg	4200
gcccgtaaat	cacacctatt	accggctgca	actggtagtt	aagagagctg	cagctgccc	4260
catccctgag	cagggggggc	acttcgttaa	gcattgtccct	gactcgcag	ttttccctga	4320
ccaaatccgc	cagaaggcgc	tgcgcccca	gcgatagcag	ttcttgcaag	gaagcaaagt	4380
ttttcaacgg	tttgagaccg	tccgcgtag	gcattgctttt	gagcgtttga	ccaagcagtt	4440
ccaggcggtc	ccacagctcg	gtcacctgct	ctacggcatc	tgcattccagc	atatctctc	4500
gtttcgcggg	ttggggcggc	tttcgctgta	cggcagtagt	cgggtgctcgt	ccagacgggc	4560
cagggtcatg	tctttccacg	ggcgcagggt	cctcgtcagc	gtagtctggg	tcacggtgaa	4620
ggggtgccc	ccgggctgcg	cgctggccag	ggtgcccctg	aggctggtcc	tgctggtgct	4680
gaagcgcctg	cggctctcgc	cctgcgcctc	ggccaggtag	catttgacca	tggtgtcata	4740
gtccagcccc	tccgcggcgt	ggcccttggc	gcgcagcttg	cccttgagg	aggcgcgca	4800
cgaggggag	tcagacttt	tgagggcgta	gagcttgggc	gcgagaaata	ccgattccgg	4860
ggagtaggca	tccgcgccgc	aggccccgca	gacggtctcg	cattccacga	gccaggtag	4920
ctctggccgt	tgggggtcaa	aaaccagggt	tccccatgc	tttttgatgc	gtttcttacc	4980
tctggtttcc	atgagccggt	gtccacgctc	ggtgacgaaa	aggctgtccg	tgtcccctga	5040
tacagacttg	agaggcctgt	cctcgagcgg	tgttcccgcg	tcctcctcgt	atagaaactc	5100
ggaccactct	gagacaaagg	ctcgcgtcca	ggccagcagc	aaggaggcta	agtgaggagg	5160
gtagcggctg	ttgtccacta	gggggtccac	tgcctccagg	gtgtgaagac	acatgtcgcc	5220
ctcttcggca	tcaaggaagg	tgattggttt	gtaggtgtag	gccacgtgac	cgggtgttcc	5280
tgaagggggg	ctataaaagg	gggtgggggc	gcgttcgtcc	tcactctctt	ccgcacgct	5340
gtctgcgagg	gccagctggt	ggggtgagta	ctccctctga	aaagcgggca	tgacttctgc	5400
gctaagattg	tcagtttcca	aaaacagga	ggatttgata	ttcacctggc	ccgcggtgat	5460
gcctttgagg	gtggccgcat	ccatctggtc	agaaaagaca	atctttttgt	tgtcaagctt	5520
ggtggcaaac	gaccctgata	ggcgttgga	cagcaacttg	gcgatggagc	gcagggtttg	5580
gtttttgtcg	cgatcggcgc	gctccttggc	cgcgatgttt	agctgcacgt	attcgcgcgc	5640
aacgcaccgc	cattcgggaa	agacggtggt	gcgctcgtcg	ggcaccagg	gcacgcgcca	5700
accgcggttg	tcaggggtga	caaggtcaac	gctggtggtc	acctctccgc	gtaggcgctc	5760
gttgggtccag	cagagggcgc	cgcccttggc	cgagcagaat	ggcggtaggg	ggtctagctg	5820
cgtctcgtcc	gggggtctg	cgtccacggt	aaagaccccg	ggcagcaggc	gcgcgtcgaa	5880
gtagtctatc	ttgcatcctt	gcaagtctag	cgcctgctgc	catgcgcggg	cggcaagcgc	5940
gcgctcgat	gggttagtg	ggggaccca	tggcatgggg	tgggtgagcg	cggaggcgta	6000
catgccgcaa	atgtcgtaaa	cgtagagggg	ctctctgagt	attccaagat	atgtagggta	6060
gcattctcca	ccgcggatgc	tggcgcgcac	gtaatcgtat	agttcgtgcg	agggagcgag	6120

-continued

gaggtcggga ccgaggttgc tacgggcccgg ctgctctgct cggaaagacta tctgcctgaa	6180
gatggcatgt gagttggatg atatggttgg acgctggaag acgttgaagc tggcgtctgt	6240
gagacctacc gcgtcacgca cgaaggaggc gtaggagtcg cgcagcttgt tgaccagctc	6300
ggcggtgacc tgcacgtcta gggcgcagta gtccagggtt tccttgatga tgcatactt	6360
atcctgtccc ttttttttcc acagctcgcg gttgaggaca aactcttcgc ggtctttcca	6420
gtactcttgg atcggaaacc cgtcggcctc cgaacggtaa gagcctagca tgtagaactg	6480
gttgacggcc tggtaggcgc agcatccctt ttctacgggt agcgcgtatg cctgcgcggc	6540
cttccggagc gaggtgtggg tgagcgc aaa ggtgtccctg accatgactt tgaggactg	6600
gtatttgaag tcagtgtcgt cgcacccgct ctgctcccag agcaaaaagt cctgctcctt	6660
tttgaacgc ggatttggca gggcgaaggt gacatcgtt aagagtatct ttcccgcgcg	6720
aggcataaaag ttgctgtgta tgcggaagg tcccggcacc tcggaacggt tgttaattac	6780
ctggcggcgc agcacgatct cgtcaaaacc gttgatgtt tggcccacaa tgtaaagtcc	6840
caagaagcgc gggatgccc t gatggaagg caatttttta agttcctcgt aggtgagctc	6900
ttcaggggag ctgagcccgt gctctgaaag ggcccagtct gcaagatgag ggttggaaac	6960
gacgaatgag ctccacaggt cacgggcat tagcatttgc aggtggctgc gaaaggtcct	7020
aaactggcga cctatggcca ttttttctg ggtgatgcag tagaagtaa gcgggtctt	7080
ttcccagcgc tcccaccaa ggttcgcgc taggtctcgc gcgcagtc ctagaggctc	7140
atctccgccc aacttcata ccagcatgaa gggcacgagc tgcttcccaa aggccccat	7200
ccaagtata gctctacat cgtaggtgac aaagagacgc tcggtgcgag gatgcgagcc	7260
gatcgggaag aactggatct cccgccacca attggaggag tggctattga tgtggtgaaa	7320
gtagaagtcc ctgcgacggg ccgaacactc gtgctggctt ttgtaaaaac gtgcgcagta	7380
ctggcagcgc tgcacgggct gtacatcctg cacagagttg acctgacgac cgcgcacaag	7440
gaagcagagt gggaatttga gcccctcgc tggcgggttt ggctggtggt cttctacttc	7500
ggctgcttgt ccttgaccgt ctggctgctc gaggggagtt acggtggatc ggaccaccac	7560
gccgcgcgag cccaaagtcc agatgtccc gcgcggcggc cggagcttga tgacaacatc	7620
gcgcagatgg gagctgtcca tggcttgag ctcccgcgc gtcaggtcag gcgggagctc	7680
ctgcaggttt acctcgcata gacgggtcag ggcgcgggct agatccaggt gatacctaat	7740
ttccaggggc tggttggtgg cggcgtcgt ggcttgaag aggccgcac cccgcggcgc	7800
gactacggta ccgcgcggc ggcggtgggc cgcgggggtg tccttgatg atgcatctaa	7860
aaagcgtgac gcgggcgagc ccccggaggt agggggggct ccggaccgc cgggagagg	7920
ggcaggggca cgtcggcgc gcgcgcgggc aggagctggt gctgcgcgc taggttgctg	7980
gcgaacgcga cgaacggcgt gttgatctcc tgaatctggc gcctctcgt gaagacgag	8040
ggcccgggta gcttgaacct gaaagagagt tcgacagaat caatttcggt gtcggtgacg	8100
gcggcctggc gcaaaatctc ctgacgtct cctgagttgt cttgataggc gatctcggcc	8160
atgaactgct cgatctcttc ctccctggaga tctccgcgct cggctcgcct caeggtggcg	8220
gcgaggtcgt tggaaatgcg ggccatgagc tgcgagaagg cgttgaggcc tccctcgttc	8280
cagacgcgcg ttagaccac gccccttcg gcatcgcggg cgcgcagatgac cacctgcgcg	8340
agattgagct ccacgtgccc ggcgaagac gcgtagtttc gcaggcgcgt aaagaggtag	8400

-continued

ttgagggtgg	tggcgggtgtg	ttctgccacg	aagaagtaca	taaccacagc	tcgcaacgtg	8460
gattcgttga	tatcccccaa	ggcctcaagg	cgctccatgg	cctcgtagaa	gtccacggcg	8520
aagttgaaaa	actgggagtt	gcgcgccgac	acggttaact	cctcctccag	aagacggatg	8580
agctcggcga	cagtgtcgcg	cacctcgcgc	tcaaaggcta	caggggcctc	ttcttcttct	8640
tcaatctcct	cttcataag	ggcctcccct	tcttcttctt	ctggcggcgg	tgggggaggg	8700
gggacacggc	ggcgacgacg	gcgcacccgg	aggcggtcga	caaagcgctc	gatcatctcc	8760
ccgcgccgac	ggcgcatggt	ctcggtgacg	gcgcgcccg	tctcgggggg	gcgcagttgg	8820
aagacgccc	ccgtcatgtc	ccggttatgg	gttggcgggg	ggctgccatg	cggcagggat	8880
acggcgctaa	cgatgcactc	caacaattgt	tgtgtaggtg	ctccgcccgc	gagggacctg	8940
agcgagtccg	catcgaccgg	atcggaaaac	ctctcgagaa	aggcgtctaa	ccagtcacag	9000
tcgcaaggta	ggctgagcac	cgtggcgggc	ggcagcgggc	ggcggtcggg	gttgtttctg	9060
gcgagggtgc	tgctgatgat	gtaattaaag	taggcggtct	tgagacggcg	gatggtcgac	9120
agaagcacca	tgtccttggg	tccggcctgc	tgaatgcgca	ggcggtcggc	catgccccag	9180
gcttcgtttt	gacatcggcg	caggtctttg	tagtagtctt	gcctgagcct	ttctaccggc	9240
acttcttctt	ctcttctctc	ttgtctgcga	tctcttgcat	ctatcgctgc	ggcggcggcg	9300
gagtttgggc	gtaggtggcg	ccctcttctc	cccatgctgt	tgacccgaa	gcccctcatc	9360
ggctgaagca	gggctaggtc	ggcgacaaag	cgctcggcta	atatggcctg	ctgcacctgc	9420
gtgagggtag	actggaagtc	atccatgtcc	acaaagcgg	ggtatgcgcc	cgtgttgatg	9480
gtgtaagtgc	agttggccat	aacggaccag	ttaacggtct	ggtgaccggg	ctgcgagagc	9540
tcggtgtacc	tgagacggca	gtaagccctc	gagtcaaata	cgtagtcggt	gcaagtccgc	9600
accaggtact	ggtatcccac	caaaaagtgc	ggcggcggct	ggcggtagag	gggccagcgt	9660
agggtgcccg	gggctccggg	ggcgagatct	tccaacataa	ggcgatgata	tccgtagatg	9720
tacctggaca	tccaggtgat	gcccggcggc	gtggtggagg	cgcgggaaa	gtcgcggacg	9780
cggttccaga	tgttgccgag	cggcaaaaag	tgctccatgg	tcgggacgct	ctggccggtc	9840
aggcgcgcgc	aatcgttgac	gctctagacc	gtgcaaaaag	agagcctgta	agcgggcaact	9900
cttcctggtt	ctggtggata	aattcgcaag	ggtatcatgg	cggacgaccg	gggttcgagc	9960
cccgtatccg	gcccgtccgc	gtgatccatg	cggttaccgc	ccgcgtgtcg	aaccagggtg	10020
tgcgacgtca	gacaacgggg	gagtgctcct	tttggcttcc	ttccaggcgc	ggcggctgct	10080
gcgctagctt	ttttggccac	tggccgcgcg	cagcgtaagc	ggttaggctg	gaaagcgaaa	10140
gcattaagtg	gctcgcctcc	tgtagccgga	gggttatttt	ccaagggttg	agtccgaggga	10200
cccccggttc	gagtcctcga	ccggccggac	tgcggcgaac	gggggtttgc	ctccccgtca	10260
tgcaagacce	cgcttgcaaa	ttcctccgga	aacagggacg	agcccccttt	ttgcttttcc	10320
cagatgcac	cggctgtcgc	gcagatgcgc	ccccctcctc	agcagcggca	agagcaagag	10380
cagcggcaga	catgcagggc	accctcccct	cctcctaccg	cgctaggagg	ggcgacatcc	10440
gcggttgacg	cggcagcaga	tgggtattac	gaacccccgc	ggcggcgggc	ccggcactac	10500
ctggaacttg	aggaggggca	gggcctggcg	cggctaggag	cgcctctctc	tgagcggcac	10560
ccaaggggtc	agctgaagcg	tgatacgcgt	gaggcgtacg	tgccggggca	gaacctgttt	10620
cgcgaccgcg	agggagagga	gcccagggag	atgcgggatc	gaaagttcca	cgcagggcgc	10680
gagctgccc	atggcctgaa	tcgcgagcgg	ttgctgcgcg	aggaggactt	tgagcccagc	10740

-continued

gcgcgaaccg ggattagtcc cgcgcgcgca cacgtggcgg ccgccgacct ggtaaccgca 10800
tacgagcaga cggatgaacca ggagattaac tttcaaaaaa gctttaacaa ccacgtgcgt 10860
acgcttgtag cgcgcgagga ggtggctata ggactgatgc atctgtggga ctttgtaagc 10920
gcgctggagc aaaacccaaa tagcaagccg ctcattggcg agctgttctct tatagtgcag 10980
cacagcaggg acaacgaggc attcagggat gcgctgctaa acatagtaga gcccgagggc 11040
cgctggctgc tcgatttgat aaacatcctg cagagcatag tggcgcagga gcgcagcttg 11100
agcctggctg acaaggtggc gcctatcaac tattccatgc ttagcctggg caagtgtttac 11160
gcccgaaga tataccatac cccttacgtt cccatagaca aggaggtaaa gatcgagggg 11220
ttctacatgc gcatggcgtc gaaggtgctt acctgagcg acgacctggg cgtttatcgc 11280
aacgagcgca tccacaaggc cgtgagcgtg agccggcggc gcgagctcag cgaccgcgag 11340
ctgatgcaca gcctgcaaaag ggccctggct ggcacgggca gcggcgatag agaggccgag 11400
tctactttg acgcgggcgc tgacctgcgc tgggcccaca gccgacgcgc cctggaggca 11460
gctggggccc gacctgggct ggccgtggca cccgcgcgcg ctggcaacgt cggcggcgtg 11520
gaggaatatg acgaggacga tgagtacgag ccagaggacg gcgagtacta agcggtgatg 11580
ttctgatca gatgatgcaa gacgcaacgg acccggcggg gcggggcggc ctgcagagcc 11640
agcctccgc ccttaactcc acggaacgact ggcgccaggc catggaccgc atcatgtcgc 11700
tgactgcgcg caatcctgac gcgttcggc agcagccgca ggccaaccg ctctccgcaa 11760
ttctggaagc ggtggtcccg gcgcgcgcaa accccacgca cgagaagggt ctggcgatcg 11820
taaacgcgct gccgcaaac agggccatcc ggcccacga ggccggcctg gtctacgacg 11880
cgctgcttca gcgcgtggct cgttacaaca gcggcaacgt gcagaccaac ctggaccggc 11940
tggtggggga tgtgcgcgag gccgtggcgc agcgtgagcg cgcgcagcag cagggcaacc 12000
tggtctccat ggttgcaact aacgccttcc tgagtacaca gcccgccaac gtgccgcggg 12060
gacaggagga ctacaccaac tttgtgagcg cactgcggct aatggtgact gagacaccgc 12120
aaagtgaggc gtaccagtct gggccagact atttttcca gaccagtaga caaggcctgc 12180
agaccgtaaa cctgagccag gctttcaaaa acttgacggg gctgtggggg gtgcgggctc 12240
ccacaggcga ccgcgcgacc gtgtctagct tgctgacgcc caactcgcgc ctgttgctgc 12300
tgctaatagc gcccttcacg gacagtggca gcgtgtcccg ggacacatac ctaggteact 12360
tgctgacact gtaccgcgag gccataggtc aggcgcattg ggacgagcat actttccagg 12420
agattacaag tgtcagccgc gcgctggggc agggagacac gggcagcctg gaggcaacc 12480
taaaactacct gctgaccaac cggcggcaga agatcccctc gttgcacagt ttaaacagcg 12540
aggaggagcg cttttgcgc tacgtgcagc agagcgtgag ccttaacctg atgcgcgacg 12600
gggtaacgcc cagcgtggcg ctggacatga ccgcgcgcaa catggaaccg ggcattgatg 12660
cctcaaacgg gccgtttatc aaccgcctaa tggactactt gcatcgcgcg gccgccgtga 12720
accccgagta tttaccaaat gccatcttga acccgactg gctaccgcc cctggtttct 12780
acaccggggg attcaggggt cccgagggta acgatggatt cctctgggac gacatagacg 12840
acagcgtggt tccccgcaa ccgcagaccc tgctagagtt gcaacagcgc gagcaggcag 12900
aggcggcgtc gcgaaaggaa agcttccgca ggccaagcag cttgtccgat ctaggcgtg 12960
cgccccgcg gtcagatgct agtagcccat ttccaagctt gatagggtct cttaccagca 13020

-continued

ctcgaccac	cgccccgc	ctgctggcg	aggaggagta	cctaacaac	tcgctgctgc	13080
agccgcagcg	cgaaaaaac	ctgcctccg	catttccaa	caacgggata	gagagcctag	13140
tggacaagat	gagtagatgg	aagacgtacg	cgcaggagca	cagggacgtg	ccaggcccc	13200
gccccccac	cgctcgtcaa	aggcacgacc	gtcagcggg	tctggtgtgg	gaggacgatg	13260
actcggcaga	cgacagcagc	gtcctggatt	tgggaggag	tggcaaccg	tttgcgcacc	13320
ttcggccag	gctggggaga	atgttttaa	aaaaaaaaa	gcatgatgca	aaataaaaa	13380
ctcaccaagg	ccatggcacc	gagcgttgg	tttcttggat	tccccttagt	atgcggcgcg	13440
cgcgatgta	tgaggaggt	cctcctcct	cctacgagag	tgtggtgagc	gcgcgccag	13500
tggcgggcg	gctgggttct	cccttogatg	ctcccctgga	cccgcggtt	gtgctccgc	13560
ggtacctg	gctaccggg	gggagaaaca	gcacccgta	ctctgagttg	gcaccctat	13620
tcgacaccac	ccgtgtgtac	ctggtggaca	acaagtcaac	ggatgtggca	tcctgaact	13680
accagaacga	ccacagcaac	tttctgacca	cggtcattca	aaacaatgac	tacagcccg	13740
gggaggcaag	cacacagacc	atcaatcttg	acgaccggtc	gactggggc	ggcgacctga	13800
aaaccatcct	gcataccaac	atgccaaatg	tgaacgagtt	catgtttacc	aataagtta	13860
aggcgggggt	gatggtgtcg	cgcttgctca	ctaaggacaa	tcaggtggag	ctgaaatag	13920
agtgggtgga	gtcacgctg	cccaggggca	actactccga	gaccatgacc	atagacctta	13980
tgaacaacgc	gatcgtggag	cactacttga	aagtgggag	acagaacggg	ggtctggaaa	14040
gcgacatcgg	ggtaaagtt	gacacccgca	acttcagact	ggggtttgac	ccgctcactg	14100
gtcttgctat	gcctggggta	tatacaaacg	aagccttcca	tccagacatc	atcttgctgc	14160
caggatcggg	ggtggacttc	acccacagcc	gctgagca	cttggtgggc	atccgcaagc	14220
ggcaaccctt	ccaggagggc	tttaggatca	cctacgatga	tctggagggt	ggtaacattc	14280
ccgcactggt	ggatgtggac	gcctaccagg	cgagcttgaa	agatgacacc	gaacaggcg	14340
ggggtggcgc	aggcggcagc	aacagcagtg	gcagcggcgc	ggaagagaac	tccaacggcg	14400
cagcccgggc	aatgcagccg	gtggaggaca	tgaacgatca	tgccattcgc	ggcgacacct	14460
ttgccacacg	ggctgaggag	aagcgcgctg	aggccgaagc	agcggccgaa	gctgcccgc	14520
ccgctgcgca	acccgaggtc	gagaagcctc	agaagaaacc	ggtgatcaaa	ccctgacag	14580
aggacagcaa	gaaacgcagt	tacaacctaa	taagcaatga	cagcaccttc	accagtagc	14640
gcagctggta	ccttgcatac	aactacggcg	accctcagac	cggaatccgc	tcattggacc	14700
tgtttgca	tcctgacgta	acctgcggct	cggagcaggt	ctactggtcg	ttgccagaca	14760
tgatgcaaga	ccccgtgacc	ttccgctcca	cgcgccagat	cagcaacttt	ccggtggtgg	14820
gcgcccagct	gttccccgtg	cactccaaga	gcttctacaa	cgaccaggcc	gtctactccc	14880
aactcatccg	ccagtttacc	tctctgacct	acgtgttcaa	tcgctttccc	gagaaccaga	14940
ttttggcgcg	cccgccagcc	cccaccatca	ccaccgtcag	tgaacaggtt	cctgctctca	15000
cagatcaccg	gacgctaccg	ctgcgcaaca	gcacggagg	agtccagcga	gtgaccatta	15060
ctgacgccag	acgcccacc	tgcccctacg	tttacaaggc	cctgggcata	gtctcgcgc	15120
gcgtcctatc	gagccgcact	ttttgagcaa	gcattgtccat	ccttatatcg	cccagcaata	15180
acacaggctg	gggctgcgc	ttcccagca	agatgtttgg	cggggccaag	aagcgtccg	15240
accaacaccc	agtgcgcgtg	cgcgggcact	accgcgcgcc	ctggggcgcg	cacaaacgcg	15300
gcccactg	gcgaccacc	gtcgatgacg	ccatcgacgc	ggtggtggag	gaggcgcgca	15360

-continued

actacacgcc cagcccgcca ccagtgtcca cagtggacgc ggccattcag accgtggtgc 15420
gcgagacccg gcgctatgct aaaatgaaga gacggcggag gcgctagca cgtcgccacc 15480
gcccgcgacc cggcactgcc gcccaacgcg cggcggcggc cctgcttaac cgcgcacgtc 15540
gcaccggccg acggggcgcc atgccccgcg ctgcaagget ggccgcggtt attgtcactg 15600
tgccccccag gtccaggcga cgagcggccg ccgcagcagc cgcggccatt agtgctatga 15660
ctcagggtcg caggggcaac gtgtattggg tgcgcgactc ggttagcggc ctgcgcgtgc 15720
ccgtgctcac ccgccccccg cgcaactaga ttgcaagaaa aaactactta gactcgtact 15780
gttgtatgta tccagcggcg gcggcgcgca acgaagctat gtccaagcgc aaaatcaaag 15840
aagagatgct ccaggtcatc gcgcccggaga tctatggccc ccggaagaag gaagagcagg 15900
attacaagcc ccgaaagcta aagcgggtca aaaagaaaaa gaaagatgat gatgatgaac 15960
ttgacgacga ggtggaactg ctgcacgcta ccgcgcccag gcgacgggta cagtggaaag 16020
gtcgacgcgt aaaacgtggt ttgcgaccgg gcaccaccgt agtctttacg cccggtgagc 16080
gctccacccc cactacaag cgcgtgtatg atgaggtgta cggcgacgag gacctgcttg 16140
agcaggccaa cgagcgcctc ggggagtgtg cctacggaaa gcgacataag gacatgctgg 16200
cgttgccgct ggacgagggc aacccaacac ctagcctaaa gcccgtaaca ctgcagcagg 16260
tgctgcccgc gcttgcaccg tccgaagaaa agcgcggcct aaagcgcgag tctggtgact 16320
tggcaccacc cgtgcagctg atggtaccga agcgcagcgc actggaagat gtcttggaag 16380
aaatgaccgt ggaacctggg ctggagcccg aggtccgctg gcggccaatc aagcaggtgg 16440
cgccgggact gggcgtgcag accgtggacg ttcagatacc cactaccagt agcaccagta 16500
ttgccaccgc cacagagggc atggagacac aaacgtcccc ggttgctca gcggtggcgg 16560
atgcccgggt gcaggcggtc gctgcggccg cgtccaagac ctctacggag gtgcaaacgg 16620
accgtggat gtttcgctt tcagcccccc ggcgcccgcg ccgttcgagg aagtacggcg 16680
ccgcagcgc gctactgccc gaatatgccc tacatccttc cattgcgctt acccccggct 16740
atcgtggcta cactaccgc ccgagaagac gagcaactac ccgacgccga accaccactg 16800
gaacccgccc ccgcccgcg cgtcgccagc ccgtgctggc cccgatttcc gtgcgcaggg 16860
tggtcgcgca aggagcagc accctggtgc tgccaacagc gcgctaccac cccagcatcg 16920
tttaaaagcc ggtctttgtg gttcttgacg atatggccct cactgcccgc ctccgtttcc 16980
cggtgcccgg attccgagga agaatgcacc gtaggagggg catggccggc cagggcctga 17040
cgggcggcat gcgtcgtgcg caccaccggc ggcggcgcgc gtcgcaccgt cgcgatgcg 17100
gcggtatcct gcccctcctt attccactga tcgcccggcg gattggcgcc gtgcccggaa 17160
ttgcatccgt gcccttcgag gcgcagagac actgattaaa aacaagtgc atgtggaaaa 17220
atcaaaaata aaagtctgga ctctcagctc cgcttggtcc tgtaactatt ttgtagaatg 17280
gaagacatca actttgcgtc tctggccccg cgacacggct cgcgcccgtt catgggaaac 17340
tggaagata tcggcaccag caatatgagc ggtggcgccct tcagctgggg ctgctgtgg 17400
agcggcatta aaaatttcgg ttccaccgtt aagaactatg gcagcaaggc ctggaacagc 17460
agcacaggcc agatgctgag ggataagttg aaagagcaaa atttccaaca aaaggtggta 17520
gatggcctgg cctctggcat tagcgggggtg gtggacctgg ccaaccaggc agtgcaaaat 17580
aagattaaca gtaagcttga tccccgcctt ccgtagagg agcctccacc ggccgtggag 17640

-continued

acagtgctc	cagagggcg	tggcgaaaag	cgcccgccc	ccgacagga	agaaactctg	17700
gtgacgcaa	tagacgagc	tccctcgtac	gaggaggcac	taaagcaagg	cctgcccacc	17760
accgctcca	tcgcgccat	ggctaccgga	gtgctgggccc	agcacacacc	cgtaacgctg	17820
gacctgcctc	ccccgcccga	caccagcag	aaacctgtgc	tgccaggccc	gaccgcccgtt	17880
gttgtaacc	gtcctagccg	cgcgtccctg	cgccgcccgcg	ccagcggctc	gcatcgttg	17940
cgcccgctag	ccagtggcaa	ctggcaaac	aaactgaaca	gcatcgtggg	tctgggggtg	18000
caatccctga	agcgcgcagc	atgcttctga	tagctaactg	gtcgtatgtg	tgtcatgtat	18060
gcgtccatgt	cgccgcccaga	ggagctgctg	agccgcccgcg	cgcccgtttt	ccaagatggc	18120
taccctctg	atgatgccgc	agtgttctta	catgcacatc	tcgggcccagg	acgctcggga	18180
gtacctgagc	cccgggctgg	tcagtttgc	cgccgcccacc	gagacgtact	tcagcctgaa	18240
taacaagttt	agaaacccca	cggtggcgcc	tacgcacgac	gtgaccacag	accggtccca	18300
gcgtttgacg	ctgcggttca	tccctgtgga	ccgtgaggat	actgcgtact	cgtacaaggc	18360
gcggttcacc	ctagctgtgg	gtgataaccg	tgtgctggac	atggcttcca	cgtactttga	18420
catccgcggc	gtgctggaca	ggggccctac	ttttaagccc	tactctggca	ctgctacaa	18480
cgccctggct	cccaagggtg	ccccaaatcc	ttgcaaatgg	gatgaagctg	ctactgctct	18540
tgaataaac	ctagaagaag	aggacgatga	caacgaagac	gaagtagacg	agcaagctga	18600
gcagcaaaaa	actcacgtat	ttgggcaggc	gccttattct	ggtataaata	ttacaaagga	18660
gggtattcaa	ataggtgtcg	aaggtcaaac	acctaataat	gccgataaaa	catttcaacc	18720
tgaacctcaa	ataggagaat	ctcagtggta	cgaaacagaa	attaatcatg	cagctgggag	18780
agtccataaaa	aagactacc	caatgaaacc	atgttacggt	tcatatgcaa	aaccacaaa	18840
tgaaatgga	gggcaaggca	ttcttgtaaa	gcaacaaat	ggaagctag	aaagtcaagt	18900
ggaaatgcaa	ttttctcaa	ctactgaggc	agccgagggc	aatggtgata	acttgactcc	18960
taaagtggta	ttgtacagtg	aagatgtaga	tatagaaacc	ccagacactc	atatttctta	19020
catgcccact	attaaggaag	gtaactcacg	agaactaatg	ggccaacaat	ctatgcccga	19080
caggccta	tacattgctt	ttagggacaa	ttttattggt	ctaattgatt	acaacagcac	19140
gggtaatatg	ggtgttctgg	cgggccaagc	atcgcagttg	aatgctgttg	tagatttgca	19200
agacagaaac	acagagcttt	cataccagct	tttgcttgat	tccattggtg	atagaaccag	19260
gtacttttct	atgtggaatc	aggctgttga	cagctatgat	ccagatgta	gaattattga	19320
aaatcatgga	actgaagatg	aacttccaaa	ttactgcttt	ccactgggag	gtgtgattaa	19380
tacagagact	cttaccgaag	taaaacctaa	aacaggtcag	gaaatggat	gggaaaaaga	19440
tgctacagaa	ttttcagata	aaaatgaaat	aagagttgga	aataattttg	ccatggaaat	19500
caatctaaat	gccaaactgt	ggagaaattt	cctgtactcc	aacatagcgc	tgtatttgcc	19560
cgacaagcta	aagtacagtc	cttccaacgt	aaaaatttct	gataacccaa	acacctacga	19620
ctacatgaac	aagcgagtg	tggctcccgcg	gctagtggac	tgctacatta	accttggagc	19680
acgctggctc	cttgactata	tggacaacgt	caaccattt	aaccaccacc	gcaatgctgg	19740
cctgcgctac	cgctcaatgt	tgctgggcaa	tggtcgctat	gtgcccttcc	acatccaggt	19800
gcctcagaag	ttctttgcca	ttaaaaacct	ccttctcctg	ccgggctcat	acacctacga	19860
gtggaacttc	aggaagatg	ttaacatggt	tctgcagagc	tccctaggaa	atgacctaa	19920
ggttgacgga	gccagcatta	agtttgatag	catttgcctt	tacgccacct	tcttccccat	19980

-continued

ggccacaac accgcctcca cgcttgaggc catgcttaga aacgacacca acgaccagtc	20040
ctttaacgac tatctctccg ccgccaacat gctctaccct ataccgcgca acgctaccaa	20100
cgtgcccata tccateccct cccgcaactg ggcggctttc cgcggctggg ccttcacgeg	20160
ccttaagact aaggaaaccc catcactggg ctggggttac gacccttatt acacctactc	20220
tggctctata ccctacctag atggaacctt ttacctcaac cacaccttta agaagggtggc	20280
cattaccttt gactctcttg tcagctggcc tggcaatgac cgctgctta cccccaacga	20340
gtttgaatt aagcgctcag ttgacgggga gggttacaac gttgccagtc gtaacatgac	20400
caaagactgg ttctctgtac aaatgctagc taactataac attggctacc agggcttcta	20460
tatcccagag agctacaagg accgcatgta ctctctcttt agaaacttcc agcccatgag	20520
ccgtcaggtg gtggatgata ctaaatacaa ggactaccaa caggtgggca tcctacacca	20580
acacaacaac tctggatttg ttggctacct tgccccacc atgctcgaag gacaggccta	20640
cctgctaac ttcccctatc cgcttatagg caagaccgca gttgacagca ttaccagaa	20700
aaagtttctt tgcgatcgca cctttggcg catcccttc tccagtaact ttatgtccat	20760
ggcgccactc acagactgg gccaaaacct tctctacgcc aactccgccc acgctctaga	20820
catgactttt gaggtggatc ccattggcga gccaccctt ctttatgttt tgtttgaagt	20880
ctttgacgtg gtccgtgtgc accagccgca ccgcgcgctc atcgaaaccg tgtacctgcg	20940
cacgccttc tggcggcga acgccacaac ataaagaagc aagcaacatc aacaacagct	21000
gcccgcattg gctccagtga gcaggaactg aaagccattg tcaaagatct tggttgtggg	21060
ccatattttt tgggaccta tgacaagcgc tttccaggt ttgtttctcc acacaagctc	21120
gctgcgcca tagtcaatac ggcgggtcgc gagactgggg gcgtacactg gatggcctt	21180
gctggaacc cgcactcaaa aacatgctac ctctttgagc cctttggctt ttctgaccag	21240
cgactcaagc aggtttacca gtttgagtac gagtcactcc tgcgccgtag cgcattgct	21300
tcttccccg accgctgtat aacgctgaa aagtccacc aaagcgtaca ggggcccac	21360
tgggcccct gtggactatt ctgctgcatg tttctccacg cctttgcaa ctggcccac	21420
actcccattg atcacaaccc caccatgaac cttattaccg gggtagccaa ctccatgctc	21480
aacagtcacc aggtacagcc caccctcgt cgcaaccagg aacagctcta cagcttctc	21540
gagcgcact cgcctactt ccgcagccac agtgccgaga ttaggagcgc cacttcttt	21600
tgtcacttga aaaacatgta aaaataatgt actagagaca cttcaataa aggcacatgc	21660
ttttatttgt aactctcgg gtgattattt acccccacc ttgctctcgc cgcctttaa	21720
aaatcaaagg ggttctgccc cgcctcgtc tgcccaactg gcagggacac gttgcgatac	21780
tgggttttag tgctccactt aaactcaggc acaaccatcc gcggcagctc ggtgaagttt	21840
tcactccaca ggctcgcac catcaccaac gcgtttagca ggtcgggccc cgatatctt	21900
aagtgcagc tggggcctcc gccctcgcgc cgcgagttgc gatacacagg gttgcagcac	21960
tggaacacta tcagcgcgg gtggtgcacg ctggccagca cgctcttctc ggagatcaga	22020
tccgctcca ggtcctcgc gttgtcagc gcgaacggag tcaactttgg tagctgcctt	22080
ccccaaaagg gcgctgccc aggctttgag ttgcaactgc accgtagtgg catcaaaagg	22140
tgaccgtgcc cggctctggc gtttaggatac agcgcctgca taaagcctt gatctgctta	22200
aaagccact gagcctttgc gcctcagag aagaacatgc cgcaagactt gccggaaaac	22260

-continued

tgattggccg	gacaggccgc	gtcgtgcacg	cagcaccttg	cgtcgggtgt	ggagatctgc	22320
accacatttc	ggccccaccg	gttcttcacg	atcttggcct	tgctagactg	ctccttcagc	22380
gcgcgctgcc	cgttttcget	cgtcacatcc	atttcaatca	cgctctcctt	atttatcata	22440
atgcttccgt	gtagacactt	aagctcgcct	togatctcag	cgcagcggtg	cagccacaac	22500
gcgcagcccg	tgggtcgtg	atgctttag	gtcacctctg	caaacgactg	caggtacgcc	22560
tgcaggaatc	gccccatcat	cgtcacaaa	gtcttgttgc	tggatgaagg	cagctgcaac	22620
ccgcggtgct	cctcgttcag	ccaggtcttg	catacggccg	ccagagcttc	cacttgggtca	22680
ggcagtagtt	tgaagtctgc	ctttagatcg	ttatccaagt	ggtagcttgc	catcagcgcg	22740
cgcgagcctc	ccatgccctt	ctcccacgca	gacacgatcg	gcacactcag	cgggttcctc	22800
accgtaattt	cactttccgc	ttcgtcgggc	tcttctctt	cctcttgcgt	ccgcatacca	22860
cgcgccactg	ggctcgtctt	attcagccgc	cgcactgtgc	gcttacctcc	tttgccatgc	22920
ttgattagca	ccggtggggt	gctgaaacc	accatttcta	gcgccacatc	ttctctttct	22980
tcctcgtctg	ccacgattac	ctctgggtgat	ggcgggctc	cgggcttggg	agaagggcgc	23040
ttctttttct	tcttgggggc	aatggccaaa	tccgcgcgcg	aggtcagatg	ccgcgggctg	23100
gggtgctcgc	gcaccagcgc	gtctttagat	gagcttctc	cgctctcggg	ctcgatacgc	23160
cgctcatccc	gcttttttgg	ggcgcgcccg	ggaggcggcg	gcgacgggga	cggggacgac	23220
acgtctctca	tggttggggg	acgtcgcgcc	gcaccgcgtc	cgcgctcggg	ggtgggttct	23280
cgctgctcct	cttcccgcct	ggccatttcc	ttctctata	ggcagaaaaa	gatcatggag	23340
tcagtcgaga	agaaggacag	cctaaccgcc	ccctctgagt	tcgccaccac	cgctccacc	23400
gatgccgcc	acgcgcctac	caccttcccc	gtcgaggcac	cccgccttga	ggaggaggaa	23460
gtgattatcg	agcaggacc	aggttttgta	agcgaagacg	acgaggaccg	ctcagtagca	23520
acagaggata	aaaagcaaga	ccaggacaac	gcagaggcaa	acgaggaa	agtcgggctg	23580
ggggacgaaa	ggcatggcga	ctacctagat	gtgggagacg	acgtgctggt	gaagcatctg	23640
cagcgcctc	gcgccattat	ctgcgacgcg	ttgcaagacg	gcagcgatgt	gcccctcgc	23700
atagcggatg	tcagccttgc	ctacgaacgc	cacctattct	caccgcgcgt	acccccaaa	23760
cgccaagaaa	acggcacatg	cgagcccaac	ccgcgcctca	acttctaccc	cgtatttgc	23820
gtgccagagg	tgcttgccac	ctatcacatc	tttttccaaa	actgcaagat	accctatcc	23880
tgcctgcca	accgcagccg	agcggacaag	cagctggcct	tgcggcaggg	cgctgtcata	23940
cctgatatcg	cctcgtcaca	cgaagtgcc	aaaatctttg	agggtcttgg	acgcgacgag	24000
aagcgcgcgc	caaacgctct	gcaacaggaa	aacagcga	atgaaagtca	ctctggagtg	24060
ttggtggaac	tcgaggggtg	caacgcgcgc	ctagccgtac	taaaacgcag	catcgaggtc	24120
acccactttg	cctaccgggc	acttaacct	cccccaagg	tcagtagcac	agtcagtagt	24180
gagctgatcg	tgcgccttgc	gcagcccctg	gagagggatg	caaatttgc	agaacaaaca	24240
gaggagggcc	taccgcagct	tggcgacgag	cagctagcgc	gctggcttca	aacgcgcgag	24300
cctgcccact	tggaggagcg	acgcaaaact	atgatggccg	cagtgctcgt	taccgtggag	24360
cttgagtgca	tgcagcgggt	ctttgctgac	ccggagatgc	agcgaagct	agaggaaaca	24420
ttgcaactaca	cctttcgaca	gggctacgta	cgccaggcct	gcaagatctc	caacgtggag	24480
ctctgcaacc	tggctccta	ccttgggaatt	ttgcacgaaa	accgccttgg	gcaaacctg	24540
cttcattcca	cgctcaaggg	cgaggcgcgc	cgcgactacg	tccgcgactg	cgtttactta	24600

-continued

tttctatgct acacctggca gacggccatg ggcgtttggc agcagtgctt ggaggagtgc 24660
aacctcaagg agctgcagaa actgctaaag caaaacttga aggacctatg gacggccttc 24720
aacgagcgct ccgtggccgc gcacctggcg gacatcattt tccccgaacg cctgcttaaa 24780
accctgcaac aggtctgccc agacttcacc agtcaaagca tgttcagaa ctttaggaac 24840
tttatcctag agcgctcagg aatcttgccc gccacctgct gtgcacttcc tagcgacttt 24900
gtgcccatta agtaccggca atgccctccg ccgctttggg gccactgcta ccttctgcag 24960
ctagccaact accttgccca ccaactgac ataatggaag acgtgagcgg tgacggctca 25020
ctggagtgtc actgtcgctg caacatgac accccgcacc gctccctggt ttgcaattcg 25080
cagctgctta acgaaagtca aattatcggg acctttgagc tgcagggctc ctcgctgac 25140
gaaaagtccg ccgctccggg gttgaaactc actccggggc tgtggacgtc ggcttacctt 25200
cgcaaatctg tacctgagga ctaccacgcc cacgagatta ggttctacga agaccaatcc 25260
cgcccgccca atgcccagct tacccgctgc gtcattacc agggccacat tcttgccca 25320
ttgcaagcca tcaacaaagc ccgccaagag tttctgctac gaaagggacg gggggtttac 25380
ttggaccccc agtccggcga ggagctcaac ccaatcccc cgccgcccga gccctatcag 25440
cagcagccgc gggcccttgc ttcccaggat ggcacccaaa aagaagctgc agctgcccgc 25500
gccaccacgc gacgaggagg aatactggga cagtcaggca gaggaggttt tggacgagga 25560
ggaggaggac atgatggaag actgggagag cctagacgag gaagcttccg aggtcgaaga 25620
ggtgtcagac gaaacaccgt caccctcggg cgcattcccc tcgcccggcg cccagaaatc 25680
ggcaaccggg tccagcatgg ctacaacctc cgctcctcag gcgcccggcg cactgcccgt 25740
tcgcccagcc aaccgtagat gggacaccac tggaaaccagg gccggtaagt ccaagcagcc 25800
gcccggctta gcccaagagc aacaacagcg ccaaggtac cgctcatggc gcgggcacaa 25860
gaaagccata gttgcttgct tgcaagactg tgggggcaac atctccttcg cccgcccgtt 25920
tcttctctac catcacggcg tggccttccc ccgtaacatc ctgcattact accgtcatct 25980
ctacagccca tactgaccgg gggcagcggg cagcaacagc agcggccaca cagaagcaaa 26040
ggcgaccgga tagcaagact ctgacaaagc ccaagaaatc cacagcggcg gcagcagcag 26100
gaggaggagc gctgctctg gcgcccacg aaccggtatc gacccgcgag cttagaaaca 26160
ggatthttcc cactctgtat gctatatttc aacagagcag gggccaagaa caagagctga 26220
aaataaaaaa caggtctctg cgatccctca cccgcagctg cctgtatcac aaaagcgaag 26280
atcagcttgc gcgcacgctg gaagacgccc aggtctctct cagtaaatac tgcgctga 26340
ctcttaagga ctagtttgc gccctttctc aaatttaagc gcgaaaacta cgtcatctcc 26400
agcggccaca cccggcgcga gcacctgtg tcagcgcctat tatgagcaag gaaattccca 26460
cgccctacat gtggagttag cagccacaaa tgggacttgc ggctggagct gcccaagact 26520
actcaaccgg aataaactac atgagcgcgg gacccacat gatatcccgg gtcaacggaa 26580
tacgcccaca ccgaaaccga attctcctgg aacagggcggc tattaccacc acacctcgt 26640
ataaccttaa tcccgtagt tggcccgtg ccctgggtga ccaggaaagt cccgctccca 26700
ccactgtggt acttcccaga gacgcccagg ccgaagtcca gatgactaac tcagggggcg 26760
agcttgcggg ccgcttctgt cacaggggtc ggtcgcccgg gcaggggata actcacctga 26820
caatcagagg gcgaggtatt cagctcaacg acgagtcggg gagctcctcg cttggtctcc 26880

-continued

gtccggacgg gacatttcag atcggcggcg ccggccgctc ttcattcacc cctcgtcagg 26940
caatcctaac tctgcagacc tcgtcctctg agccgcgctc tggaggcatt ggaactctgc 27000
aatattattga ggagtttggt ccacgtgtct actttaaccc cttctcggga cctcccggcc 27060
actatccgga tcaatttatt cctaactttg acgcggtaaa ggactcggcg gacggctacg 27120
actgaatggt aagtggagag gcagagcaac tgcgcctgaa acacctggtc cactgtcggc 27180
gccacaagtg ctttgcccgc gactccgggt agttttgcta ctttgaattg cccgaggatc 27240
atatcgaggg ccggcggcac ggcgtccggc ttaccgccc gggagagctt gcccgtagcc 27300
tgattcggga gtttaccag cgcctcctgc tagttgagcg ggacagggga cctgtgttcc 27360
tcaactgtgat ttgcaactgt cctaaccctg gattacatca agatctttgt tgccatctct 27420
gtgctgagta taataaatac agaaatataa atatactggg gctcctatcg ccatcctgta 27480
aacgccaccg tcttcaccgg cccaagcaaa ccaaggcgaa ccttacctgg tacttttaac 27540
atctctccct ctgtgattta caacagtttc aaccagagcg gagtgagtct acgagagAAC 27600
ctctccgagc tcagctactc catcagaaaa aacaccacc ccttacctg ccgggaacgt 27660
acgagtgcgt caccggccgc tgcaccacac ctaccgctg accgtaaac agacttttcc 27720
cggacagacc tcaataactc tgtttaccag aacaggaggt gagcttagaa aacccctagg 27780
gtattagccc aaaggcgcag ctactgtggg gtttatgaac aattcaagca actctacggg 27840
ctattctaat tcaggtttct ctagaatcgg gggtgggggt attctctgtc ttgtgattct 27900
ctttattctt atactaacgc ttctctgctc aaggctcgc gcttgcctg tgcacatttg 27960
catttattgt cagcttttta aacgctgggg tcgccacca agatgattag gtacataatc 28020
ctaggtttac tcacccttgc gtcagccacc ggtaccacc aaaagggtga ttttaaggag 28080
ccagcctgta atgttacatt cgcagctgaa gctaatgagt gcaccactct tataaaatgc 28140
accacagaac atgaaaaagct gcttattcgc cacaaaaaca aaattggcaa gtatgctgtt 28200
tatgctatth ggagccagg tgacactaca gagtataatg ttacagtttt ccagggtaaa 28260
agtcataaaa cttttatgta tacttttcca ttttatgaaa tgtgcgacat taccatgtac 28320
atgagcaaac agtataagtt gtggccccc caaaattgtg tggaaaacac tggcactttc 28380
tgctgcactg ctatgctaat tacagtgtc gctttggtct gtaccctact ctatattaaa 28440
tacaaaagca gacgcagctt tattgaggaa aagaaaatgc ctttaattac taagttacaa 28500
agctaatgtc accactaact gctttactcg ctgcttgcaa aacaaattca aaaagttagc 28560
attataatta gaataggatt taaaccccc ggtcatttcc tgetcaatac cattcccctg 28620
aacaattgac tctatgtggg atatgtccca gcgctacaac cttgaagtca ggcttccctg 28680
atgtcagcat ctgactttgg ccagcacctg tcccgggat ttgttccagt ccaactacag 28740
cgaccacccc taacagagat gaccaacaca accaacggg ccgcccgtac cggacttaca 28800
tctaccacaa atacacccc agttttctgc tttgtcaata actgggataa cttgggcatg 28860
tggtggttct ccatagcgt tatgtttgta tgccttatta ttatgtggct catctgctgc 28920
ctaaagcgca aacgcgccc accacccatc tatagtccca tcattgtgct acacccaaac 28980
aatgatggaa tccatagatt ggacggactg aaacacatgt tcttttctct tacagatga 29040
ttaaatgaga catgattcct cgagttttta tattactgac ccttgttgcg ctttttttgt 29100
gcgtgctcca cattggctgc ggtttctcac atcgaagtag actgcattcc agccttcaca 29160
gtctatttgc tttacggatt tgtcacctc acgctcatct gcagcctcat cactgtggtc 29220

-continued

atcgccttta tccagtgc atgactgggtc tgtgtgcgct ttgcatact cagacaccat 29280
ccccagtaca gggacaggac tatagctgag cttcttagaa ttctttaatt atgaaattta 29340
ctgtgacttt tctgctgatt atttgcaccc tatctgcggt ttgttccccg acctccaagc 29400
ctcaaagaca tatatcatgc agattcactc gtatatggaa tattccaagt tgctacaatg 29460
aaaaaagcga tctttccgaa gcctgggtat atgcaatcat ctctgttatg gtgttctgca 29520
gtaccatctt agccctagct atatatccct accttgacat tggtctggaac gcaatagatg 29580
ccatgaacca cccaacttcc cccgcgcccc ctatgcttcc actgcaacaa gttgttgccg 29640
gcygctttgt cccagccaat cagcctcgcc caccttctcc cccccact gaaatcagct 29700
actttaatct aacaggagga gatgactgac accctagatc tagaaatgga cggaaattatt 29760
acagagcagc gcctgctaga aagacgcagg gcagcggccg agcaacagcg catgaatcaa 29820
gagctccaag acatggttaa cttgcaccag tgcaaaaggg gtatcttttg tctggtaaag 29880
caggccaag tcacctacga cagtaatacc accggacacc gccttagcta caagttgcca 29940
accaagcgtc agaaattggt ggtcatggtg ggagaaaagc ccattaccat aactcagcac 30000
tcggtagaaa ccgaaggctg cattcactca cctgtcaag gacctgagga tctctgcacc 30060
cttattaaga ccctgtgcgg tctcaaagat cttattccct ttaactaata aaaaaaata 30120
ataaagcatc acttacttaa aatcagttag caaatttctg tccagtttat tcagcagcac 30180
ctccttgccc tctcccagc tctggtattg cagcttctc ctggctgcaa actttctcca 30240
caatctaaat ggaatgtcag tttctctctg ttctgtcca tccgcacca ctatcttcat 30300
gttgttgca atgaagcgcg caagaccgtc tgaagatacc ttcaaccccg tgtatccata 30360
tgacacggaa accggtcctc caactgtgcc ttttcttact cctcccttg tatccccaa 30420
tgggtttcaa gagagtcccc ctgggtact ctctttgcgc ctatccgaac ctctagttac 30480
ctccaatggc atgcttgcgc tcaaaatggg caacggcctc tctctggacg aggcggcaa 30540
ccttacctcc caaaatgtaa ccaactgtgag cccacctc aaaaaacca agtcaaacat 30600
aaacctggaa atatctgcac cctcacagt tacctcagaa gccctaactg tggctgccgc 30660
cgcacctcta atggtcgcgg gcaacacact caccatgcaa tcacaggccc cgtaaccgt 30720
gcacgactcc aaacttagca ttgccacca aggaccctc acagtgtcag aaggaaagct 30780
agccctgcaa acatcaggcc cctcaccac caccgatagc agtaccctta ctatcactgc 30840
ctcaccctc ctaactactg ccaactgtag cttgggcatt gacttgaaag agccattta 30900
tacacaaat ggaaaactag gactaaagta cggggctcct ttgcatgtaa cagacgacct 30960
aaacactttg accgtagcaa ctggtccagg tgtgactatt aataactt ccttgcaaac 31020
taaagttact ggagccttg gttttgatc acaaggcaat atgcaactta atgtagcagg 31080
aggactaagg attgattctc aaaacagacg ccttatactt gatgttagtt atccgttga 31140
tgctcaaac caactaaatc taagactagg acaggccct cttttataa actcagccca 31200
caacttggat attaactaca acaaggcct ttacttgttt acagcttcaa acaattcaa 31260
aaagcttgag gttaacctaa gcaactgcaa ggggttgatg tttgacgcta cagccatagc 31320
cattaatgca ggagatgggc ttgaatttgg ttcacctaat gcaccaaaca caaatcccct 31380
caaacaaaa attgccatg gcctagaatt tgattcaaac aaggctatgg ttccataact 31440
aggaactggc cttagtttg acagcacagg tgccattaca gtaggaaaca aaaataatga 31500

-continued

taagctaact ttgtggacca caccagctcc atctcctaac tgtagactaa atgcagagaa 31560
agatgctaaa ctcaactttgg tcttaacaaa atgtggcagt caaatacttg ctacagtttc 31620
agttttggct gttaaaggca gtttggctcc aatatctgga acagttcaaa gtgctcatct 31680
tattataaga tttgacgaaa atggagtgtc actaaacaat tccttcctgg acccagaata 31740
ttggaacttt agaaatggag atcctactga aggcacagcc tatacaaacg ctgttggatt 31800
tatgcctaac ctatcagctt atccaaaatc tcacggtaaa actgccaaaa gtaacattgt 31860
cagtcaagtt tacttaaacg gagacaaaac taaacctgta aactaacca ttactactaa 31920
cggtagacag gaaacaggag acacaactcc aagtgcatac tctatgtcat tttcatggga 31980
ctggtctggc cacaactaca ttaatgaaat atttgccaca tcctcttaca ctttttcata 32040
cattgcccga gaataaagaa tcgtttgggt tatgtttcaa cgtgtttatt tttcaattgc 32100
agaaaatttc aagtcatttt tcattcagta gtatagcccc accaccacat agcttataca 32160
gatcaccgta ccttaatcaa actcacagaa ccctagtatt caacctgcca cctccctccc 32220
aacacacaga gtacacagtc ctttctcccc ggctggcctt aaaaagcctc atatcatggg 32280
taacagacat attcttaggt gttatattcc acacggtttc ctgtcgagcc aaacgctcat 32340
cagtgatatt aataaactcc cggggcagct cacttaagtt catgtcgtg tccagctgct 32400
gagccacagg ctgctgtcca acttgcggtt gcttaacggg cggcgaagga gaagtccacg 32460
cctacatggg ggtagagtca taatcgtgca tcaggatagg gcggtggtgc tgcagcagcg 32520
cgcgaataaa ctgctgccgc cgccgctccg tcctgcagga atacaacatg gcagtggtct 32580
cctcagcgat gattcgcacc gcccgcagca taaggcgctt tgcctcgg gcacagcagc 32640
gcaccctgat ctcaactaaa tcagcacagt aactgcagca cagcaccaca atattgttca 32700
aaatcccaca gtgcaaggcg ctgtatccaa agctcatggc ggggaccaca gaaccacgt 32760
ggccatcata ccacaagcgc aggtagatta agtggcgacc cctcataaac acgctggaca 32820
taaacattac ctcttttggc atggtgtaat tcaccacctc ccggtacatc ataaacctct 32880
gattaacat ggcccatcc accaccatcc taaaccagct ggccaaaacc tgcccgcgg 32940
ctatacactg cagggaaccg ggactggaac aatgacagtg gagagcccag gactcgtaac 33000
catggatcat catgctcgtc atgatatcaa tgttggcaca acacaggcac acgtgcatac 33060
acttcctcag gattacaagc tcctcccgcg ttagaacat atcccaggga acaaccatt 33120
cctgaatcag cgtaaatccc aactgcagc gaagacctcg cacgtaactc acgttgtgca 33180
ttgtcaaagt gttacattcg ggcagcagcg gatgatctc cagtatggtg ggcggggtt 33240
ctgtctcaa aggaggtaga cgatccctac tgtacggagt gcgcccagac aaccgagatc 33300
gtgttggctg tagtgcctg ccaaatggaa cgccggcagc agtcatattt cctgaagcaa 33360
aaccagggtg gggcgtgaca aacagatctg cgtctccggt ctccgctt agatcgtct 33420
gtgtagtagt tgtagtatat ccactctctc aaagcatcca ggcgccccct ggcttcgggt 33480
tctatgtaaa ctcttcctg cgccgctgcc ctgataacat ccaccaaccg agaataagcc 33540
acaccagcc aacctacaca ttcgttctgc gagtcacaca cgggaggagc ggaagagct 33600
ggaagaacca tgtttttttt tttattccaa aagattatcc aaaacctcaa aatgaagatc 33660
tattaagtga acgctctccc ctccgggtgc gtggtcaaac tctacagcca aagaacagat 33720
aatggcattt gtaagatgtt gcacaatggc ttccaaaagg caaacggccc tcacgtccaa 33780
gtggacgtaa aggctaaacc cttcagggtg aatctcctct ataacattc cagcaccttc 33840

-continued

```

aaccatgccc aaataattct catctcgcca ctttctcaat atatctctaa gcaaatcccc 33900
aatattaagt cgggccattg taaaaatctg ctccagagcg ccctccacct tcagcctcaa 33960
gcagcgaate atgattgcaa aaattcaggt tcttcacaga cctgtataag attcaaaagc 34020
ggaacattaa caaaaatacc gcgatcccgt aggtcccttc gcagggccag ctgaacataa 34080
tcgtgcaggt ctgcacggac cagcgcggcc acttccccgc caggaacct gacaaaagaa 34140
cccacactga ttatgacacg catactcgga gctatgctaa ccagcgtagc cccgatgtaa 34200
gcttgttgca tgggcggcga tataaatgc aaggtgctgc tcaaaaaatc aggcaaagcc 34260
tcgcgcaaaa aagaaagcac atcgtagtca tgctcatgca gataaaggca ggtaagctcc 34320
ggaaccacca cagaaaaaga caccattttt ctctcaaaca tgtctgctggg tttctgcata 34380
aacacaaaat aaaataacaa aaaaacattt aacattaga agcctgtctt acaacaggaa 34440
aaacaaccct tataagcata agacggacta cggccatgcc ggcgtgaccg taaaaaaact 34500
ggtcaccgty attaaaaagc accaccgaca gctcctcggg catgtccgga gtcataatgt 34560
aagactcggg aaacacatca ggttgattca catcggtcag tgctaaaaag cgaccgaaat 34620
agcccggggg aatacatacc cgcagggcga gagacaacat tacagcccc ataggaggta 34680
taaaaaaatt aataggagag aaaaacacat aaacacctga aaaaccctcc tgctaggca 34740
aatagcacc ctcccctcc agaacaacat acagcgcttc cacagcggca gccataacag 34800
tcagccttac cagtaaaaaa gaaaacctat taaaaaaaca cactcgcaca cggcaccagc 34860
tcaatcagtc acagtgtaaa aaagggccaa gtgcagagcg agtatatata ggactaaaaa 34920
atgacgtaac ggttaaagtc cacaaaaaac acccagaaaa ccgcacgcga acctacgccc 34980
agaaacgaaa gccaaaaaac ccacaacttc ctcaaatcgt cacttccggt tcccacggt 35040
acgtcacttc ccattttaag aaaactacaa ttcccaacac atacaagtta ctccgaccta 35100
aaacctcgt caccgccccc gttcccagc cccgcgccac gtcacaaact ccaccacctc 35160
attatcatat tggcttcaat ccaaaataag gtatattatt gat 35203

```

<210> SEQ ID NO 11

<211> LENGTH: 33093

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Empty Ad5 vector sequence (repeats included)

<400> SEQUENCE: 11

```

catcatcaat aatatacctt attttgatt gaagccaata tgataatgag ggggtggagt 60
ttgtgacgty gcgcggggcy tgggaacggg gcgggtgacg tagtagtgty gcggaagtgt 120
gatgttgcaa gtgtggcgga acacatgtaa gcgacggatg tggcaaaagt gacgtttttg 180
gtgtgcgcy gtgtacacag gaagtgacaa ttttcgcgcy gtttaggcy gatgttgtag 240
taaatgtggg cgtaaccgag taagatttgg ccattttcgc gggaaaactg aataagagga 300
agtgaaatct gaataattht gtgttactca tagcgcgtaa tatttgtcta gggccgcygg 360
gactttgacc gtttactggy agactcgcgc aggtgttttt ctccaggtgtt tcccgcttc 420
cgggtcaaaag ttggcgtttt attattatag tcagtacgty tcgagcatgc atctaggcgg 480
ccgatggca gaaattcgcg aattcgcgtag cgtaaacgga tcctctagac gagatccgaa 540
cttgtttatt gcagcttata atggttacia ataaagcaat agcatcacia atttcacia 600

```

-continued

taaagcattt	ttttcactgc	attctagttg	tggtttgcc	aaactcatca	atgtatctta	660
tcattgtctag	atctgtactg	aaatgtgtgg	gcgtggctta	aggggtggaa	agaatatata	720
aggtgggggt	cttatgtagt	tttgtatctg	ttttgcagca	gccgccgccg	ccatgagcac	780
caactcgttt	gatggaagca	ttgtgagctc	atatttgaca	acgcgcatgc	ccccatgggc	840
cggggtgctg	cagaatgtga	tgggtccag	cattgatggg	cgccccgtcc	tgccccgaaa	900
ctctactacc	ttgacctacg	agaccgtgtc	tggaacgccg	ttggagactg	cagcctccgc	960
cgcgccttca	gccgctgcag	ccaccgcccg	cgggattgtg	actgactttg	ctttcctgag	1020
cccgttgca	agcagtgcag	cttccgcttc	atccgccgcg	gatgacaagt	tgacggctct	1080
tttgacaaa	ttggattctt	tgaccoggga	acttaatgtc	gtttctcagc	agctgttgga	1140
tctgcgccag	caggtttctg	ccctgaaggc	ttcctccctc	cccaatgcgg	tttaaacat	1200
aaataaaaaa	ccagactctg	tttggatttg	gatcaagcaa	gtgtcttctg	gtctttattt	1260
aggggttttg	cgcgcgcggg	aggccoggga	ccagcggctc	cggtcgttga	gggtcctgtg	1320
tattttttcc	aggacgtggt	aaaggtgact	ctggatgttc	agatacatgg	gcataagccc	1380
gtctctgggg	tggaggtagc	accactgcag	agcttcatgc	tgcgggggtg	tgtttagat	1440
gatccagtcg	tagcaggagc	gctgggcgtg	gtgcctaaaa	atgtctttca	gtagcaagct	1500
gattgccagg	ggcaggccct	tgggtgaagt	gtttacaaag	cggttaagct	gggatgggtg	1560
catacgtggg	gatatgagat	gcattcttga	ctgtattttt	aggttggtta	tgttcccagc	1620
catatccctc	cggggattca	tgttgtgcag	aaccaccagc	acagtgtatc	cgggtgcactt	1680
gggaaatttg	tcattgtagt	tagaagga	tgcgtggaag	aacttgaga	cgccttctg	1740
acctccaaga	ttttccatgc	attcgtccat	aatgatggca	atgggccacc	gggocggcgc	1800
ctgggcgaag	atatttctgg	gatcactaac	gtcatagttg	tgttccagga	tgagatcgtc	1860
ataggccatt	tttacaagc	gcgggcggag	gggtccagac	tgcggtataa	tggttccatc	1920
cggcccaggg	gcgtagtta	cctcacagat	ttgcatttcc	cacgcttga	gttcagatgg	1980
ggggatcatg	tctacctgcg	gggcgatgaa	gaaaacggtt	tccggggtag	gggagatcag	2040
ctgggaagaa	agcaggttcc	tgagcagctg	cgacttaccg	cagccggtgg	gcccgtaaat	2100
cacacctatt	accgggtgca	actggtagtt	aagagagctg	cagctgccgt	catccctgag	2160
caggggggccc	acttcgttaa	gcattgtccct	gactcgcag	ttttccctga	ccaaatccgc	2220
cagaaggcgc	tcgccgccca	gcgatagcag	ttcttgcaag	gaagcaaagt	ttttcaacgg	2280
tttgagaccg	tccgccgtag	gcattgcttt	gagcgtttga	ccaagcagtt	ccaggcggtc	2340
ccacagctcg	gtcacctgct	ctacggcatc	tcgatccagc	atatctctctc	gtttcgcggg	2400
ttggggcggc	tttcgctgta	cggcagtagt	cgggtgctct	ccagacgggc	cagggtcatg	2460
tctttccacg	ggcgcagggt	cctcgtcagc	gtagtctggg	tcacgggtgaa	ggggtgcgct	2520
ccgggctgcg	cgtgcccag	ggtgctctg	aggctggtcc	tgtggtgct	gaagcgtctc	2580
cggctctcgc	cctgcgctgc	ggccaggtag	catttgacca	tggtgtcata	gtccagcccc	2640
tccggggcgt	ggcccttgcc	gcgcagcttg	cccttgagg	aggcggccga	cagggggcag	2700
tgacagcttt	tgaggcgta	gagcttgggc	gcgagaaata	ccgattccgg	ggagtaggca	2760
tccgcgccgc	aggccccgca	gacggtctcg	cattccacga	gccaggtgag	ctctggccgt	2820
tccgggtcaa	aaaccaggtt	tccccatgc	tttttgatgc	gtttcttacc	tctggtttcc	2880
atgagccggt	gtccacgctc	ggtgaogaaa	aggctgtccg	tgtccccgta	tacagacttg	2940

-continued

agaggcctgt cctcgagcgg tgttcgcgg tctcctcgt atagaaactc ggaccactct	3000
gagacaaagg ctcgctcca gccagcacg aaggaggcta agtgggagg gttagcgtcg	3060
ttgtccacta ggggtccac tcgctocagg gtgtgaagac acatgtcgcc ctcttcggca	3120
tcaaggaagg tgattggtt taggtgtag gccacgtgac cgggtgtcc tgaaggggg	3180
ctataaaagg ggggtggggc gcgttcgtcc tcaactctct cgcacatcgt gtctgcgagg	3240
gccagctgtt ggggtgagta ctccctctga aaagcgggca tgacttctgc gctaagattg	3300
tcagtttcca aaaacgagga ggattgata ttcactctgg ccgcggtgat gcctttgagg	3360
gtggccgcat ccatctggtc agaaaagaca atctttttgt tgtcaagctt ggtggcaaac	3420
gaccctaga gggcgttga cagcaacttg gcgatggagc gcagggtttg gtttttgcg	3480
cgatcggcgc gctccttggc cgcgatgtt agctgcacgt attcgcgcgc aacgcaccgc	3540
cattcgggaa agacggtggt gcgctcgtc ggcaccaggc gcacgcgcca accgcggtt	3600
tgcaggggta caaggtcaac gctggtggtt acctctcgc gtaggcgtc gttggtccag	3660
cagagcggc cgccttgcg cgagcagaat ggcggtagg ggtctagctg cgtctcgtcc	3720
gggggtctg cgtccacggt aaagacccc ggcagcaggc gcgcgtcga gtagtctatc	3780
ttgcatcctt gcaagtctag cgcctcgtc catgcgcggg cggcaagcgc gcgctcgtat	3840
gggttgagt ggggacccc tggcatggg tgggtgagc cggaggcgt catgcccaa	3900
atgctgtaaa cgtagaggg ctctctgagt attccaagat atgtagggt gcatctcca	3960
ccgcggatgc tggcgcgac gtaatcgtat agttcgtcgc agggagcgc gaggtcggga	4020
ccgaggtgc taaggcggc ctgctctgct cggaaagacta tctgcctgaa gatggcatgt	4080
gagttggtg atatggttg acgctggaag acgttgaagc tggcgtctgt gagacctacc	4140
gcgtcacgca cgaaggaggc gtaggagtc gcgacctgt tgaccagctc ggcggtgacc	4200
tgcacgtcta gggcgcagta gtccagggtt tccttgatga tgcatactt atcctgtccc	4260
tttttttcc acagctcgcg gttgaggaca aactctcgc ggtcttcca gtactcttg	4320
atcgaaaacc cgtcggcctc cgaacggtaa gagcctagca tgtagaactg gttgacggc	4380
tggtaggcgc agcatccctt ttctaagggt agcgcgatg cctgcgcggc cttccggagc	4440
gaggtgtgg tgagcga aaa ggtgtccctg accatgactt tgaggactg gtatttgaag	4500
tcagtgtcgt cgcacccgct ctgctcccag agcaaaaagt ccgtgcgctt tttggaacgc	4560
ggatttgga gggcgaagg gacatcgtt aagagtatct tcccgcgcg aggcataaag	4620
ttcgtgtga tgcggaagg tcccggcacc tcggaacggt tgttaattac ctggcggcg	4680
agcacgatct cgtcaaagcc gttgatgtt tggccacaa tgtaaagttc caagaagcgc	4740
gggatgccct tgatggaagg caattttta agttcctcgt aggtgagctc ttcaggggag	4800
ctgagccgct gctctgaaag gcccagctc gcaagatgag ggttgaagc gacgaatgag	4860
ctccacaggt cacgggcat tagcatttgc aggtggtcgc gaaaggtcct aaactggcga	4920
cctatggcca tttttctg ggtgatgcag tagaaggtaa gcgggtcttg tcccagcgg	4980
tcccatccaa ggttcgcgcc taggtctcgc gcggcagtea ctagggtc atctccgccc	5040
aaactcatga ccagcatgaa gggcacgagc tgcttccaa agggcccat ccaagtatag	5100
gtctctacat cgtagggtgac aaagagacgc tcggtgagc gatgcgagcc gatcgggaag	5160
aaactgatct cccgccacca attggaggag tggctattga tgtggtgaaa gtagaagtc	5220

-continued

ctgcgacggg	ccgaacactc	gtgctggctt	ttgtaaaaac	gtgcgagta	ctggcagcgg	5280
tgcaacgggt	gtacatcctg	cacgaggttg	acctgacgac	cgcgcacaag	gaagcagagt	5340
gggaatttga	gcccctcgcc	tggcgggttt	ggctgggtgt	cttctacttc	ggctgcttgt	5400
ccttgaccgt	ctggctgctc	gaggggagtt	acggtggatc	ggaccaccac	gccgcgcgag	5460
cccaaagtcc	agatgtccgc	gcgcggcggg	cggagcttga	tgacaacatc	gcgcagatgg	5520
gagctgtcca	tggctgtgag	ctcccgcggc	gtcaggtcag	gcgggagctc	ctgcaggttt	5580
acctcgcata	gacgggtcag	ggcgcgggct	agatccaggt	gataccta	ttccaggggc	5640
tggttggtgg	cggcgtcgat	ggccttgaag	aggccgcatac	cccgcggcgc	gactacggta	5700
ccgcgcggcg	ggcgggtggc	cgcgggggtg	tccttggatg	atgcatactaa	aagcgggtgac	5760
gcgggcgagc	ccccggaggt	agggggggct	cggaccgcgc	cgggagaggg	ggcaggggca	5820
cgctggcgcc	gcgcgggggc	aggagctggt	gctgcgcgcg	taggttgctg	gcgaacgcga	5880
cgacgcggcg	gttgatctcc	tgaatctggc	gcctctgcgt	gaagacgacg	ggcccgggtga	5940
gcttgaacct	gaaagagagt	tcgacagaat	caatttcggt	gtcgttgacg	gcggcctggc	6000
gcaaaatctc	ctgcacgtct	cctgagttgt	cttgataggc	gatctcggcc	atgaactgct	6060
cgatctcttc	ctcctggaga	tctccgcgtc	cggctcgtc	cacggtggcg	gcgaggtcgt	6120
tggaaatgcg	ggccatgagc	tgcgagaagg	cggtgaggcc	tcctcgttc	cagacgcggc	6180
tgtagaccac	gcccccttcg	gcacgcgggg	cgcgcacgac	cacctgcgcg	agattgagct	6240
ccacgtgccg	ggcgaagacg	gcgtagtttc	gcaggcgcgtg	aaagaggtag	ttgagggtgg	6300
tggcgggtgtg	ttctgccacg	aagaagtaca	taaccacgcg	tcgcaacgtg	gattcgttga	6360
tatcccccaa	ggcctcaagg	cgctccatgg	cctcgtagaa	gtccacggcg	aagttgaaaa	6420
actgggagtt	gcgcgcggac	acggttaact	cctcctccag	aagacggatg	agctcggcga	6480
cagtgtcgcg	cacctcgcgc	tcaaaggcta	caggggcctc	ttcttcttct	tcaatctcct	6540
cttcataag	ggcctcccct	tcttcttctt	ctggcggcgg	tgggggaggg	gggacacggc	6600
ggcgcgacg	gcgcaccggg	aggcggctca	caaagcgcctc	gatcatctcc	ccgcggcgac	6660
ggcgcaggt	ctcggtgacg	gcgcggccgt	tctcgcgggg	gcgcagttgg	aagacgcgcg	6720
ccgtcatgct	ccggttatgg	gttggcgggg	ggctgccatg	cggcagggat	acggcgctaa	6780
cgatgcactc	caacaattgt	tgtgtaggta	ctccgccgcc	gaggacctg	agcaggtccg	6840
catcgaccgg	atcggaaaaac	ctctcgagaa	aggcgtctaa	ccagtcacag	tcgcaaggta	6900
ggctgagcac	cgtggcgggc	ggcagcgggc	ggcggtcggg	gttgtttctg	gcggaggtgc	6960
tgctgatgat	gtaattaaag	taggcggtct	tgagacggcg	gatggtcgac	agaagcacca	7020
tgtccttggg	tccggcctgc	tgaatgcgca	ggcggtcggc	catgccccag	gcttcgtttt	7080
gacatcggcg	caggtctttg	tagtagtctt	gcacgagcct	ttctaccggc	acttcttctt	7140
ctccttctc	ttgtcctgca	tctcttgcat	ctatcgctgc	ggcggcggcg	gagtttgcc	7200
gtaggtggcg	ccctcttctc	cccatgcgtg	tgaccccgaa	gccccctc	ggctgaagca	7260
gggctaggtc	ggcgacaacg	cgctcggcta	atatggcctg	ctgcacctgc	gtgagggtag	7320
actggaagtc	atccatgtcc	acaaagcggg	ggatgcgcc	cgtgttgatg	gtgtaagtgc	7380
agttggccat	aacggaccag	ttaacggtct	ggtagccggg	ctgcgagagc	tcgggtgacc	7440
tgagacgcga	gtaagccctc	gagtcaaata	cgtagtcggt	gcaagtcgcg	accaggtact	7500
ggtatcccac	caaaaagtgc	ggcggcggct	ggcggtagag	gggccagcgt	agggtggccg	7560

-continued

gggctccggg ggcgagatct tccaacataa ggcgatgata tccgtagatg tacctggaca	7620
tccaggtgat gccggcggcg gtggtggagg cgcgcgaaa gtcgcgacg cggttccaga	7680
tgttgccgag cggcaaaaag tgctccatgg tcgggacgct ctggccggtc aggcgcgcgc	7740
aatcgttgac gctctagacc gtgcaaaaag agagcctgta agcgggcact cttccgtggt	7800
ctggtggata aattcgcaag ggtatcatgg cggacgaccg gggttcgagc cccgatccg	7860
gccgtccgce gtgatecatg cggttaccgc ccgctgtcg aaccagggtg tgcgacgca	7920
gacaacgggg gagtgcctct tttggtctcc ttcaggcgc ggcggctgct gcgctagctt	7980
ttttggccac tggccgcgcg cagcgtaagc ggttaggctg gaaagcgaaa gcattaagtg	8040
gctcgtccc tgtagccgga gggttatctt ccaagggttg agtcgcgga cccccggtc	8100
gagtctcgga ccggccggac tgcggogaac gggggtttgc ctccccgtca tgcaagacc	8160
cgcttgcaaa ttctccgga aacagggacg agccctttt ttgcttttcc cagatgcac	8220
cggctgtgcy gcagatgcgc cccctcctc agcagcggca agagcaagag cagcggcaga	8280
catgcagggc acctcccct cctctaccg cgtcaggagg ggcgacatcc gcggttgacg	8340
cggcagcaga tggtgattac gaacccccgc ggcgcgggc ccggcactac ctggacttg	8400
aggagggcga gggcctggcg cggctaggag cgcctctcc tgagcggcac ccaagggtg	8460
agctgaagcg tgatacgcgt gaggcgtacg tgcgcggca gaacctgtt cgcgaccgc	8520
agggagagga gcccagggag atgcgggac gaaagtcca cgcagggcg gcgctgcggc	8580
atggcctgaa tcgcgagcgg ttgctgcgcg aggaggactt tgagcccagc gcgcgaaccg	8640
ggattagtcc cgcgcgcgca cacgtggcg ccgcgcacct ggtaacgca tacgagcaga	8700
cggtgaaaca ggagattaac tttcaaaaaa gctttaacaa ccacgtgctg acgcttggtg	8760
cgcgcgagga ggtggctata ggactgatgc atctgtggga ctttgtaagc gcgctggagc	8820
aaaacccaaa tagcaagccg tccatggcg agctgttctc tatagtgcag cacagcagg	8880
acaacgagcg attcagggat gcgctgctaa acatagtaga gcccgagggc cgtggtgctg	8940
tcgatttgat aaacatccg cagagcatag tgggtcgagga gcgcagcttg agcctggctg	9000
acaaggtggc gccatcaac tattccatgc ttagcctggg caagtgttac gcccgcaaga	9060
tataccatac cccttacgt cccatagaca aggaggtaaa gatcgagggg ttctacatgc	9120
gcatggcgt gaaggtgctt accttgagcg acgacctggg cgtttatcgc aacgagcga	9180
tccacaagcg cgtgagcgtg agccggcggc gcgagctcag cgaccgcgag ctgatgcaca	9240
gcctgcaaa ggcctggctt ggcacgggca gcgcgatag agaggccgag tcctactttg	9300
acgcggggc tgacctgcgc tgggccccaa gccgacgcgc cctggaggca gctggggccg	9360
gacctgggct ggcggtggca cccgcgcgcg ctggcaactg cggcggcgtg gaggaatatg	9420
acgaggacga tagtacgag ccagaggacg gcgagtacta agcggtgatg tttctgatca	9480
gatgatgcaa gacgcaacgg acccggcggg gcggggcgcg ctgcagagcc agccgtccgg	9540
ccttaactcc acggacgact ggcgcaggt catggaccgc atcatgtcgc tgaactgcgcg	9600
caatcctgac gcgttccgca agcagccgca ggccaaccg ctctccgcaa ttctggaagc	9660
ggtggtccc gcgcgcgcaa accccacgca cgagaaggtg ctggcgatcg taaacgcgct	9720
ggccgaaaac agggccatcc ggcccagca ggcggcctg gtctacgacg cgtgcttca	9780
gcgctggct cgttacaaca gcggcaact gcagaccaac ctggaccggc tgggtggggga	9840

-continued

tgtgcgcgag gccgtggcgc agcgtgagcg cgcgcagcag cagggcaacc tgggctccat	9900
ggttgcaacta aacgccttcc tgagtacaca gcccgccaac gtgccgcggg gacaggagga	9960
ctacaccaac tttgtgagcg cactgoggct aatggtgact gagacaccgc aaagtgaggt	10020
gtaccagtct gggccagact attttttcca gaccagtaga caaggcctgc agaccgtaaa	10080
cctgagccag gctttcaaaa acttgacagg gctgtggggg gtgccgggctc ccacaggcga	10140
ccggcgacc gtgtctagct tgctgacgcc caactcgcgc ctgttgctgc tgctaatagc	10200
gcccttcacg gacagtggca gcgtgtcccc ggacacatac ctaggtcact tgctgacact	10260
gtaccgcgag gccataggtc aggcgcagct ggacgagcat actttccagg agattacaag	10320
tgtcagccgc gcgctggggc aggaggacac gggcagcctg gaggcaacc taaactacct	10380
gctgaccaac cggcggcaga agatcccc cttgcacagt ttaaacagcg aggaggagcg	10440
cattttgcgc tacgtgcagc agagcgtgag ccttaacctg atgcgcgacg gggtaacgcc	10500
cagcgtggcg ctggacatga ccgcgcgcaa catggaaccg ggcagtgatg cctcaaaccg	10560
gccgtttatc aaccgcctaa tggactactt gcctcgcgcg gccccgtga accccgagta	10620
ttccaccaat gccatettga acccgactg gctaccgcc cctggtttct acaccggggg	10680
attcgaggtg cccgagggta acgatggatt cctctgggac gacatagacg acagcgtgtt	10740
ttccccgcaa ccgcagacc tgctagagtt gcaacagcgc gagcaggcag aggcggcgct	10800
gcgaaaggaa agcttccgca ggccaagcag cttgtccgat ctaggcctg cggccccgcg	10860
gtcagatgct agtagcccat ttccaagctt gatagggtct cttaccagca ctgcaccac	10920
ccgccgcgc ctgctggggc aggaggagta cctaaacaac tcgctgctgc agccgcagcg	10980
cgaaaaaac ctgcctccgg catttcccaa caacgggata gagagcctag tggacaagat	11040
gagtagatgg aagacgtacg cgcaggagca cagggacgtg ccaggccgcg gcccgccac	11100
ccgtcgtcaa aggcacgacc gtcagcgggg tctggtgtgg gagacgatg actcggcaga	11160
cgacagcagc gtccctggatt tgggagggag tggcaaccg tttcgcacc ttcgccccag	11220
gctggggaga atgttttaaa aaaaaaaaa gcctgatgca aataaaaaa ctcaccaagg	11280
ccatggcacc gagcgttggt tttcttgat tcccctagt atgcggcgcg cggcgtgta	11340
tgaggaaggt cctcctccct cctacgagag tgtggtgagc gcggcgcag tggcggcggc	11400
gctgggttct cccttcgatg ctcccotgga cccgcgctt gtgcctcgcg ggtacctgcg	11460
gcctaccggg gggagaaaca gcctccgta ctctgagttg gcaccctat tcgacaccac	11520
ccgtgtgtac ctggtggaca acaagtcaac ggatgtggca tcctgaact accagaacga	11580
ccacagcaac tttctgacca cggtcattca aaacaatgac tacagcccg gggaggcaag	11640
cacacagacc atcaatcttg acgaccggtc gcaactggggc ggcgacctga aaaccatcct	11700
gcataccaac atgccaaatg tgaacgagtt catgtttacc aataagtta aggcgcgggt	11760
gatggtgtcg cgcttccta ctaaggacaa tcagggtgag ctgaaatcg agtgggtgga	11820
gttcacgctg cccgagggca actactccga gaccatgacc atagacctta tgaacaacgc	11880
gatcgtggag cactacttga aagtgggcag acagaacggg gttctggaaa gcgacatcgg	11940
ggtaaagttt gacaccgcga acttcagact ggggtttgac cccgtcactg gtcttgtcat	12000
gcctggggta tatacaaacg aagccttcca tccagacatc attttctgc caggatgcgg	12060
ggtggacttc acccacagcc gcctgagcaa cttgttgggc atccgcaagc ggcaaccctt	12120
ccaggagggc tttaggatca cctacgatga tctggagggt ggtaacattc ccgcactgtt	12180

-continued

ggatgtggac	gcctaccagc	cgagcttgaa	agatgacacc	gaacagggcg	ggggtggcgc	12240
aggcgcgagc	aacagcagtg	gcagcggcgc	ggaagagaac	tccaacgcgg	cagccgcggc	12300
aatgcagccg	gtggaggaca	tgaacgatca	tgccattcgc	ggcgacacct	ttgccacacg	12360
ggctgaggag	aagcgcgctg	aggccgaagc	agcggccgaa	gctgccgccc	ccgctgcgca	12420
acccgaggtc	gagaagcctc	agaagaaacc	ggtgatcaaa	cccctgacag	aggacagcaa	12480
gaaacgcagt	tacaacctaa	taagcaatga	cagcaccttc	accagttacc	gcagctggta	12540
ccttgcatac	aactacggcg	accctcagac	cggaatccgc	tcattggaacc	tgctttgcac	12600
tcctgacgta	acctgcggct	cggagcaggt	ctactggtcg	ttgccagaca	tgatgcaaga	12660
ccccgtgacc	ttccgctcca	cgcgcagat	cagcaacttt	ccggtggtgg	gcgcccagct	12720
ggtgcccgtg	cactccaaga	gcttctacaa	cgaccaggcc	gttactccc	aactcatccg	12780
ccagtttacc	tctctgacct	acgtgttcaa	tcgctttccc	gagaaccaga	ttttggcgcg	12840
cccgcagcc	cccaccatca	ccaccgtcag	tgaaaacgtt	cctgctctca	cagatcacgg	12900
gacgctaccg	ctgcgcaaca	gcacgggag	agtccagcga	gtgaccatta	ctgacgccag	12960
acgcccacc	tgcccctacg	ttacaaggc	cctgggcata	gtctcgcgc	gcgtcctatc	13020
gagccgcact	ttttgagcaa	gcattgtccat	ccttatatcg	cccagcaata	acacaggctg	13080
gggctgcgc	ttcccagca	agatgtttgg	cggggccaag	aagcgtccg	accaacaccc	13140
agtgcgcgtg	cgcgggcact	accgcgcgcc	ctggggcgcg	cacaaacgcg	gcccactgg	13200
gcgcaccacc	gtcgatgacg	ccatcgacgc	ggtggtggag	gaggcgcgca	actacagcc	13260
cacgcccgca	ccagtgtcca	cagtgagcgc	ggcattcag	accgtggtgc	gcggagcccc	13320
gcgctatgct	aaaatgaaga	gacggcggag	gcgcgtagca	cgtcgccacc	gcccgcgacc	13380
cggcactgcc	gcccacgcg	cggcggcggc	cctgcttaac	cgcgcacgtc	gcaccggccg	13440
acgggcccgc	atgcccggcc	ctcgaaggct	ggcgcgggt	attgtcactg	tgccccccag	13500
gtccaggcga	cgagcggccc	ccgcagcagc	cgcggccatt	agtgtatga	ctcagggtcg	13560
caggggcaac	gtgtattggg	tgccgcgactc	ggttagcggc	ctgcgcgtgc	ccgtgcgcac	13620
ccgccccccc	cgcaactaga	ttgcaagaaa	aaactactta	gactcgtact	gttgtatgta	13680
tccagcggcg	gcggcgcgca	acgaagctat	gtccaagcgc	aaaatcaaag	aagagatgct	13740
ccaggtcacc	gcgcccggaga	tctatggccc	cccgaagaag	gaagagcagg	attacaagcc	13800
ccgaaagcta	aagcgggtca	aaaagaaaa	gaaagatgat	gatgatgaac	ttgacgacga	13860
ggtggaactg	ctgcacgcta	ccgcgcccag	gcgacgggta	cagtggaaag	gtcgacgcgt	13920
aaaaagctgt	ttgcgacccc	gcaccaccgt	agtctttacg	cccggtgagc	gctccacccc	13980
cacctacaag	cgcgtgtatg	atgaggtgta	cggcgcagag	gacctgcttg	agcaggccaa	14040
cgagcgcctc	ggggagtgtg	cctacggaaa	gcgacataag	gacatgctgg	cgttgccgct	14100
ggacgagggc	aacccaacac	ctagcctaaa	gcccgttaaca	ctgcagcagg	tgctgcccgc	14160
gcttgaccgc	tcccgaagaa	agcgcggcct	aaagcgcgag	tctggtgact	tgccaccacc	14220
cgtgcagctg	atggtaccca	agcgcagcgc	actggaagat	gtcttgaaa	aaatgaccgt	14280
ggaacctggg	ctggagcccc	aggtccgcgt	gcggccaatc	aagcaggtgg	gcgcccggact	14340
ggcgtgcag	accgtggagc	ttcagatacc	cactaccagt	agcaccagta	ttgccaccgc	14400
cacagagggc	atggagacac	aaacgtcccc	ggttcctcca	gcggtggcgg	atgccgcggt	14460

-continued

gcagggcggtc gctgcggccg cgtccaagac ctctacggag gtgcaaacgg acccgtggat 14520
gtttcgcggt tcagccccc ggcgcccgcg cgttcgagg aagtaaggcg ccgccagcgc 14580
gctactgccc gaatatgccc tacatccttc cattgcgcct acccccggct atcgtggcta 14640
cacctaccgc ccagaagac gagcaactac ccgacgccga accaccactg gaaccgccg 14700
ccgcgctcgc cgtgccagc cgtgctggc cccgatttc gtgcgcaggg tggctcgcga 14760
aggaggcagg accctggcgc tgccaacagc gcgctaccac ccagcatcg tttaaaagcc 14820
ggctcttggt gttcttgag atatggccct cacctgccgc ctccgttcc cggcgccggg 14880
attccaggga agaatgcacc gtaggagggg catggccggc caggcctga cggcgccat 14940
gcgtcgtcgc caccaccggc ggccggcgc gtcgcaccgt cgcagcgcg gcggtatcct 15000
gcccctcctt attccactga tcgccggcgc gattggcgc gtgccggaa ttgcatcct 15060
ggccttgag gcgcagagac actgattaaa aacaagttgc atgtggaaaa atcaaaataa 15120
aaagtctgga ctctcacgct cgcttggtcc tgtaactatt ttgtagaatg gaagacatca 15180
actttgcgct tctggcccc cgacacggct cgcgccggtt catgggaaac tggcaagata 15240
tcggcaccag caatatgagc ggtggcgcct tcagctgggg ctccgtgtgg agcggcatta 15300
aaaaattcgg ttccaccggt aagaactatg gcagcaaggc ctggaacagc agcacaggcc 15360
agatcgtgag ggataagttg aaagagcaaa attccaaca aaagggtgta gatggcctgg 15420
cctctggcat tagcgggggt gtggacctgg ccaaccaggc agtgcaaaat aagattaaca 15480
gtaagcttga tccccgccct ccctagagg agcctccacc ggccgtggag acagtgtctc 15540
cagagggggc tggcgaaaa cgtccgcgcc ccgacaggga agaaaactctg gtgacgcaaa 15600
tagacgagcc tccctcgtac gaggaggcac taaagcaagg cctgcccacc acccgtccca 15660
tcgcgcccat ggctaccgga gtgctgggcc agcacacacc cgtaacgctg gacctgcctc 15720
ccccgcgca caccagcag aaacctgtgc tgccaggccc gaccgccgtt gttgtaacc 15780
gtcctagccg cgcgtccctg cgcgcgcgc ccagcggctc gcgatcgttg cggcccgtag 15840
ccagtggcaa ctggcaaa acactgaaca gcctcgtggg tctgggggtg caatccctga 15900
agcgcgagc atgcttctga tagctaacgt gtcgtatgtg tgcgatgat gcgtccatgt 15960
cgccgccaga ggagctgctg agcgcgcgc gcgccgttt ccaagatggc taccctctg 16020
atgatccgc agtggctcta catgcacatc tcgggcccagg acgcctcggg gtacctgagc 16080
ccccggctgg tgcagtttgc ccgcgccacc gagacgtact tcagcctgaa taacaagttt 16140
agaaacccca cgggtggcgc tacgcacgac gtgaccacag accggtccca gcgtttgacg 16200
ctgcggttca tccctgtgga ccgtgaggat actgcgtact cgtacaaggc gcggttcacc 16260
ctagctgtgg gtgataaccg tgtgtggac atggcttcca cgtacttga catccgcggc 16320
gtgctggaca ggggccctac ttttaagccc tactctggca ctgcctaca cgccctggct 16380
cccaagggtg ccccaaatcc ttgcgaatgg gatgaagctg ctactgctct tgaataaac 16440
ctagaagaag aggacgatga caacgaagc gaagtagacg agcaagctga gcagcaaaaa 16500
actcacgcat ttgggcaggc gccttattct ggtataaata ttacaaagga gggatttcaa 16560
ataggtgtcg aaggtcaaac acctaaatat gccgataaaa catttcaacc tgaacctcaa 16620
ataggagaat ctcaagtgtg cgaaacagaa attaactatg cagctgggag agtcctaaaa 16680
aagactacce caatgaaacc atgttacggt tcatatgcaa aaccacaaa tgaatatgga 16740
gggcaaggca ttctgtgaaa gcaacaaaat ggaaagctag aaagtcaagt ggaatgcaa 16800

-continued

tttttctcaa ctactgaggc agccgcaggc aatggtgata acttgactcc taaagtggta 16860
ttgtacagtg aagatgtaga tatagaaacc ccagacactc atattttetta catgcccact 16920
attaaggaag gtaactcacg agaactaatg ggccaacaat ctatgcccac caggcctaata 16980
tacattgctt ttagggacaa ttttattggt ctaatgtatt acaacagcac gggtaatatg 17040
gggtgtctgg cgggccaagc atcgcagttg aatgctgttg tagatttgca agacagaaac 17100
acagagcttt cataccagct tttgcttgat tccattggtg atagaaccag gtacttttct 17160
atgtggaatc aggctgttga cagctatgat ccagatgta gaattatga aaatcatgga 17220
actgaagatg aacttccaaa ttactgcttt ccactgggag gtgtgattaa tacagagact 17280
cttccaaggt taaaacctaa aacaggtcag gaaaatggat gggaaaaaga tgctacagaa 17340
ttttcagata aaaatgaaat aagagttgga aataattttg ccatggaaat caatctaaat 17400
gccaacctgt ggagaaatct cctgtactcc aacatagcgc tgtatttgcc cgacaagcta 17460
aagtacagtc cttccaacgt aaaaatttct gataacccaa acacctacga ctacatgaac 17520
aagcgagtgg tggctcccgg gctagtggac tgctacatta acctgggagc acgctggctc 17580
cttgactata tggacaacgt caaccattt aaccaccacc gcaatgctgg cctgcgctac 17640
cgctcaatgt tgctgggcaa tggctgctat gtgcccctcc acatccaggt gctcagaag 17700
ttctttgcca ttaaaacct ccttctcctg ccgggctcat acacctacga gtggaacttc 17760
aggaaggatg ttaacatggt tctgcagagc tccctaggaa atgacctaaag ggttgacgga 17820
gccagcatta agtttgatag catttgctt tacgccacct tcttccccat ggcccacaac 17880
accgcctcca cgcttgagge catgcttaga aacgacacca acgaccagtc ctttaacgac 17940
tatctctccg ccgccaacat gctctacct ataccgcca acgctaccaa cgtgcccata 18000
tccatcccc cccgcaactg ggccgcttcc cgcggctggg ccttcaacgg ccttaagact 18060
aaggaaacct catcactggg ctcgggctac gacccttatt acacctactc tggctctata 18120
ccctacctag atggaacctt ttacctcaac cacacctta agaaggtggc cattacctt 18180
gactcttctg tcagctggcc tggcaatgac cgctgctta cccccaacga gtttgaatt 18240
aagcgctcag ttgacgggga gggttacaac gttgccagc gtaacatgac caaagactgg 18300
ttctggtagc aaatgctagc taactataac attggctacc agggcttcta tatcccagag 18360
agctacaagg accgcatgta ctcttcttt agaaacttcc agccatgag ccgtcagggtg 18420
gtggatgata ctaaatacaa ggactaccaa caggtgggca tcctacacca acacaacaac 18480
tctggatttg ttggctacct tgccccacc atgcgcgaag gacaggccta cctgctaac 18540
ttcccctatc cgcttatagg caagaccgca gttgacagca ttaccagaa aaagtttctt 18600
tgcatcgca ccctttggcg catcccattc tccagtaact ttatgtccat gggcgactc 18660
acagacctgg gccaaaaacct tctctacgcc aactccgccc acgctgtaga catgactttt 18720
gaggtggatc ccatggacga gccaccctt ctttatgttt tgtttgaagt ctttgacgtg 18780
gtcctgtgac accagccgca ccgcgcgctc atcgaaaccg tgtacctgag cacgcccttc 18840
tcggccggca acgcccacaac ataaagaagc aagcaacatc aacaacagct gccccatgg 18900
gctccagtga gcaggaactg aaagccattg tcaaagatct tggttgtggg ccatattttt 18960
tgggaccta tgacaagcgc tttccaggct ttgtttctcc acacaagctc gctgcccga 19020
tagtcaatac ggccggctgc gagactgggg gcgtacactg gatggcctt gcttggaaac 19080

-continued

cgcaactcaaa aacatgctac ctctttgagc cctttggctt ttctgaccag cgactcaagc	19140
aggtttacca gtttgagtac gagtcaactcc tgcgccttag cgccattgct tcttcccccg	19200
accgctgtat aacgctgtaa aagtcacccc aaagcgtaca ggggcccac tcggccgct	19260
gtggactatt ctgctgcatg tttctccacg cctttgccc a ctggcccaca actcccatgg	19320
atcacaaccc caccatgaac cttattaccg gggtagccaa ctccatgctc aacagtcccc	19380
aggtagacgc caccctcgct cgcaaccagg aacagctcta cagcttctg gagcgccact	19440
cgccctactt ccgcagccac agtgcgcaga ttaggagcgc cacttctttt tgtcaactga	19500
aaaaatgta aaaataatgt actagagaca ctttcaataa aggcaaatgc ttttatttgt	19560
acaactctcg gtgattatct acccccaccc ttgcccctg cgccgtttaa aatcaaagg	19620
ggttctgccc cgcategcta tgcgccactg gcagggacac gttgcgatac tgggttttag	19680
tgtccactt aaactcaggc acaaccatcc gcggcagctc ggtgaagttt tcaactccaca	19740
ggctgcgcac catcaccac gcggttagca ggtcgggccc cgatatctg aagtgcagct	19800
tggggcctcc gccctgcgag cgcgagttgc gatacacagg gttgcagcac tggaaacta	19860
tcagcgcagg gtggtgcacg ctggccagca cgctcttctc ggagatcaga tccgcgtcca	19920
ggtcctccgc gttgctcagg gcgaacggag tcaactttgg tagctgcctt cccaaaagg	19980
gcgctgccc aggctttgag ttgcactcgc accgtagtgg catcaaaagg tgaccgtgcc	20040
cggtctgggc gtttagatac agcgcctgca taaaagcctt gatctgctta aaagccacct	20100
gagcctttgc gccttcagag aagaacatgc cgcaagactt gccggaaaac tgattggccg	20160
gacaggccc gcctgacag cagcaccttg cgtcgggtgt ggagatctgc accacattc	20220
ggccccaccg gttcttcacg atcttggcct tgctagactg ctccctcagc ggcgctgcc	20280
cgttttcgtc cgtcacatcc atttcaatca cgtgctcctt atttatac atgcttccgt	20340
gtagacactt aagctcgcct tcgatctcag cgcagcggtg cagccacaac gcgcagccc	20400
tgggctcgtg atgctttag gtcacctctg caaacgactg caggtacgccc tgcaggaaac	20460
gccccatcat cgtcacaaa gtcttgttgc tggtagaagg cagctgcaac ccgctgtgct	20520
cctcgttcag ccaggtcttg catacggccg ccagagcttc cacttggta ggcagtagtt	20580
tgaagttcgc ctttagatcg ttatccactg ggtacttctc catcagcgcg cgcgcagcct	20640
ccatgcctt ctcccacgca gacacgatcg gcacactcag cgggttcac accgtaattt	20700
cacttccgc ttcgctgggc tcttctctt cctcttgcgt ccgcatacca cgcgccactg	20760
ggtcgtctt attcagccc gcgactgtgc gcttacctcc tttgccatgc ttgattagca	20820
ccggtgggtt gctgaaaccc accatttcta gcgccacatc ttctcttct tctcgcctgt	20880
ccacgattac ctctggtgat ggcgggctc cgggcttggg agaagggcgc tctttttct	20940
tcttgggccc aatggccaaa tccgcgcgag aggtcagatg ccgcccgtg ggtgtgcgcg	21000
gcaccagcgc gtctttagat gactcttctc cgtcctcggg ctccatacgc cgcctcatcc	21060
gcttttttg gggcgcgccc ggaggcggcg gcgacgggga cggggacgac acgtcctcca	21120
tgggtggggg acgtcgcgccc gcaccgcgct cgcgctcggg ggtggtttcg cgtgctcct	21180
cttcccgact ggccatttcc ttctctata ggcagaaaa gatcatggag tcagtcgaga	21240
agaaggacag cctaaccgccc cctctgagt tcgccaccac cgcctccacc gatgcccga	21300
acgcgcctac cacttcccc gtcgaggcac ccccgcttga ggaggaggaa gtgattatcg	21360
agcaggacc aggttttcta agcgaagacg acgaggaccg ctcaatcca acagaggata	21420

-continued

aaaagcaaga ccaggacaac gcagaggcaa acgaggaaca agtcgggceg ggggacgaaa 21480
ggcatggcga ctacctagat gtgggagacg acgtgctggt gaagcatctg cagcgccagt 21540
gcccattat ctgcgacgcg ttgcaagagc gcagcgatgt gcccctcgcc atagcggatg 21600
tcagccttgc ctacgaacgc cacctattct caccgcgcggt acccccaaaa cgccaagaaa 21660
acggcacatg cgagcccaac ccgcgccctca acttctaccc cgtatttgcc gtgccagagg 21720
tgcttgccac ctatcacatc tttttccaaa actgcaagat acccctatcc tgccgtgcca 21780
accgcagccg agcggacaag cagctggcct tggcgagggg cgctgtcata cctgatatcg 21840
cctcgctcaa cgaagtgcc aaaaatcttg agggctcttg acgcgacgag aagcgcgcg 21900
caaacgctct gcaacaggaa aacagcgaaa atgaaagtca ctctggagtg ttggtggaac 21960
tcgaggggta caacgcgcg ctagcogtac taaaacgcag catcgaggtc acccactttg 22020
cctaccgcg acttaaccta ccccccaagg tcatgagcac agtcatgagt gagctgatcg 22080
tgcgccgtgc gcagcccctg gagagggatg caaatcttga agaacaaca gagggggg 22140
taccgcagtg tggcgacgag cagctagcgc gctggcttca aacgcgag cctgccgact 22200
tggaggagcg acgcaaaact atgatggccg cagtgcctgt taccgtggag cttgagtgca 22260
tgcagcggtt ctttgetgac ccggagatgc agcgaagct agaggaaaca ttgcaactaca 22320
cctttcgaca gggctacgta cgccaggcct gcaagatctc caacgtggag ctctgcaacc 22380
tggctcctca ctttgaatt ttgcaagaaa accgccttgg gcaaaacgtg cttcattcca 22440
cgctcaaggg cgaggcgcg cgcgactacg tccgcgactg cgtttactta tttctatgct 22500
acacctggca gacggccatg ggcgtttggc agcagtgctt ggaggagtgc aacctcaagg 22560
agctgcagaa actgctaagg caaaacttga aggacctatg gacggccttc aacgagcgct 22620
ccgtggccgc gcacctggcg gacatcattt tccccgaacg cctgcttaaa accctgcaac 22680
agggctctgc agacttcacc agtcaaagca tgttcagaaa ctttaggaac tttatcctag 22740
agcgtcagg aatcttgcgc gccacctgct gtgcacttcc tagcgacttt gtgcccatta 22800
agtaccgca atgcctccg ccgctttggg gccactgcta ccttctgcag ctagccaact 22860
accttgccca ccactctgac ataatggaag acgtgagcgg tgacggtcta ctggagtgtc 22920
actgtcgctg caacctatgc accccgcacc gctccctggg ttgcaattcg cagctgctta 22980
acgaaagtca aattatcggg acctttgagc tgcagggctc ctgcctgac gaaaagtccg 23040
cggtccggg gttgaaactc actccggggc tgtggacgtc ggcttacctt cgcaaatctg 23100
tacctgagga ctaccacgcc cacgagatta ggttctacga agaccaatcc cgcccgccta 23160
atcgggaget taccgctgac gtcattaccc agggccacat tcttggccaa ttgcaagcca 23220
tcaacaaagc ccgccaagag tttctgctac gaaagggagc gggggtttac ttggaccccc 23280
agtccggcga ggagctcaac ccaatcccc cgcccgccca gccctatcag cagcagccgc 23340
gggccccttc tccccaggat ggcacccaaa aagaagctgc agctgccgcc gccaccacg 23400
gacgaggagg aatactggga cagtcaggca gaggaggttt tggacgagga ggaggaggac 23460
atgatggaag actgggagag cctagacgag gaagcttccg aggtcgaaga ggtgtcagac 23520
gaaacaccgt caccctcggg cgcattcccc tcgcccggcg cccagaaatc ggcaaccggg 23580
tccagcatgg ctacaacctc cgctcctcag gcgcccggcg cactgcccgt tcgcccaccc 23640
aaccgtagat gggacaccac tggaaaccag gccggtaagt ccaagcagcc gccgcccgtta 23700

-continued

gcccagagc aacaacagc ccaaggctac cgctcatggc gcgggcacaa gaacgccata 23760
gttgcttget tgcaagactg tgggggcaac atctccttcg cccgccgctt tcttctctac 23820
catcacggcg tggccttccc ccgtaacatc ctgcattact accgtcatct ctacagccca 23880
tactgcaccg gcggcagcgg cagcaacagc agcggccaca cagaagcaaa ggcgaccgga 23940
tagcaagact ctgacaaaagc ccaagaaaac cacagcggcg gcagcagcag gaggaggagc 24000
gctgcttctg gcgcccacg aaccctgata gaccgcgag cttagaaaca ggatttttcc 24060
cactctgtat gctatatctc aacagagcag gggccaagaa caagagctga aaataaaaaa 24120
caggtctctg cgatccctca cccgcagctg cctgtatcac aaaagcgaag atcagcttcg 24180
gcgcacgctg gaagacgcgg aggcctctct cagtaaatac tgcgcgctga ctcttaagga 24240
ctagtttcgc gccctttctc aaatttaagc gcgaaaacta cgtcatctcc agcggccaca 24300
cccgccgcca gcacctgttg tcagcgcgat tatgagcaag gaaattccca cgccctacat 24360
gtggagtac cagccacaaa tgggacttgc ggctggagct gcccaagact actcaaccg 24420
aataaactac atgagcgcgg gaccccatat gatatcccgg gtcaacggaa tacgcgcca 24480
ccgaaaaccg attctcctgg aacagggcgg tattaccacc acacctcgtg ataacctaa 24540
tcccctagtg tggcccctg ccttgggtga ccaggaaagt cccgctccca ccaactgtgt 24600
acttcccaga gacgcccagg ccgaagtca gatgactaac tcaggggccc agcttgcggg 24660
cggcttctg cacaggggtc ggtcgcccgg gcaggggata actcacctga caatcagagg 24720
gcgaggtatt cagctcaacg acgagtcggt gagctcctcg cttggctctc gtcgggacgg 24780
gacatttcag atcggcggcg ccggcgcctc ttcattcacg cctcgtcagg caatcctaac 24840
tctgcagacc tcgtcctctg agccgcgctc tggaggcatt ggaactctgc aatttattga 24900
ggagtttgct ccacgtgctc actttaacc cttctcggga cctcccggcc actatccgga 24960
tcaatttatt cctaacttg acgcggtaaa ggactcggcg gacggctacg actgaaatgt 25020
aagtggagag gcagagcaac tgcgcctgaa acacctggtc cactgtcggc gccacaagtg 25080
ctttgcccgc gactccgggt agttttgcta ctttgaattg cccgaggatc atatcgaggg 25140
cccgccgcac gcgctcggc ttaccgcca gggagagctt gcccgtagcc tgattcggga 25200
gtttaccag cgcctcctgc tagttgagcg ggacagggga ccctgtgttc tcaactgtgat 25260
ttgcaactgt cctaaccctg gattacatca agatctttgt tgccatctct gtgtgagta 25320
taataaatac agaaattaaa atatactggg gctcctatcg ccacccgta aacgccaccg 25380
tcttaccg cccaagcaaa ccaaggcgaa ccttacctgg tacttttaac atctctccct 25440
ctgtgattta caacagtttc aaccagacg gagtgagtct acgagagaac ctctccgagc 25500
tcagctactc catcagaaaa aacaccaccc tccttacctg ccgggaacgt acgagtgcgt 25560
cacccggccc tgcaccacac ctaccgctg accgtaaacc agacttttcc cggacagacc 25620
tcaataactc tgttaccag aacaggaggt gagcttagaa aacccttagg gtattaggcc 25680
aaagggcag ctactgtggg gtttatgaac aattcaagca actctacggg ctattctaata 25740
tcaggtttct ctagaatcgg ggttgggggt attctctgtc ttgtgattct ctttattctt 25800
atactaacgc ttctctgcct aaggetcggc gcctgctgtg tgcacatttg catttattgt 25860
cagcttttta aacgctgggg tcgccacca agatgattag gtacataatc ctaggtttac 25920
tcacccttgc gtcagcccac ggtaccaccc aaaaggtgga ttttaaggag ccagcctgta 25980
atgttacatt cgcagctgaa gctaattgag gcaccactct tataaaatgc accacagAAC 26040

-continued

atgaaaagct gcttattcgc cacaaaaaca aaattggcaa gtatgctggt tatgctattt 26100
ggcagccagg tgacactaca gagtataatg ttacagtttt ccagggtaaa agtcataaaa 26160
cttttatgta tacttttcca ttttatgaaa tgtgcgacat taccatgtac atgagcaaac 26220
agtataagtt gtggccccc caaaattgtg tggaaaacac tggcactttc tgctgcactg 26280
ctatgcta atacagtgctc gctttggctc gtaccctact ctatattaaa tacaaaagca 26340
gacgcagctt tattgaggaa aagaaaatgc cttaatttac taagttacaa agctaattgc 26400
accactaact gctttactcg ctgcttgcaa aacaattca aaaagttagc attataatta 26460
gaataggatt taaaccccc ggtcatttcc tgcctcaatac cattcccctg aacaattgac 26520
tctatgtggg atatgctcca gcgctacaac cttgaagtca ggcttcctgg atgtcagcat 26580
ctgactttgg ccagcacctg tccccgggat ttgttccagt ccaactacag cgaccacccc 26640
taacagagat gaccaacaca accaacgcgg cgcgcgctac cggacttaca tctaccacaa 26700
atacacccca agtttctgcc tttgtcaata actgggataa cttgggcatg tgggtggtct 26760
ccatagcgct tatgtttgta tgccttatta ttatgtggct catctgctgc ctaaagcgca 26820
aacgcgcccc accaccctc tatagtccca tcattgtgct acacccaac aatgatggaa 26880
tccatagatt ggacggactg aaacacatgt tcttttctct tacagtatga ttaaatgaga 26940
catgattcct cgagttttta tattaactgac cctgtttgog cttttttgt gcgtgctcca 27000
cattggctgc ggtttctcac atcgaagtag actgcattcc agccttcaca gtctatttgc 27060
tttacggatt tgtcaccctc acgctcatct gcagcctcat cactgtggtc atcgccttta 27120
tccagtgcat tgactgggct tgtgtgctct ttgcatatct cagacacct cccagttaca 27180
gggacaggac tatagctgag cttcttagaa ttctttaatt atgaaattta ctgtgacttt 27240
tctgctgatt atttgacccc tatctgctgt ttgttccccg acctccaagc ctcaaagaca 27300
tatatcatgc agattcactc gtatatggaa tattccaagt tgtacaatg aaaaaagcga 27360
tctttccgaa gcctggttat atgcaatcat ctctgttatg gtgttctgca gtaccatctt 27420
agcctagct atatatccct accttgacat tggctggaac gcaatagatg ccatgaacca 27480
cccaacttcc cccgcgcccc ctatgcttcc actgcaacaa gttgttgccg gcggctttgt 27540
cccagccaat cagcctcgcc caccttctcc caccctcact gaaatcagct actttaatct 27600
aacaggagga gatgactgac accttagatc tagaaatgga cggaaattatt acagagcagc 27660
gcctgctaga aagacgcagg gcagcggccg agcaacagcg catgaatcaa gagctccaag 27720
acatggttaa cttgcaccag tgcaaaaggg gtatcttttg tctggtaaag caggccaaag 27780
tcacctacga cagtaatacc accggacacc gccttagcta caagttgcca accaagcgtc 27840
agaaattggt ggtcatggtg ggagaaaagc ccattacat aactcagcac tcggtagaaa 27900
ccgaaggctg cattcactca ccttgtaag gacctgagga tctctgcacc cttattaaga 27960
ccctgtgctg tctcaaagat cttattccct ttaactaata aaaaaaata ataaagcctc 28020
acttacttaa aatcagttag caaatttctg tccagtttat tcagcagcac ctcttgcctc 28080
tcctcccagc tctggtattg cagcttctcc ctgctgcaa actttctcca caatctaaat 28140
ggaaatgctg tttcctcctg ttcctgtcca tccgcaccca ctatcttcat gttgttgctg 28200
atgaagcgcg caagaccgct tgaagatacc ttcaaccccg tgtatccata tgacacggaa 28260
accggtcctc caactgtgct ttttcttact cctcccttg tatcccccaa tgggtttcaa 28320

-continued

gagagtcccc ctgggggtact ctctttgccc ctatccgaac ctctagttag ctccaatggc 28380
atgcttgccc tcaaaatggg caacggcctc tctctggagc aggcgggcaa ccttacctcc 28440
caaaatgtaa ccaactgtgag cccacctctc aaaaaacca agtcaaacat aaacctggaa 28500
atatctgcac ccctcacagt tacctcagaa gccctaactg tggctgccc cgcacctcta 28560
atggtcggcg gcaacacact caccatgcaa tcacaggccc cgtaaccgt gcacgactcc 28620
aaacttagca ttgccaccca aggacccctc acagtgtcag aaggaaagct agccctgcaa 28680
acacagggcc ccctcaccac caccgatagc agtaccctta ctatcactgc ctcaccccct 28740
ctaactactg ccaactgtgag ctgtggcatt gacttgaag agccattta tacacaaaat 28800
ggaaaactag gactaaagta cggggctcct ttgcatgtaa cagacgacct aaacctttg 28860
accgtagcaa ctgggtccagg tgtgactatt aataaactt ccttgcaaac taaagtact 28920
ggagccttg gttttgatc acaaggcaat atgcaacta atgtagcagg aggactaagg 28980
attgattctc aaaacagacg ccttatactt gatgttagt atccgttga tgctcaaac 29040
caactaaatc taagactagg acagggccct cttttataa actcagccca caacttggat 29100
attaactaca acaaaaggcct ttacttgtt acagcttcaa acaattcaa aaagcttgag 29160
gttaaccta gcaactgcaa ggggttgatg tttgacgcta cagccatagc cattaatgca 29220
ggagatggcg ttgaatttgg ttcacctaat gcaccaaaca caaatcccct caaaacaaaa 29280
attggccatg gcctagaatt tgattcaaac aaggctatgg ttccctaaact aggaactggc 29340
cttagttttg acagcacagg tgccattaca gtaggaaaca aaaataatga taagctact 29400
ttgtggacca caccagctcc atctcctaac tgtagactaa atgcagagaa agatgctaaa 29460
ctcactttgg tcttaacaaa atgtggcagt caaatacttg ctacagtttc agttttggct 29520
gttaaaggca gtttgctccc aatatctgga acagttcaa gtgctcatct tattataaga 29580
ttgacgaaa atggagtgt actaaacaat tcctcctgg acccagaata ttggaacttt 29640
agaaatggag atcttactga aggcacagcc tatacaaacg ctgttggatt tatgcctaac 29700
ctatcagctt atccaaaatc tcacggtaaa actgcaaaa gtaacattgt cagtcaagtt 29760
tacttaaacg gagacaaaac taaacctgta aactaacca ttactactaa cggtagacag 29820
gaaacaggag acacaactcc aagtgcatac tctatgtcat tttcatggga ctggctggc 29880
cacaactaca ttaatgaaat atttgccaca tcctcttaca cttttcata cattgcccga 29940
gaataaagaa tcgtttgggt tatgtttcaa cgtgtttatt tttcaattgc agaaaatttc 30000
aagtcatttt tcattcagta gtatagcccc accaccacat agcttataca gatcaccgta 30060
ccttaatcaa actcacagaa ccctagtatt caacctgcca cctccctccc aacacacaga 30120
gtacacagtc ctttctcccc ggctggcctt aaaaagcatc atatcatggg taacagacat 30180
attcttaggt gttatattcc acacggtttc ctgtcgagcc aaacgctcat cagtgatatt 30240
aataaactcc cggggcagct cacttaagtt catgtcgtg tccagctgct gagccacagg 30300
ctgctgtcca acttgcggtt gcttaacggg cggcgaagga gaagtccacg cctacatggg 30360
ggtagagtca taactgtgca tcaggatagg gcggtgggtc tgcagcagcg cgcgaataaa 30420
ctgctgccc cgcctctccg tcctcagga atacaacatg gcagtggtct cctcagcgat 30480
gattcgcacc gcccgagca taaggcgct tgcctcctgg gcacagcagc gcaccctgat 30540
ctcacttaa tcagcacagt aactgcagca cagcaccaca atattgttca aaatcccaca 30600
gtgcaaggcg ctgtatcaa agctcatggc ggggaccaca gaaccaagt ggccatcata 30660

-continued

ccacaagcgc aggtagatta agtggcgacc cctcataaac acgctggaca taaacattac 30720
ctcttttggc atgttgtaat tcaccacctc cgggtacatc ataacctct gattaacat 30780
ggcgccatcc accaccatcc taaaccagct ggccaaaacc tgcccgcgg ctatacactg 30840
cagggaaccg ggactggaac aatgacagt gagagcccag gactcgtaac catggatcat 30900
catgctcgtc atgatataca tgttggcaca acacaggcac acgtgcatac acttcctcag 30960
gattacaagc tcctcccgcg ttagaacct atcccaggga acaaccatt cctgaatcag 31020
cgtaaatccc aactgcagg gaagaactcg cacgtaactc acgttgtgca ttgtcaaagt 31080
gttacattcg ggcagcagcg gatgatcctc cagtatggta gcgcgggttt ctgtctcaa 31140
aggaggtaga cgatccctac tgtacggagt gcgcggagac aaccgagatc gtgttggtcg 31200
tagtgtcatg ccaaatggaa cgccggagct agtcatattt cctgaagcaa aaccaggtgc 31260
gggctgtaac aacagatctg cgtctccggt ctgcgcgctt agatcgctct gtgtagtagt 31320
tgtagtatat ccaactctct aaagcatcca ggcgcccctt ggcttcgggt tctatgtaaa 31380
ctcctcatg cgccgctgcc ctgataacat ccaccaccgc agaataagcc acaaccagcc 31440
aacctacaca ttcgttctgc gagtcacaca cgggaggagc ggaagagct ggaagaacca 31500
tgtttttttt ttattccaa aagattatcc aaaacctcaa aatgaagatc tattaagtga 31560
acgcgctccc ctccggtggc gtggtcaaac tctacagcca aagaacagat aatggcattt 31620
gtaagatggt gcacaatgac ttccaaaagg caaacggccc tcacgtccaa gtggacgtaa 31680
aggctaaacc cttcagggtg aatctcctct ataacattc cagcaccttc aacctgccc 31740
aaataattct catctcgcca ccttctcaat atatctctaa gcaaatcccg aatattaagt 31800
ccggccattg taaaaatctg ctccagagcg cctccacct tcagcctcaa gcagcgaatc 31860
atgattgcaa aaattcaggt tcctcacaga cctgtataag attcaaaagc ggaacattaa 31920
caaaaatacc gcgatcccgt aggtcccttc gcagggccag ctgaacataa tcgtgcaggt 31980
ctgcacggac cagcgcggcc acttcccgcg caggaacct gacaaaagaa cccacactga 32040
ttatgacacg cataactcgga gctatgctaa ccagcgtagc cccgatgtaa gcttgttgca 32100
tgggcgcgca tataaatgc aaggtgctgc tcaaaaaatc aggcгааagcc tcgcgcaaaa 32160
aagaaagcac atcgtagtca tgctcatgca gataaaggca ggtaagctcc ggaaccacca 32220
cagaaaaaga caccattttt ctctcaaaaca tgtctgctggg tttctgcata aacacaaaat 32280
aaaaatacaa aaaaacattt aacattaga agcctgtctt acaacaggaa aaacaacct 32340
tataagcata agacggacta cggccatgcc ggcgtgaccg taaaaaaact ggtcacctg 32400
attaaaaagc accaccgaca gctcctcggg catgtccgga gtcataatgt aagactcgg 32460
aaacacatca ggttgattca catcggctcag tgctaaaaag cgaccgaaat agccccgggg 32520
aatacatacc cgcaggcgta gagacaacat tacagcccc ataggaggta taacaaaatt 32580
aataggagag aaaaacacat aaacacctga aaaacctcc tcctaggca aaatagcacc 32640
ctcccgtcc agaacaacat acagcgtctc cacagcgca gccataacag tcagccttac 32700
cagtaaaaaa gaaaacctat taaaaaaaca ccactcgaca cggcaccagc tcaatcagtc 32760
acagtgtaaa aaagggccaa gtgcagagcg agtatatata ggactaaaaa atgacgtaac 32820
ggttaaagtc cacaaaaaac acccagaaaa ccgcacgca acctacgcc agaaacgaaa 32880
gccaaaaaac ccacaacttc ctcaaatcgt cacttccggt tccccaggt acgtcacttc 32940

-continued

```

ccattttaag aaaactacaa ttoccaaacac atacaagtta ctccgccccta aaacctacgt 33000
caccgcgccc gttcccacgc cccgcgccac gtcacaaaact ccaccccctc attatcatat 33060
tggettcaat ccaaaataag gtatattatt gat 33093

```

```

<210> SEQ ID NO 12
<211> LENGTH: 978
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: PPE-1-3X promoter

```

<400> SEQUENCE: 12

```

acgtgtactt ctgatcgggc atactagggg gataaggatg tacctgacaa aaccacattg 60
ttgttgttat cattattatt tagttttcct tccttgctaa ctctgacgg aatctttctc 120
acctcaaatg cgaagtactt tagtttagaa aagacttggg ggaagggggg gtggtggaaa 180
agtaggggta tcttccaaac taatctggtt ccccgcccgc ccagtagct gggattcaag 240
agcgaagagt ggggatcgtc cccttgttg atcagaaaga cataaaagga aaatcaagtg 300
aacaatgac agccccacct ccaccccacc cccctgcgcg cgcacaatac aatctattta 360
attgtacttc atacttttca ttccaatggg gtgactttgc tctggagaa actcttgatt 420
cttgaactct ggggctggca gctagcctcc agaagcaaag tcacccatt ggaatgaaaa 480
gtatgaagta caatgaaaag tatgaagtac tggtccaga agcaaagtca cctccagaa 540
gcaaagtac cccattggaa tgaaaagtat gaagtacgct agcaaaggg gaagcgggct 600
gtgctctct gcaggtctg cagcggctc tgtctagtgg gtgtttctt tttcttagcc 660
ctgcccctgg attgtcagac ggccggcgtc tgcctctgaa gttagccgtg atttctctc 720
gagccgggct ttatctctgg ctgcaogttg cctgtgggtg actaatcaca caataacatt 780
gtttagggct ggaataaagt cagagctgtt tacccccact ctataggggt tcaataataa 840
aaggcggcgg agaactgtcc gagtccagaag cgttctctgca ccggcgctga gagcctgacc 900
cggctctctc cgtctcctt gcgcgctgcc tcccggctgc ccgcgacgt ttcgccccag 960
tggaagggcc acttgctg 978

```

```

<210> SEQ ID NO 13
<211> LENGTH: 1334
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

```

<400> SEQUENCE: 13

```

gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtagtga cttctgatcg 60
gcgatactag ggagataaag atgtacctga caaaaccaca ttgttgtgt tatcattatt 120
atntagtttt ccttctctgc taactcctga cggaaatctt ctcacctcaa atgcgaagta 180
ctttagttta gaaaagactt ggtggaaggg gtggtgggtg aaaagtaggg tgatcttcca 240
aactaatctg gttccccgcc cgcgccagta gctgggatcc aagagcgaag agtggggatc 300
gtccccttgt ttgatcagaa agacataaaa ggaaaatcaa gtgaacaatg atcagcccca 360
cctccacccc acccccctgc gcgcgcacaa tacaatctat ttaattgtac ttcatacttt 420
tcattccaat ggggtgactt tgcttctgga gaaactcttg attcttgaac tctggggctg 480
gcagctagca aaaggggaag cgggctgctg ctctctgcag gttctgcage ggtctctgct 540
tagtgggtgt tttcttttct ttagcctctg ccttgattg tcagacggcg ggcgtctgcc 600

```

-continued

tctgaagtta gccgtgattt cctctagagc cgggtcttat ctctggetgc acgttgectg	660
tgggtgacta atcacacaat aacattgttt agggctggaa taaagtcaga gctgtttacc	720
cccactctat aggggttcaa tataaaaagg cggcggagaa ctgtccgagt cagacgctt	780
cctgcaccgg cgctgagagc ctgacccggc ctgctccgct gtccttgcgc gctgectccc	840
ggctgcccgc gacgctttcg cccagtgga agggccactt gctgaggacc gcgctgagat	900
ctaaaaaaaa aacaaaaaac aaaaaacaaa aaaaccaga ggcgatcaga gcgaccagac	960
accgtctctt tcgttttgca ttgagttcca tttgcaaccg agttttcttt ttttctttt	1020
tcccactctt tctgaccctt ttgcagaatg gattattttc ccgtgatctt ctctctgctg	1080
ttcgtgactt tccaaggagc tccagaaaca ggtagggcc acttgcaaat ctttctactt	1140
cagcgcagca gttatcgctt ctgttttcca cttttctttc tttcttttct ttcattcttt	1200
cttttttatt tttttttta attactgaag ctccagcagc aagtgcctta caattaatta	1260
acttctgtgt gaagcgaag aaataaaacc cctgtttgaa tacagctgac tacaaccgag	1320
tatcgcatag cttc	1334

1. (canceled)
2. (canceled)
3. A method of treating a malignant glioma in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a viral vector comprising:
 - (i) a first polynucleotide sequence encoding a Fas-chimera (Fas c); and
 - (ii) a second polynucleotide sequence encoding an endothelial cell-specific promoter or a periendothelial cell-specific promoter, thereby treating the malignant glioma.
4. The method of claim 3, wherein said promoter is the sequence set forth in SEQ ID NO: 12.
5. The method of claim 3, wherein said promoter is the sequence set forth in SEQ ID NO: 13.
6. The method of claim 3, wherein the viral vector is an adenoviral vector.
7. The method of claim 6, wherein said adenoviral vector is a non-replicating adenoviral vector.
8. The method of claim 3, wherein said promoter comprises at least one copy of the sequence set forth in SEQ ID NO: 6, or the complementary sequence thereof.
9. The method of claim 8, wherein said promoter comprises at least two copies of the sequence set forth in SEQ ID NO: 6, or the complementary sequence thereof.
10. The method of claim 8, wherein said promoter comprises the sequence set forth in SEQ ID NO: 8, or the complementary sequence thereof.
11. The method of claim 8, wherein said promoter comprises the sequence set forth in SEQ ID NO: 7, or the complementary sequence thereof.
12. The method of claim 3, wherein said promoter comprises the hypoxia response element (HRE) set forth in SEQ ID NO: 5.
13. The method of claim 3, wherein the viral vector consists of the sequence set forth in SEQ ID NO: 9 or SEQ ID NO: 10.
14. The method of claim 3, wherein the malignant glioma is selected from the group consisting of glioblastoma, astrocytoma, oligodendroglioma, ependymoma, and juvenile pilocytic astrocytoma.
15. The method of claim 3, wherein the therapeutically effective amount of said viral vector is about 10^3 to about 10^{16} virus particles.
16. The method of claim 15, wherein the therapeutically effective amount of said viral vector is about 10^5 to about 10^{13} virus particles.
17. The method of claim 15, wherein the therapeutically effective amount of said viral vector is about 10^7 to about 10^{12} virus particles.
18. The method of claim 15, wherein the therapeutically effective amount of said viral vector is about 1×10^{12} to about 5×10^{12} virus particles.
19. The method of claim 15, wherein the therapeutically effective amount of said viral vector is about 1×10^{13} to about 5×10^{13} virus particles.
20. The method of claim 3, wherein said administering comprises intravenous administration.
21. The method of claim 3, wherein said administering comprises local administration.
22. The method of claim 3, wherein said administering is in at least two doses of said viral vector.
23. The method of claim 3, wherein said administering is in at least three doses of said viral vector.
24. The method of claim 3, wherein the viral vector is administered as a single unit dose.
25. The method of claim 3, wherein the Fas-c comprises an extracellular domain of TNFR1 and a trans-membrane region and an intracellular region of Fas polypeptide.
26. The method of claim 25, wherein the Fas-c comprises SEQ ID NO: 2 and SEQ ID NO: 3.
27. The method of claim 3, further comprising administering to the subject an anti-cancer drug.
28. The method of claim 27, wherein said anti-cancer drug is bevacizumab.

29. The method of claim **3**, further comprising administering a therapy selected from the group consisting of chemotherapy, radiotherapy, phototherapy and photodynamic therapy, surgery, nutritional therapy, ablative therapy, brachiotherapy, proton beam therapy, immunotherapy, cellular therapy and photon beam radiosurgical therapy.

30. The method of claim **28**, wherein said therapy is immunotherapy.

* * * * *